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ABSTRACT 
This work was undertaken to characterise the interaction of the leukocyte- 
restricted integrin LFA-1 (CD1la/CD18) with its ligands. LFA-1 function is critical 
for an immune response and, for example, allows leukocyte binding and 
transmigration across the endothelium, antigen presentation and cytotoxic T 
lymphocyte-mediated killing. The ligands for LFA-1 are the Intercellular Adhesion 
Molecules (ICAMs), with ICAM-1, ICAM-2 and ICAM-3 being the best 
characterised. 
The binding sites on ICAM-1 and ICAM-3 for LFA-1 were investigated with 
the use of antibodies and mutated proteins. The following regions were found to 
have a role in binding LFA-1: the CFG face of ICAM-3 domain 1; domain 2 of 
ICAM-1; a residue in domain 1 of ICAM-1 that is mutated at high frequency in 
African populations and is associated with susceptibility to cerebral malaria. 
Binding of Mg2+ or Mn 2+ to the extracellular region of LFA-1 and 
intracellular signalling can both stimulate LFA-1 to adhere to ICAM-1, but by 
different processes. The former mechanism induces a high affinity form of LFA-1, 
which was shown to be achieved by an inter-domain movement involving the I 
domain of the LFA-1 a subunit. This is the first physical evidence for a 
conformational change occurring in an integrin upon activation. The mechanism by 
which intracellular signalling activates LFA-1 was demonstrated to involve calpain- 
dependent clustering of LFA-1 in the membrane, thus increasing the avidity of 
LFA-1 for ICAM-1. 
Leukocyte Adhesion Deficiency-1 and Glanzmann's Thrombasthenia are 
genetic disorders in which mutations in the integrin genes result in absence of 
expression or expression of a non-functional integrin. The defects in function of 
leukocytes from a patient with clinical features of both disorders were studied. The 
results suggest that the patient has a novel form of integrin dysfunction in which 
integrins are expressed at normal levels, can be induced to bind their ligands by 
mechanisms which increase the affinity of interaction, but cannot be stimulated to 
bind ligand by intracellular signalling pathways. 
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ABBREVIATIONS AND DEFINITIONS 
APC antigen presenting cell 
APS ammonium persulphate 
ARF ADP ribosylation factor 
BCECF 2', 7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein- 
acetoxymethyl ester 
Brij 96 polyoxyethylene 10 oleyl ether 
BSA bovine serum albumin 
[Ca2+]; intracellular Ca 2+ concentration 
CBZ-LVG CBZ-Leu-Val-Gly diazomethyl ketone 
CD circular dichroism 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1- 
propanesulphonate 
cSMAC central supramolecular activation cluster 
C-terminal carboxy-terminal 
DAG diacylglycerol 
DC dendritic cell 
DC-SIGN dendritic cell-specific ICAM-3 grabbing non-integrin 
DEAE-dextran Diethylaminoethyl-dextran 
DHR di-hydrorhodamine 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethyl sulphoxide 
ECM extracellular matrix 
EDTA ethylenediaminetetra-acetic acid disodium salt 
EGF epidermal growth factor 
EGTA ethylene glycol-bis (ß-aminoethy ether) N, N, N', N'-tetraacetic 
acid 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum 
ERM ezrin/radixin/moesin 
FCS foetal calf serum 
FITC fluorescein isothiocyanate 
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fMLP N-formyl-methionyl-leucyl-phenylalanine 
GEF guanine exchange factor 
GMEM-S supplemented Glasgow minimum essential medium 
GST glutathione S-transferase 
HBSS Hanks balanced salt solution 
HEPES N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid] 
HEY high endothelial venules 
H-HBSS HEPES buffered HBSS 
HRP horseradish peroxidase 
ICAM intercellular adhesion molecule 
ICAM-1Fc the extracellular domains of ICAM-1 fused to the Fc portion 
of human IgG, 
ICAM-1K'1 ICAM-1 with the Lys29/Met polymorphism 
ICRF Imperial Cancer Research Fund 
I domain inserted/interactive domain 
I-Fc LFA-1 I domain fused to the Fc portion of human IgGI 
I-GST LFA-1 I domain fused to glutathione S-transferase 
IFN-y interferon-y 
Ig immunoglobulin 
IgSF immunoglobulin supergene family 
IL-10 ß interleukin- 1 
IL-2 interleukin-2 
IP immunoprecipitate 
IP3 inositol 1,4,5-trisphosphate 
IPTG isopropyl-l-thio-ß-D-galactopyranoside 
JAB-1 jun activation domain binding protein-1 
JAM junctional adhesion molecule 
JNK c-jun N-terminal kinase 
kDa kilo daltons 
LAD-1 leukocyte adhesion deficiency-1 
LFA-1 leukocyte function associated antigen-1 
LIBS ligand induced binding site 
LW Landsteiner Wiener 
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ABBREVIATIONS AND DEFINITIONS 
mAb monoclonal antibody 
MacMARCKS macrophage-enriched myristoylated alanine-rich C kinase 
MAdCAM-1 mucosal addressin cell adhesion molecule-1 
MHC major histocompatibility complex 
MIDAS metal ion-dependent adhesion site 
min minute 
MTT 3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; 
thiazolyl blue 
m1h2-3 ICAM-3Fc murine ICAM-1 domain lfused to human ICAM-3 domains 2 
and 3 fused to the Fc portion of human IgG, 
NIF neutrophil inhibitory factor 
NK natural killer 
N-terminal amino-terminal 
OPD o-phenylenediamine dihydrochloride 
PBMC peripheral blood mononuclear cells 
PBS phosphate-buffered saline 
PdBu phorbol-12,13-dibutyrate 
PECAM-1 platelet endothelial cell adhesion molecule-1 
P. falciparum Plasmodium falciparum 
PHA phytohaemagglutinin 
PIP2 phosphatidylinositol 4,5, bisphosphate 
PKC protein kinase C 
PLC phospholipase C 
PSI plexins, semaphorins and integrins 
pSMAC peripheral supramolecular activation cluster 
Rack-1 Receptor for activated protein kinase C-1 
RPMI 1640 Roosevelt Park Memorial Institute medium 1640 
RT room temperature 
SCID severe combined immunodeficiency 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SHIP SH2-containing inositol phosphatase 
TCR T cell receptor 
TEMED N, N, N', N'-tetramethylethylenediamine 
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TNF-a tumour necrosis factor-a 
Triton X-100 t-octylphenoxypolyethoxyethanol 
Tween 20 polyoxyethylenesorbitan monolaurate 
VCAM-1 vascular cell adhesion molecule-1 
wt wild type 
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CHAPTER 1 
INTRODUCTION 
1.1 THE INTEGRINS 
The integrins are a widely expressed family of cell adhesion molecules which 
mediate cell-cell and cell-extracellular matrix (ECM) interactions. They were 
termed "integrins" to denote their role in integrating the extracellular environment 
and the cytoskeleton (Tamkun et al., 1986; Hynes, 1987). Integrins are 
heterodimeric integral membrane glycoproteins composed of non-covalently linked 
a and ß subunits. Each subunit consists of a large extracellular region 
(approximately 1000 amino acids for the a subunit and 700 amino acids for the ß 
subunit), a single hydrophobic transmembrane domain and a cytoplasmic tail, which 
is short in most subunits. To date eighteen a subunits and eight ß subunits have been 
identified that associate to form more than twenty different aß complexes (Fig. 1.1). 
The extracellular region of integrins recognises a variety of ligands including 
extracellular matrix proteins, cell surface Immunoglobulin Superfamily members and 
plasma proteins (Table 1.1). In addition, several pathogens bind to integrins. Each 
combination of a and ß subunit defines a particular ligand binding specificity. Most 
integrins bind more than one ligand and, conversely, each ligand can often bind more 
than one integrin. Many ligands contain the motif Arg-Gly-Asp (RGD), which 
mediates binding to integrins. The cytoplasmic tails bind cytoskeletal and regulatory 
proteins and the transmembrane domains can make lateral associations with other 
cell surface molecules, such as members of the tetraspan family. Both these types of 
associations can regulate integrin activation. 
19 
INTRODUCTION 
al 
a2 
a3 
as ß7 °CE 
as 
a6 ßa 
a8 
ay 
°c io ßs a'IIb 
all/ ßs 
aV 
ß6 
ß8 
ßz (AM 
ax 
ý'D 
Figure 1.1 The integrin family of adhesion molecules 
The subunits in red are members of the leukocyte integrin family. 
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INTEGRIN SUBUNITS LIGANDS 
ßl al Collagen, Laminin 
a2 Collagen, Laminin, Echovirus 1 
a3 Collagen, Laminin, Fibronectin, Epiligrin, Entactin, Invasin, 
Thrombospondin 
a4 Fibronectin, VCAM-1, Invasin, Osteopontin 
as Fibronectin, Invasin 
a6 Laminin 
OC7 Laminin 
as Fibronectin, Vitronectin, Tenascin, Osteopontin 
a9 Tenascin, Osteopontin, VCAM-1 
OClo Collagen 
OCit Collagen 
GCv Fibronectin, Vitronectin 
ß2 CZL ICAM-1, ICAM-2, ICAM-3, ICAM-4 and ICAM-5 
am Fibrinogen, iC3b, Factor X, ICAM-1, ICAM-2, Elastase, 
Heparin, High Molecular Weight Kininogen, NIF, 
Denatured proteins 
aax 
Fibrinogen, iC3b, Collagen, Denatured proteins, (ICAM-1? ) 
CCD ICAM-3, VCAM-1 
ß3 aIlb Fibrinogen, Fibronectin, Thrombospondin, von Willebrand 
Factor, Vitronectin 
OLv Fibrinogen, Fibronectin, Thrombospondin, von Willebrand 
Factor, Vitronectin, Collagen, Osteopontin, Tenascin 
ß4 a6 Laminin 
ßs OGv Vitronectin 
ß6 OXv Fibronectin, latent TGF- 31 
ß7 Ol4 MAdCAM-1, VCAM-1, Fibronectin 
OtE E-cadherin 
ßg C (v Vitronectin 
Table 1.1 The integrins and their ligands 
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Divalent cations are essential for ligand binding by integrins and also for 
heterodimer formation. Putative cation binding sites exist in both the a and ß 
subunits. Most integrins are constitutively inactive in resting leukocytes but are 
rapidly activated in a tightly regulated fashion in response to stimuli. Activation of 
integrins is associated with increased affinity for ligand, epitopes for certain mAbs 
being revealed, clustering of the integrin, and alterations in connections with the 
cytoskeleton (reviewed in (Arnaout, 1990; Hynes, 1992)). 
1.1.1 The Leukocyte Integrins 
Lymphocyte function-associated antigen 1 (LFA-1), Mac-1, p150,95 and 
aD(32 are integrins which share a common ß chain, f2 (CD18), in association with the 
a chains aL (CD11a), am (CD11b), ax (CD11c) and aD (CD11d), respectively (Fig. 
1.1). These four integrins are referred to as the Leukocyte Integrins as their 
expression is restricted to leukocytes. The genes for all four leukocyte integrin a 
subunits are located in a cluster on chromosome 16 band p11 (Corbi et al., 1988; 
Wong et al., 1996), while the ß2 gene is on chromosome 22 band q21 (Marlin et al., 
1986; Corbi et al., 1988). aM, aX and (XD share approximately 60% amino acid 
identity, but aL is less homologous with 35% identity. 
1.1.1. a LFA-1 
LFA-1 was first discovered through characterisation of monoclonal 
antibodies in the early 1980s, first in mice (Kurzinger et al., 1981; Pierres et al., 
1982), and a few years later in humans (Hildreth et al., 1983). LFA-1 is expressed 
on virtually all leukocytes and binds to the intercellular adhesion molecules (ICAM)- 
1 (Marlin and Springer, 1987), ICAM-2 (Staunton et al., 1989a), ICAM-3 (de 
Fougerolles et al., 1993; Fawcett et al., 1992; Vazeux et al., 1992), ICAM-4 (Bailly 
et al., 1995) and ICAM-5 (Mizuno et al., 1997; Tian et al., 1997). These interactions 
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play an important role in the immune response allowing, for example, proliferation 
of lymphocytes, cytotoxic T cell responses, natural killer (NK) cell activity, T cell-B 
cell interaction and leukocyte extravasation (reviewed in (Shimizu et al., 1999)). 
1.1.1. b Mac-1 
Mac-1 is primarily expressed on granulocytes, monocytes and NK cells. In 
unstimulated neutrophils only 5% of Mac-1 is expressed on the cell surface, 75% is 
found in granules and the remaining 20% in secretory vesicles (Sengelov et al., 
1993). Upon cell activation there is a ten fold upregulation of cell surface expression 
(Miller et al., 1987; Sengelov et al., 1993). The principal ligands for Mac-1 are the 
coagulation factors fibrinogen (Altieri et al., 1990) and factor X (Altieri and 
Edgington, 1988), the complement C3 fragment iC3b (Ross and Lambris, 1982), and 
ICAM-1 (Diamond et al., 1991). However, Mac-1 is promiscuous and binds to 
denatured proteins (Davis, 1992). Neutrophil inhibitory factor (NIF), a hookworm 
glycoprotein, is an antagonist of Mac-1 (Moyle et al., 1994). Mac-1 is involved in 
the adhesion and transmigration of myeloid cells across endothelium, binding to and 
ingestion of iC3b-coated target cells, neutrophil homotypic aggregation, neutrophil 
and monocyte chemotaxis, binding and phagocytosis of opsonised particles 
(reviewed in Plow and Zhang, 1997). 
1.1.1. c p150,95 
p150,95 is expressed on myeloid cells, dendritic cells, activated B cells and 
some T cell populations. Its ligands are not well characterised. Like Mac-1, 
however, it is thought that p150,95 binds to iC3b (Bilsland et al., 1994), fibrinogen 
(Loike et al., 1991), denatured proteins (Davis, 1992), and perhaps ICAM-1 
(Diamond et al., 1993). Recently, p150,95, but not LFA-1 or Mac-1, has been 
reported to mediate monocyte binding to collagen I (Garnotel et al., 2000). 
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1.1.1. d aDß2 
The most recently identified member of the leukocyte integrin family, aD 2, 
is expressed on monocytes, macrophages, NK cells, a subpopulation of T and B 
cells, basophils, eosinophils and neutrophils. No binding of aD02 to ICAM-1 can be 
detected, but it does bind to ICAM-3 (Van der Vieren et al., 1995) and to vascular 
cell adhesion molecule (VCAM)-1 (Grayson et al., 1998). 
1.1.2 Integrin structure and cation binding sites 
Electron microscopy indicates that the amino-terminal (N-terminal) regions 
of the integrin a and ß subunits form an extracellular globular head that is 
approximately 100 A in diameter (Weisel et al., 1992). The more carboxy-terminal 
(C-terminal) portions of the a and ß subunits form two long stalks, approximately 
100 A in length, which link the globular head to the membrane spanning helices. 
Each subunit has a short cytoplasmic tail. 
1.1.2. a The alpha subunit 
Within the extracellular region of the a subunit are seven N-terminal 
homologous repeats, each approximately 60 amino acids. An insertion of 
approximately 200 amino acids is present between repeats II and III in nine of the a 
subunits (a a2, a, o, a,,, aL, (XM, aX, aD and aE), and is known as the I 
(inserted/interactive) domain. The remainder of the a subunit, which is not 
characterised structurally, links to the transmembrane sequence and is followed by an 
approximately fifty residue cytoplasmic tail (Larson et al., 1989) (Fig. 1.2). 
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(i) The I domain 
The I domain folds autonomously (Huang and Springer, 1997) and, until 
recently, was the only integrin domain to be produced as an isolated recombinant 
protein. It is for this reason that the I domain is the only region for which detailed 
structural information is available. The structures of the I domains of (XL (Qu and 
Leahy, 1995), am (Lee et al., 1995a; Lee et al., 1995b), al (Nolte et al., 1999) and a2 
(Emsley et al., 1997) have been solved. They have a classic dinucleotide binding 
fold, similar to that originally described for small G proteins, composed of a six 
stranded ß-sheet, with five parallel strands and one anti-parallel strand, surrounded 
by seven a helices (Fig. 1.3). Helix 5 is shorter in LFA-1 due to a seven amino acid 
deletion (Qu and Leahy, 1995). A Mgt/Mn2' binding site forms a crevice at the top 
of the domain (Lee et al., 1995b). 
Michishita et al. were the first to identify a divalent cation binding site in an I 
domain (Michishita et al., 1993). It has become apparent that an Asp-X-Ser-X- 
Ser... Thr... Asp motif (where X is any amino acid), conserved in all integrin I 
domains, and termed the metal ion-dependent adhesion site (MIDAS), coordinates 
the cation (Lee et at., 1995b). For example, for LFA-1 the side chains of Ser139, 
Ser14' and Asp239 directly coordinate the divalent cation while the Thr206 and Asp137 
side chains are hydrogen bonded to coordinating water molecules (Qu and Leahy, 
1995). 
(ii) The N-terminal repeats 
The seven N-terminal repeats of the a subunit have been predicted to fold 
into a seven bladed ß-propeller domain (Springer, 1997) (Fig. 1.4). This structure 
consists of seven ß-sheets arranged cylindrically around a central cavity. Each 0- 
sheet has four anti-parallel ß-strands, with strand 1 closest to the centre and strand 4 
on the outside of the structure. The angle of successive strands increases with 
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Figure 1.3 The crystal structure of the CD11a I domain 
A ribbon diagram of the CD11a I domain crystal structure with bound Mn2 (red), 
adapted from Qu and Leahy, 1995. The six ß-strands (yellow) are surrounded by 
seven a-helices (blue). 
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Figure 1.4 A model of an integrin ß-propeller domain 
A ribbon diagram of an integrin ß-propeller domain viewed from the top, adapted 
from the model of Springer, 1997. Each of the seven blades of the propeller is 
shown in a different colour. The putative Ca2+ binding sites are indicated by yellow 
circles. 
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respect to the central axis, with the result that the overall structure resembles a 
propeller with each ß-sheet representing one blade. The I domain is predicted to sit 
above the ß-propeller domain, connected by a hydrophilic hinge (Springer, 1997). 
Folding of the ß-propeller domain is reported to be dependent on association with the 
0 subunit (Huang and Springer, 1997; Lu et al., 1998). 
The three most C-terminal repeats (V-VII) or, in non-I domain containing 
integrins, the four most C-terminal repeats (IV-VII), each has a putative Ca2+ binding 
motif, resembling an EF hand sequence. The classical EF hand motif has a 13 
residue consensus sequence with the side chains at positions 1,3,5,7,9 and 12 
coordinating divalent cation. In the integrin sequence, however, a non-coordinating 
leucine occupies position 12. Another major difference between the integrin Ca2+ 
binding motif and the classical EF hands has been proposed by a model in which the 
integrin Ca2+ binding site is preceded and followed by a-strands rather than a-helices 
(Tuckwell et al., 1994). A recently described Ca2+ binding motif, present in the 
crystal structure of an alkaline protease, and termed a ß-hairpin loop, fits with this 
type of model and also with the ß-propeller model (Springer et al., 2000). 
On the ß-propeller model the putative Ca2+ binding sites lie close to each 
other on the lower surface of the domain (Springer, 1997). Interestingly, the 
mapping of a Ca2+ dependent monoclonal antibody (mAb) to discontinuous residues 
has provided support for the concept of the ß-propeller model. Although these 
residues are almost 100 amino acids apart in the a subunit primary structure, on the 
ß-propeller model they lie in adjacent loops on the lower surface of the domain and, 
notably, include a putative Ca2+ binding motif (Oxvig and Springer, 1998). 
Although, as discussed above, there is experimental evidence to support the 
ß-propeller model, circular dichroism (CD) studies on truncated a subunit proteins 
containing repeats IV-VII or III-VII indicate that the secondary structure consists of 
approximately 30% a-helix and 25% ß-strand (Baneres et al., 1998; Baneres et al., 
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2000). These data are not compatible with the ß-propeller model, which contains 
only ß-strands and coils. Further structural studies are therefore required. 
(iii) The C-terminal region 
Secondary structure predictions indicate that the extracellular C-terminal 
region of the a subunit folds into four to six ß-sandwich domains (Lu et al., 1998). 
1.1.2. b The beta subunit 
The 0 subunit consists of four extracellular regions, the boundaries of which 
are ill defined. A cysteine-rich region at the N-terminus is followed by a region of 
approximately 240 amino acids that is highly conserved in the different ß subunits as 
well as between species. This conserved region has homology with the a subunit I 
domain. The remainder of the extracellular portion of the ß subunit forms another 
cysteine-rich region. The cytoplasmic tail is approximately 50 amino acids long 
(Kishimoto et al., 1987; Law et al., 1987; Tamkun et al., 1986) (Fig. 1.2). 
(i) The N-terminal cysteine rich region 
The N-terminal region of the 0 subunit has homology to the repeat regions in 
plexins and to a region in semaphorins, therefore it has been named the PSI domain 
(Plexins, Semaphorins and Integrins) (Bork et al., 1999). This region has seven 
cysteine residues, six of which disulphide bond to each other, but the first forms a 
long range disulphide bond to link to the C-terminal cysteine rich region. It is 
predicted that the PSI domain contains two cc-helices, and is followed by four ß 
strands that form a 00 sandwich (Huang et al., 2000). 
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(ii) The ß I-like domain 
It has been proposed that the conserved region folds in a similar manner to 
the a subunit I domain (Lee et al., 1995b; Tozer et al., 1996), and a feature of the 
conserved region is a putative divalent cation binding motif, Asp-X-Ser-X- 
Ser.... Asp-X-Pro-Glu (where X is any amino acid), similar to the MIDAS motif. 
Recently, this region has been produced as an isolated protein which has 35% a- 
helix and 30% n-strand (Baneres et al., 2000), compatible with an I domain-like 
structure. Structural algorithms, however, have provided conflicting predictions on 
whether or not the conserved region does adopt an I domain-like fold (Lin et al., 
1997b; Tuckwell and Humphries, 1997). A model for the conserved region shows 
that, although it has some areas of uncertain topology, it is similar in structure to an I 
domain. The major difference between this model and an I domain are two long 
insertions, one between ß-strands 2 and 3 and the other between ß-strand 4 and cc- 
helix 4. This model is supported by antibody mapping experiments (Huang et al., 
2000). This region will therefore be referred to as the 0 I-like domain. 
(iii) The cysteine rich region 
C-terminal to the 0 I-like domain are four cysteine-rich repeats. 
Approximately 20% of the residues in these repeats are cysteines, indicating that the 
structure is likely to be rigid (Kishimoto et al., 1987; Law et al., 1987). It is 
predicted that this region forms approximately twenty ß-strands that fold into ßß 
sandwiches (Huang et al., 2000). 
1.1.2. c Association of integrin alpha and beta subunits 
Mutations in integrin genes that lead to inherited diseases often result in 
failure of heterodimer formation. Most of these mutations occur in the 0 I-like 
domain. Recently, these mutations have been mapped on a model of the 0 I-like 
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domain and many cluster around the MIDAS motif (Hogg and Bates, 2000). 
Mutation of the MIDAS motif itself does not affect heterodimer formation however. 
These results suggest that the MIDAS face, but not the MIDAS itself, forms an 
interface with the a subunit. 
It has been demonstrated that, although not adequate for cell surface 
expression, the N-terminal 301 amino acids of the (32 subunit are sufficient for 
association with the aL or aM subunit (Tan et al., 2000). This provides further 
evidence that the ß subunit interacts with the a subunit via the ß I-like domain. 
There is increasing support for a model of the integrin quaternary structure in which 
the ß subunit I-like domain contacts the ß-propeller domain in the a subunit. More 
specifically, there is evidence that the top of the ß I-like domain interacts with a loop 
between repeats 2 and 3 on the upper surface of the (3-propeller domain, with the 0 
subunit MIDAS motif orientated towards the loop. The opposite edge of the top of 
the 0 I-like domain is in close proximity with the bottom of the ß-propeller in ß- 
sheet 2, and the side of the domain in ß-sheet 4 (Humphries et al., 2000; Puzon- 
McLaughlin et al., 2000; Zang et al., 2000). The a subunit stalk region may also be 
involved in heterodimer formation, as mutation of this region disrupts interaction 
with the ß subunit (Lu et al., 1998; Zeller et al., 1998). A model of the integrin 
quaternary structure is shown in Figure 1.5. 
1.1.3 Ligand binding sites in integrins 
A number of sites in both the a and (3 subunits of integrins have been 
identified as ligand contact points. The three major regions are the I domain and the 
N-terminal repeats in the a subunit and the I-like domain of the 0 subunit. It is 
likely that all these sites must cooperate for binding to ligand to be of sufficient 
affinity to support cell adhesion. However, whether they combine to form the 
complete ligand binding face or operate in a sequential manner has yet to be 
unequivocally established. 
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Figure 1.5 A hypothetical model of the quarternary structure of an integrin 
The model shows the I domain sitting above the ß-propeller domain in the a subunit. 
The I-like domain of the ß subunit contacts the ß-propeller between repeats II and 
III. The MIDAS face on the I domain and ß I-like domain are indicated by `M'. 
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1.1.3. a The alpha subunit 
(i) The 1 domain 
I domains, when present, play an important role in ligand binding. The first 
inference that the I domain is important in regulating integrin function came when 
cloning of integrin a subunits revealed homology to the A domains of von 
Willebrand Factor, which had been shown to interact with ligand (Larson et al., 
1989). Further evidence came when the epitopes of both function blocking and 
activating mAbs were mapped to this domain (Champe et al., 1995; Landis et al., 
1993; Randi and Hogg, 1994). Binding of recombinant I domains to ligands 
demonstrated a direct role in ligand binding. For example, the I domain from LFA- 1 
has been shown to bind to ICAM-1 (Randi and Hogg, 1994), ICAM-2 (Edwards et 
al., 1998) and ICAM-3 (van Kooyk et al., 1996); the Mac-1 I domain binds to iC3b 
(Ueda et al., 1994), fibrinogen, ICAM-1 (Zhou et al., 1994), ICAM-2 (Xie et al., 
1995) and neutrophil inhibitory factor (Muchowski et al., 1994; Rieu et al., 1994); 
the aD02 I domain binds to VCAM-1 (Van der Vieren et al., 1999); the a, I domain 
binds collagen I, collagen IV and laminin (Calderwood et al., 1997); the a2 I domain 
binds collagens I, II, IV and XI (Kamata and Takada, 1994; Tuckwell et al., 1995; 
Tuckwell et al., 1996) and echovirus 1 (King et al., 1997). 
Mutation of any of the I domain MIDAS motif residues abolishes ligand 
binding (Edwards et al., 1995; Kamata et al., 1995; McGuire and Bajt, 1995; 
Michishita et al., 1993), demonstrating the critical role of the divalent cation in 
ligand binding. It has been suggested that the divalent cation bound to the I domain 
may directly participate in ligand binding by interacting with an acidic residue in the 
ligand. The crystal lattice of the aM I domain, in which the bound Mg2+ is 
coordinated by a glutamic acid side chain in an adjacent molecule, supports this idea 
(Lee et al., 1995b). All the known integrin ligands contain an acidic residue in their 
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binding motif, for example Glu34 in ICAM-1. Mutation of this residue in ICAM-1 
abolishes adhesion to the LFA-1 I domain (Stanley and Hogg, 1998). Another 
example is the triplet Gly-Glu-Arg in a peptide from collagen I, which is essential for 
binding of this peptide to the a2 I domain (Knight et al., 1998). The recent co- 
crystallisation of the a2 I domain complexed with a collagen peptide directly 
demonstrates that the Glu of the Gly-Glu-Arg motif coordinates Mg2+ bound to the I 
domain MIDAS motif (Emsley et al., 2000). However, this structure contradicts the 
evidence that ligand binding to the a2 I domain results in displacement of the 
divalent cation to form a divalent cation free ligand-I domain complex (Dickeson et 
al., 1997). 
Other residues that are essential for aL, am and a2 I domain binding to ligand 
are located on the surface of the I domain surrounding the MIDAS motif, indicating 
that this face contacts ligand (Edwards et al., 1998; Huang and Springer, 1995; 
Käpylä et al., 2000; Rieu et al., 1996; Smith et al., 2000a; Zhang and Plow, 1997). 
These results, obtained by mutagenesis, were confirmed by the co-crystallisation of 
the a2 I domain complexed with a collagen peptide (Emsley et al., 2000). The 
critical residues are not well conserved, therefore may provide specificity for ligand 
binding. In support of this, mutational analysis has identified additional residues on 
the MIDAS face of the a1, I domain required for ICAM-2 binding in comparison to 
ICAM-1 binding (Edwards et al., 1998). For the collagen binding I domains, 
however, these residues are invariant suggesting that these I domains bind collagen 
in a similar manner (Emsley et al., 2000). 
(ii) The N-terminal repeats of I domain containing integrins 
A chimeric form of LFA-1, in which the murine I domain replaces the human 
I domain, does not bind human ICAM-1 (Edwards et al., 1995), and LFA-1 from 
which the I domain has been removed does not bind ICAM-1 (Leitinger and Hogg, 
2000; Yalamanchili et al., 2000). These results demonstrate that the I domain is 
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essential for LFA-1 binding. Intact LFA-1 mediates stable adhesion to lipid bilayers 
containing ICAM-1 under flow conditions. In the same system, however, a GPI 
linked LFA-1 I domain supports rolling adhesion (Knorr and Dustin, 1997). Other 
sites in the intact integrin must therefore cooperate with the I domain to allow stable 
adhesion to ligand. Another region of the N-terminal of the LFA-1 a chain, repeated 
domains V and VI, has been shown to bind ICAM-1 in an in vitro translation system 
(Stanley et al., 1994). In this study it was observed that binding to ICAM-1 was 
much stronger when the protein was extended to include the I domain. A role for 
these repeated domains in ligand binding has also been demonstrated for a2. 
Recombinant a2 I domain binding to collagen is enhanced when the recombinant 
protein is extended to include the first putative Cat+-binding motif. This effect is 
prevented by mutation of the Cat+-binding motif (Dickeson et al., 1997). For Mac-1, 
iC3b, which binds to the isolated aM I domain (Ueda et al., 1994), also binds to Mac- 
1 from which the I domain has been deleted (Yalamanchili et al., 2000). These 
results indicate that, although the I domain is a major ligand binding site in those 
integrins that contain them, sequences outside the I domain also contribute to 
binding. 
(iii) The N-terminal repeats of integrins without I domains 
In integrins that do not have an I domain, the N-terminal repeat domains 
appear to be the main ligand binding site in the a subunit. Many of the mutations of 
the repeated domains that diminish ligand binding lie in loops on the upper surface of 
the ß-propeller model. For example, for a5 residues in the 2-3 loop of repeat III (Irie 
et al., 1995), loops in repeat II and IV of a4 (Irie et al., 1997), the 4-1 loop between 
repeats II and III of a5 (Mould et al., 1998), the boundary of repeat I and II and the 4- 
1 loop at the boundary of repeats II and III of a3 (Zhang et al., 1999), residues 184- 
193 in the 2-3 loop in repeat III and residue 224 of the 4-1 loop between repeats II 
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and III of ate, (Kamata et al., 1996; Tozer et al., 1999) have all been shown to be 
important for interaction with ligand. 
A number of early studies indicated that the putative cation binding sites in 
the N-terminal repeats directly interact with ligand (D'Souza et al., 1990; D'Souza et 
al., 1991; Masumoto and Hemler, 1993). These sites lie on the bottom of the 13- 
propeller model, on the opposite side of the domain to the predicted ligand binding 
surface. Therefore, if the ß-propeller model is correct, it is difficult to conceive how 
ligand can bind to both sides of the domain. Integrins in which the putative Ca2+ 
binding sites in the repeat domains are mutated are often not expressed on the cell 
surface (Basani et al., 1996; Gidwitz et al., 2000). Conservative mutations, however, 
allow expression and indicate that these sites may not directly bind ligand but may be 
involved in adhesion strengthening (Pujades et al., 1997). 
It is of interest that VCAM-1, which binds to the non-I domain integrins a4(3, 
and a4ß,, also binds to the I domain of aD02 (Van der Vieren et al., 1999). The Asp40 
residue of VCAM-1, which is crucial for binding to a4ß, and a4ß,, is also essential 
for binding to the aD(32 I domain, suggesting a common mechanism for ligand 
binding in I domain containing and non-I domain containing integrins. 
1.1.3. b The beta subunit 
Other than the I domain, the only region of an integrin to be shown to directly 
bind ligand is the ß I-like domain. A recombinant ß3 I-like domain binds to 
fibrinogen and to an RGD containing peptide (Cierniewski et al., 1999). A peptide 
corresponding to the C-terminus of the fibrinogen y chain does not bind to the I-like 
domain, but to a distinct site elsewhere in al13 (Cierniewski et al., 1999). 
Mutation of the MIDAS-like motif residues Asp134, Ser'36, Asp232 and Glu23S 
in (32 prevents LFA-1 and Mac-i binding to their ligands (Bajt et al., 1995; Goodman 
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and Bajt, 1996). Homologous residues in other ß subunits are also critical for ligand 
binding (Bajt and Loftus, 1994; Lin et al., 1997b; Puzon-McLaughlin and Takada, 
1996; Tozer et al., 1996). Peptides covering the ß subunit Asp-X-Ser-X-Ser motif 
inhibit ligand binding and have been shown to directly bind to ligands and RGD 
containing peptides (D'Souza et al., 1994; Liu et al., 1997). 
a4ß1 does not bind to mucosal addressin cell adhesion molecule 
(MAdCAM)-1, whereas a, ß, does. The region of the ß subunit involved in 
determining this specificity of ligand binding is the putative I domain, as swapping 
this region of ßl for that of ß, enables the chimeric aaß, n to bind to MAdCAM-1 
(Tidswell et al., 1997). This is also the case for other ß subunits: when a highly 
divergent sequence in ß, is replaced with the corresponding residues of ß3 the 
mutated a. 431 integrin recognises av03 ligands (Takagi et al., 1997), and a similar 
region of ß3 substituted into ßs allows binding to fibrinogen (Lin et al., 1997a). 
Although a recombinant aM I domain has been shown to bind iC3b (Ueda et 
al., 1994), cells transfected with the aM or the ß2 subunit individually do not bind to 
iC3b. However, cells transfected with aM and a truncated form of the ß2 subunit 
(residues 23-457), containing the ß I-like domain, bind to iC3b in a manner similar to 
the complete aMf32 heterodimer (Goodman et al., 1998). These results imply that the 
affinity of the interaction of the individual subunits is not high enough to support cell 
binding, and that the I-like domain of the (32 subunit cooperates with the aM subunit 
for high affinity binding. 
1.1.4 Conformational changes in integrins 
A change in the shape of integrins upon activation has been demonstrated by 
fluorescence resonance energy transfer (Sims et al., 1991) and electron microscopy 
(Du et al., 1993), but details of the structural changes that occur are not yet known. 
Three pieces of evidence indicate that one of the changes that occurs is movement of 
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the a subunit relative to the 1 subunit. A mAb epitope, which is located in the stalk 
region of the ß, subunit, is masked when complexed with the a5 subunit but revealed 
upon ligand binding (Tsuchida et al., 1998). A second mAb, which recognises an 
epitope spanning the aL and ß2 subunits, preferentially recognises activated LFA-1 
(Zang et al., 2000). Finally, electron microscopy shows a separation of the a and ß 
chain globular heads upon binding ligand mimetic peptides (Hantgan et al., 1999). 
The Mac-1 activation dependent epitope recognised by mAb CBRM1/5 has 
been mapped to the I domain, close to the MIDAS motif, suggesting that a 
conformational change in the I domain also occurs (Oxvig et al., 1999). For some 
time there has been evidence from crystallographic studies for different 
conformations of the I domain. Lee et al. showed that the structure of the am I 
domain crystallised in the presence of Mg2+ differed from that crystallised in the 
presence of Mn" (Lee et al., 1995a; Lee et al., 1995b). In the former structure a Glu 
side chain from a neighbouring I domain in the crystal contributed to the 
coordination of the Mg` ion. It was proposed that the Glu would normally be 
donated by ligand and that these structures therefore represented the active (ligand- 
bound) and inactive (unliganded) conformation respectively. Others, however, did 
not find any major differences in structure (Baldwin et al., 1998; Qu and Leahy, 
1995; Qu and Leahy, 1996), consequently there has been some debate on whether or 
not there is an "active" conformation of the I domain, or whether it is a crystal lattice 
artefact (Baldwin et al., 1998; Liddington and Bankston, 1998). The recently solved 
structure of the a2 I domain complexed with a peptide from collagen resolves this 
issue by demonstrating that a ligand-induced conformational change does occur 
(Emsley et al., 2000). Moreover, the differences between the two forms of the aM I 
domain are nearly identical to the changes seen between unliganded and collagen- 
bound a2 I domain. The alterations which occur upon the shift from the inactive to 
the active conformation include loss of direct coordination of the metal ion by an 
Asp and the formation of a direct bond to a Thr and Glu from a neighbouring 
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molecule (or ligand) providing the sixth metal coordination site. These 
modifications in cation coordination result in significant changes in the conformation 
of the MIDAS face and propagate through to the opposite face of the domain, 
altering the position of the C-terminal a-helix (Emsley et al., 2000; Huth et al., 2000; 
Li et al., 1998). 
Evidence for the functional importance of changes in I domain structure has 
been obtained by mutagenesis. Substitution of residues in the hydrophobic core of 
the I domain can activate ligand binding (Huth et al., 2000; Li et al., 1998; Shimaoka 
et al., 2000; Xiong et al., 2000). Mutations on the bottom of the I domain (i. e. on the 
opposite side of the molecule to the MIDAS face) also modulate activation (Oxvig et 
al., 1999; Zhang and Plow, 1996). The fungal metabolite lovastatin binds to a 
hydrophobic pocket on the bottom of the LFA-1 I domain and locks it in its inactive 
conformation. Lovastatin thus acts as a small molecule antagonist of LFA-1, 
inhibiting binding to ICAM-1 without binding to the MIDAS face (Kallen et al., 
1999). These results suggest the bottom of the I domain is involved in allosteric 
control of ligand binding to the MIDAS face. 
There are several lines of evidence which support the idea that the cysteine 
rich region in the I subunit is involved in regulating adhesion. Firstly, the epitopes 
of a number of activation dependent mAbs have been located in this region (Du et 
al., 1993; Huang et al., 2000; Stephens et al., 1995). Secondly, chimeric LFA-1 in 
which the P. subunit cysteine-rich region is replaced with that of the (31 subunit is 
constitutively active for binding ICAM-1 (Douglass et al., 1998). Finally, a single 
amino acid substitution in the cysteine rich region of 03 renders aßß3 constitutively 
active for ligand binding (Kashiwagi et al., 1999). These results suggest that the 
cysteine rich region must be involved in a change in integrin conformation upon 
activation. 
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1.1.5 LFA-1 activation 
Integrin activation is tightly regulated by a complex interplay between cation 
binding, signalling events, associations with the cytoskeleton and interaction with 
other accessory molecules. On resting cells LFA-1 is in an inactive form which is 
unable to mediate stable binding to the ICAMs. Ligation of cell surface receptors, 
such as the T cell receptor (Dustin and Springer, 1989), the costimulatory molecule 
CD28 (Shimizu et al., 1992) or chemokine receptors (Campbell et al., 1998) 
generates intracellular signals that lead to activation of LFA-1-mediated cell 
adhesion. This is termed "inside-out" activation. Artificial agents, such as phorbol 
esters, which are activators of protein kinase C (PKC), can be used as a means to 
induce intracellular signalling leading to LFA-1 activation. LFA-1 can also be 
activated by "outside-in" mechanisms, for instance by the addition of Mn 2+ or Mg2+ 
in the presence of EGTA to chelate Ca 2+ (Dransfield et al., 1992; Stewart et al., 
1996). A number of mAbs directed against either the a or ß subunit of LFA-1 can 
directly cause activation (Landis et al., 1993; Stephens et al., 1995). Both the 
divalent cations and the activating mAbs bind to the extracellular portion of LFA-1, 
thereby inducing a conformational change that reveals or forms a ligand contact site 
and unmasks the epitope recognised by mAb 24. There is evidence that activation 
from the outside increases the affinity of LFA-1 for its ligands, but that inside-out 
activation does not (Stewart et al., 1996). Therefore, it has been proposed that 
inside-out activation involves an increase in the avidity of LFA-1 interaction 
(Stewart et al., 1996). The factors reported to contribute to LFA-1 activation are 
discussed below and are summarised in Figure 1.6. The mechanisms of LFA-1 
activation constitute the subject matter of this thesis, and will be discussed in detail 
in the following chapters. 
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Figure 1.6 Summary of the factors that are reported to contribute to LFA-1 
activation 
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1.1.5. a Divalent cations 
Integrin binding to ligand requires physiological concentrations of divalent 
cations. Mg2+ and Mn" induce activation of LFA-1 and adhesion to ligand, 
presumably by inducing a conformational change, (Dransfield et al., 1992). In 
contrast, Ca2+ inhibits LFA-1 adhesion (Dransfield et al., 1992). These effects of 
divalent cations on integrin-mediated cell adhesion may be a consequence of cation 
binding to the I domain MIDAS motif. Evidence for this comes from the fact that 
the cation binding properties of recombinant I domain, and the cation-dependency of 
ligand binding to the recombinant I domain or intact integrin, are similar (Michishita 
et al., 1993; Ueda et al., 1994). Mutations in the I domain which abolish cation 
binding also abolish ligand binding (McGuire and Bajt, 1995; Michishita et al., 
1993). 
Removal of Ca2+ activates integrin adhesion (Dransfield et al., 1992), and 
also weakens the association of integrin a and ß subunits (Dustin et al., 1992). 
Putative Ca2+ binding motifs are predicted to lie close to one another on the bottom 
of the ß-propeller domain (Springer, 1997) (see Fig. 1.4), therefore Ca 2+ may 
regulate the association of this region with the ß subunit and thereby regulate ligand 
binding. As discussed in Chapter 1.1.2. c, there is evidence that the ß-propeller does 
interact with the 0 subunit I-like domain. 
1.1.5. b The LFA-1 cytoplasmic tail and cytoskeletal interactions 
There is growing evidence that in its non-active state LFA-1 is tethered to the 
cytoskeleton and upon cell activation these cytoskeletal associations are altered, 
allowing LFA-1 to move in the membrane (Kucik et al., 1996; Zhou and Li, 2000). 
It has been demonstrated that deletion of the entire a subunit or ß subunit 
cytoplasmic tail results in constitutively active LFA-1 (Tan et al., 2000; van Kooyk 
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et al., 1999). The lack of the cytoplasmic tails means that mobility of the integrin 
cannot be constrained by the cytoskeleton and so these forms of the integrin cluster, 
facilitating adhesion. Mutation of the membrane proximal residues, KVGFFKR in 
the a subunit and DLRE in the f subunit, also result in constitutively active LFA-1 
(van Kooyk et al., 1999). It is thought that these residues form a salt bridge between 
the subunits that keeps the integrin in its inactive state (Hughes et al., 1996). 
Mutation of amino acids more C-terminal in the ß2 tail results in LFA-1 that cannot 
bind ICAM-1 (Hibbs et al., 1991). 
Despite much research on the subject it is still unclear how LFA-1 interacts 
with the cytoskeleton and how these associations are altered upon cell activation. 
The cytoskeletal proteins talin (Sampath et al., 1998), a-actinin (Sharma et al., 1995) 
and filamin (Sharma et al., 1995) all bind to a peptide corresponding to the ß2 tail. 
However, convincing evidence that these associations occur directly in vivo is 
lacking. 
1.1.5. c Signalling 
The signalling events involved in the activation of LFA-1 are still poorly 
understood, although there is a growing list of second messengers that are reported to 
alter LFA-1 activity. There is recent evidence that upon activation LFA-1 associates 
with specialised membrane regions known as lipid rafts, which act as platforms for 
signalling molecules and adapter proteins (Krauss and Altevog, 1999). 
It has been known for many years that activation of protein kinase C (PKC) 
with phorbol esters triggers LFA-1 mediated adhesion. More recently it has been 
demonstrated that the conventional PKC isoforms, a, 01 and 011 and the novel PKC, 
PKCS, but not the atypical PKCý, activate LFA-1 (Katagiri et al., 2000). The 
receptor for activated protein kinase C (Rackl) associates with the integrin 02 subunit 
upon phorbol ester stimulation of the lymphoblastoid cell line, JY (Liliental and 
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Chang, 1998). It is thought that this interaction serves to recruit activated PKC to 
sites of cell adhesion, and may thereby regulate LFA-1-cytoskeleton interaction. 
Macrophage-enriched myristoylated alanine-rich C kinase substrate (MacMARCKS) 
is a PKC substrate that is involved in regulation of LFA-1 adhesion in macrophages. 
Phosphorylation of MacMARCKS by PKC results in LFA-1 diffusion in the 
membrane and induces LFA-1-mediated adhesion (Zhou and Li, 2000). It is 
speculated that MacMARCKS is involved somehow in maintaining a cytoskeletal 
complex that restrains LFA-1 movement and that this restraint is released upon 
MacMARCKS phosphorylation. Another protein downstream of PKC is SH2- 
containing inositol phosphatase (SHIP), overexpression of which enhances phorbol 
ester-induced LFA-1 activation by an as yet unidentified pathway (Rey-Ladino et al., 
1999) 
Cytohesin-1 is a guanine nucleotide exchange factor (GEF) for ADP- 
ribosylation factor (ARF) GTPases that is expressed predominantly in 
haematopoietic cells (Meacci et al., 1997). It has a central SECT domain that 
directly interacts with the integrin ß2 subunit, and a C-terminal PH domain that binds 
to phophatidylinositol-(3,4,5)-trisphosphate (PIP3) (Kolanus et al., 1996; Nagel et al., 
1998). Activation of phosphatidylinositol-3-OH kinase (P13-kinase) generates PIPS, 
resulting in recruitment of cytohesin-1 to the membrane, where it interacts with the 
integrin (32 subunit cytoplasmic tail. This interaction induces cell spreading through 
the ARF-GEF activity of cytohesin-1, thus activating LFA-1-mediated adhesion 
(Geiger et al., 2000; Nagel et al., 1998). The small GTPase H-Ras has been shown 
to lie downstream of chemokine receptors and, similarly to Rac, activates LFA-1 
adhesion through P13-kinase (Katagiri et al., 2000; Tanaka et al., 1999). Another 
small GTPase, Rap-1, is activated following ligation of the T cell receptor (TCR) or 
CD31 and also lies in the pathway to LFA-1 activation (Katagiri et al., 2000; 
Reedquist et al., 2000). 
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1.1.5. d Lateral associations 
Lateral associations of integrins with other membrane proteins also modulate 
integrin activity. Molecules that have been shown to form lateral associations with 
integrins are either tetraspans or members of the immunoglobulin superfamily (IgSF) 
(Hemler, 1998). The tetraspans are thought to interact with the integrin a subunits 
and to recruit signalling proteins to the complex. They have been implicated in the 
control of cell migration. The only tetraspan shown to be associated with LFA-1 is 
CD82 (Shibagaki et al., 1999). T cell stimulation upregulates CD82 expression 
leading to association with LFA-1 and stimulation of LFA-1 mediated adhesion. 
DNAM-1 (CD226) is a member of the IgSF that associates with LFA-1 in stimulated 
T cells (Shibuya et al., 1999). This association requires the PKC-mediated 
phosphorylation of Ser329 in DNAM-1. Engagement of LFA-1 then augments 
tyrosine phosphorylation of the protein tyrosine kinase Fyn. Fyn is thought to be 
responsible for phosphorylation of Tyr322 of DNAM-1 and this enables DNAM-1 to 
transduce signals which initiate NK or T cell cytotoxic responses against target cells. 
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1.2 THE INTERCELLULAR ADHESION MOLECULES 
To date five Intercellular Adhesion Molecules (ICAMs) have been identified, 
namely ICAM-1 (CD54), ICAM-2 (CD102), ICAM-3 (CD50), ICAM-4 (LW, 
CD242), and ICAM-5 (telencephalin) (Fig. 1.7). Each of these proteins has a 
distinct cell and tissue distribution. The ICAMs are members of the immunoglobulin 
Supergene family (IgSF) and are type I integral membrane glycoproteins composed 
of immunoglobulin (1g)-like extracellular domains, a single spanning transmembrane 
region, and a short C-terminal cytoplasmic tail (Simmons et al., 1988; Staunton et al., 
1988). The N-terminal domain of all five ICAMs contains a ligand binding site for 
the leukocyte integrin LFA-1. A Glu residue, conserved in all but ICAM-4, is 
critical for this interaction. As the cytoplasmic tails of the ICAMs have low identity 
they may have different associations and deliver distinct signals within the cell. 
1.2.1 ICAM-1 
ICAM-1 was the first ligand to be described for LFA-1 (Marlin and Springer, 
1987; Rothlein et al., 1986). It is a 55 kDa polypeptide with five Ig-like extracellular 
domains. Differential glycosylation of the eight potential N-linked glycosylation 
sites produces heterogeneity in molecular weight of 80-115 kDa, depending on cell 
origin. In non-inflammatory situations ICAM-1 is constitutively expressed at low 
levels on various cells of haematopoietic and non-haematopoietic origin, including 
leukocytes, endothelium, epithelium and fibroblasts. Inflammatory mediators, such 
as the cytokines interleukin (IL)-10, tumour necrosis factor (TNF)-a, and interferon 
(IFN)-y, initiate a transcription-dependent upregulation of ICAM-1 cell surface 
expression. The gene encoding ICAM-1 is located on chromosome 19 band p13.3- 
13.4 (Trask et al., 1993) and has a complex promoter containing consensus 
sequences for multiple transcription factors, including SP-1, AP-1, AP-2, AP-3, Ets- 
1 and NF-KB. The signal transduction pathways and transcription complexes that 
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Figure 1.7 The ICAM family of adhesion molecules 
A schematic diagram of the domain structure of the ICAMs. The domains to which 
their ligands bind are indicated. 
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regulate ICAM-1 expression are complex and display cell type and stimulus 
specificity (reviewed in (Roebuck and Finnegan, 1999)). ICAM-1 can also transmit 
signals into the cell (see Chapter 1.3.2. d). 
A form of ICAM-1 (sICAM-1), thought to be composed of the five 
extracellular domains of the molecule, is secreted by activated leukocytes and 
endothelium. It is found in the serum of healthy individuals at a concentration of 
100-200ng/ml (Rothlein et al., 1991; Seth et al., 1991) and has been reported to be 
elevated in inflammation, infection and cancer. No alternative splice forms of 
ICAM-1 mRNA have been observed, therefore sICAM-1 is thought to be the result 
of protease-mediated shedding. sICAM-1 retains the ability to bind LFA-1, and it 
has been speculated that by acting as a competitor it may inhibit cell-cell adhesion 
and "switch off' the immune response (reviewed in (Gearing and Newman, 1993)). 
1.2.2 ICAM-2 
ICAM-2 (CD102) is encoded by a gene located on chromosome 17 q23-q25 
(Sansom et al., 1991). It has a 28 kDa polypeptide backbone, but glycosylation of 
the six N-linked sites produces a 55-65 kDa protein. The extracellular portion of 
ICAM-2 forms two Ig-like domains, which are most homologous to the two N- 
terminal domains of ICAM-1, showing 34% amino acid identity (Staunton et al., 
1989a). ICAM-2 is constitutively expressed by lymphocytes and monocytes, but not 
neutrophils, as well as vascular endothelium (de Fougerolles et al., 1991) and 
platelets (Diacovo et al., 1994). In contrast to ICAM-1, expression is down- 
regulated at the transcriptional level on endothelium by the inflammatory cytokines 
IL-13 and TNF-a (McLaughlin et al., 1998). 
It had been postulated that ICAM-2 had a role in lymphocyte recirculation, 
but data from ICAM-2 knockout mice does not support this. Rather, these mice 
exhibit elevated and prolonged eosinophil accumulation in allergic lung interstitium, 
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with a resultant airway hyerresponsiveness (Gerwin et al., 1999). Consistent with 
the fact that megakaryocytes express ICAM-2 but not ICAM-1 or ICAM-3 (Diacovo 
et al., 1994), the ICAM-2 deficient mice have a reduced number of these cells in the 
bone marrow (Gerwin et al., 1999). There is evidence that on NK target cells 
ICAM-2 and the cytoskeletal protein ezrin become concentrated in the uropod, and 
thus the target cells become sensitive to NK activity (Helander et al., 1996). 
ICAM-2 is thought to bind directly to the ERM (Ezrin/Radixin/Moesin) family of 
proteins via a positively charged amino acid cluster in the membrane proximal region 
of the cytoplasmic tail (Yonemura et al., 1998). 
1.2.3 ICAM-3 
ICAM-3 was cloned in 1992/93 by three groups (de Fougerolles et al., 1993; 
Fawcett et al., 1992; Vazeux et al., 1992). It has a core polypeptide of 57 kDa 
comprising a 37 amino acid cytoplasmic tail, 25 amino acid transmembrane region 
and 456 amino acid extracellular domain. Cell surface ICAM-3 has a molecular 
mass between 116 and 140 kDa, depending on the degree of glycosylation of the 15 
potential N-linked glycosylation sites. Like ICAM-1, ICAM-3 has five extracellular 
Ig-like domains and is encoded by a gene located on chromosome 19 p13.3-13.2 
(Bossy et al., 1994). The extracellular domains of ICAM-3 share 48% amino acid 
identity with ICAM-1 and 31% with ICAM-2, however there is little conservation of 
the cytoplasmic and transmembrane domains. ICAM-3 has a 37 amino acid 
cytoplasmic tail with five serine and two tyrosine residues, whereas ICAM-1 and 
ICAM-2 do not contain serines and have only one tyrosine. ICAM-3 is 
constitutively expressed at high levels on all leukocytes but, unlike ICAM-1 and 
ICAM-2, is not expressed on endothelium. LFA-1 (Fawcett et al., 1992) and (XD P2 
(Van der Vieren et al., 1995) bind to ICAM-3, but Mac-1 and p150,95 do not (de 
Fougerolles et al., 1995). 
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Recently, DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN, CD209) 
was identified as a receptor for ICAM-3 (Geijtenbeek et al., 2000). Expression of 
DC-SIGN is restricted to dendritic cells (DC). It is a 44 kDa type II transmembrane 
protein with a 40 amino acid N-terminal cytoplasmic tail, a transmembrane domain, 
a region containing seven complete and one incomplete repeat sequences and a C- 
terminal region with homology to Cat+-dependent lectins. DC-SIGN adhesion to 
ICAM-3 is Ca 2-dependent and can be inhibited by mannose, and, therefore, is likely 
to be mediated by the lectin domain. DC-SIGN, rather than the (32 integrins, 
mediates DC interaction with resting T cells, which express high levels of ICAM-3. 
This interaction allows T cell proliferation (Geijtenbeek et al., 2000). 
There is some evidence that ligation of ICAM-3 transmits signals into the cell 
that generate a Ca2+ flux and tyrosine phosphorylation of a number of proteins (Juan 
et al., 1994). Although tyrosine phosphorylation of ICAM-3 occurs (Skubitz et al., 
1995), it is phosphorylation of Ser489, potentially by PKC-6, that is crucial for 
ICAM-3 signalling (Hayflick et al., 1997). 
Leukocytes become polarised upon ligation of ICAM-3 or in response to 
chemoattractants, such as IL-8 and fMLP. Coincidentally, there is a myosin 
dependent redistribution of ICAM-3 to the uropod at the rear of the cell. ICAM-3 in 
the uropod colocalises with the ERM protein moesin, and biochemical studies 
indicate that moesin interacts directly with the ICAM-3 cytoplasmic tail (Alonso- 
Lebrero et al., 2000; Campanero et al., 1994; Serrador et al., 1997). One function of 
ICAM-3 in the uropod appears to be to capture other cells. This recruitment of 
leukocytes provides a mechanism for enhancing transendothelial migration (del Pozo 
et al., 1997). 
A circulating form of ICAM-3 (sICAM-3) is found in the plasma of healthy 
individuals at concentrations up to 360 ng/ml. These levels are elevated in 
inflammatory conditions. sICAM-3 is released by proteolytic cleavage of cell 
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surface ICAM-3 upon activation of neutrophils (del Pozo et al., 1994; Martin et al., 
1995). 
No information on ICAM-3 function can be obtained from knockout mice as 
murine ICAM-3 has not been identified. Analysis of the region of murine 
chromosome 9, where the ICAM genes are clustered, has failed to identify an ICAM- 
3 gene (Kilgannon et al., 1998). 
1.2.4 ICAM-4 
ICAM-4, or LW (Landsteiner-Wiener), is a 42 kDa member of the ICAM 
family that is expressed on erythrocytes. The two extracellular Ig-like domains of 
ICAM-4 have approximately 30% identity with domains 1 and 2 of ICAM-1,2 and 3 
and contain four potential N-glycosylation sites (Bailly et al., 1994). Like ICAM-1, 
ICAM-4 binds to LFA-1, Mac-1 and perhaps to p150,95 (Bailly et al., 1995; 
Hermand et al., 2000). Whether these interactions occur in vivo, however, is 
uncertain. 
1.2.5 ICAM-5 
ICAM-5, also known as telencephalin, is a 130 kDa glycoprotein expressed 
exclusively on neurones. It has nine Ig-like domains, with 14 potential glycosylation 
sites, a transmembrane region and a 61 amino acid cytoplasmic tail (Yoshihara et al., 
1994). The ICAM-5 gene is located in the ICAM cluster on chromosome 19p13.2, 
between the ICAM-1 and ICAM-3 genes (Kilgannon et al., 1998). 
Domain 1 of ICAM-5 binds to LFA-1 and it is speculated that this interaction 
mediates adhesion of LFA-1 expressing microglia or leukocytes with telecephalic 
neurones (Mizuno et al., 1997; Tian et al., 2000a; Tian et al., 1997). Unlike LFA-1 
interactions with the other members of the ICAM family, LFA-1 binding to ICAM-5 
is cell activation and divalent cation independent (Mizuno et al., 1997). Domain 1 of 
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ICAM-5 can also bind to domains 4 and 5 to promote homophilic interactions (Tian 
et al., 2000b). Homophilic interactions mediate binding between neurones and 
promote dendritic outgrowth. There is also some evidence that domain 6 of ICAM-5 
binds to an as yet uncharacterised ligand (Tian et al., 2000a). 
1.2.6 Structure of the ICAMs 
Primary sequence analysis of ICAM-1 predicted that each extracellular 
domain had an immunoglobulin (1g)-like structure with seven anti-parallel ß strands 
(A to G) linked by a disulphide bond (Simmons et al., 1988; Staunton et al., 1988). 
A characteristic of the IgSF members that bind to integrins is the presence of an 
additional disulphide bond, which links the BC loop to the end of the F strand at the 
top of the domain. ICAM-1 and ICAM-3 have five Ig-like extracellular domains, 
ICAM-2 and ICAM-4 have two, and ICAM-5 has nine (Fig 1.7). These domains are 
numbered sequentially from the amino terminal domain. Electron microscopic 
studies with a soluble form of ICAM-1 composed of the five extracellular domains 
show that these domains are aligned in a linear fashion and have a bend 
approximately two fifths along the molecule, probably between domains 3 and 4 
(Kirchhausen et al., 1993). This bend is not seen in ICAM-3 (Sadhu et al., 1994). 
The crystal structures of domains 1 and 2 of ICAM-1 and ICAM-2 have now 
been solved (Bella et al., 1998; Casasnovas et al., 1997; Casasnovas et al., 1998b). 
The structure of domains 1 and 2 of ICAM-1 is depicted in Figure 1.8. Domain 1 of 
both ICAM-1 and 2 is a ß-sandwich composed of two sheets, one containing the A', 
G, F and C strands and the other the A, B, E and D strands. The presence of both an 
A' and D ß-strand means that domain 1 belongs to the Intermediate 1 (I1) class of 
immunoglobulin domains. Unlike the typical I-set domains, it lacks the short C' 
strand and instead the C strand runs directly into the CD loop that connects to the D 
strand. G1u34 of ICAM-1 (and G1u37 in ICAM-2) is critical for binding to LFA-1. 
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amain 1 
Domain 2 
Figure 1.8 The crystal structure of domains 1 and 2 of ICAM-1 
A ribbon diagram of the crystal structure of ICAM-1 domains 1 and 2. The ß-strands 
are shown in red, a-helix in blue, the disulphide bonds in green and the N-linked 
carbohydrates in yellow. This figure is adapted from Casasnovas et al., 1998b. 
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This is the last residue in the C strand and the surrounding residues form a flat 
integrin binding surface, the rigidity of which is maintained by a hydrogen bonding 
network. 
Domain 2 lacks aD strand, therefore was originally classified as a constant 2 
(C2)-set Ig domain, but the presence of an A' strand has led it to be re-classified as 
an 12-set domain (Casasnovas et al., 1998b). ICAM-2 has an unusually long C'E 
loop compared to ICAM-1 and to other 12 and C2 set domains. The prominent FG 
loop of domain 2 cradles domain 1. In ICAM-2, hydrophobic areas at the bottom of 
domain 1 and the top of domain 2 are closely associated and, together with the 
hydrogen bonding network between the A', G and F strands in domain 1 and the FG 
and BC loops in domain 2, may limit interdomain flexibility. For ICAM-1, the 
hydrogen bonding network is more limited and, therefore, interdomain flexibility 
may be greater than for ICAM-2. Domain 1 is rotated 152° and has a bend of 35° in 
relation to domain 2 for ICAM-2, and at 170° with a bend of 30° for ICAM-1. Thus 
strand C in domain 1, which contains the LFA-1 binding site, is orientated away 
from the membrane. 
ICAM-1 has no glycosylation sites in domain 1 but has four N-linked 
glycosylation sites in domain 2, two near the top of the domain, which may limit 
interdomain movement, and two near the bottom of the domain. Six N-linked 
glycosylation sites are present in ICAM-2, three in each domain. The three 
glycosylation sites in domain 1 are circumferential to the putative LFA-1 binding site 
around G1u37. The three sites in domain 2 are described as forming a tripod that is 
predicted to orientate the molecule with respect to the cell surface. ICAM-3 also has 
glycosylation sites in domain 1. The lack of glycosylation of ICAM-1 domain 1 may 
therefore explain why ICAM-1 is a more promiscuous receptor than these other two 
members of the family. 
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ICAM-1 contains a dimerisation motif in its transmembrane region that 
partially contributes to the formation of ICAM-1 dimers on the cell surface (Reilly et 
al., 1995). However, it is likely that dimerisation through the extracellular domains 
also occurs. Consistent with this, ICAM-1 exists as a dimer in the crystal, with the 
face formed by the BED strands of domain 1, and, in particular Vals' in the E strand, 
forming the contact between the monomers. Domain 5 of ICAM-1 is also implicated 
in dimer formation (Miller et al., 1995). Vals' is not conserved in ICAM-2 and 
ICAM-2 is only a two domain molecule, which is likely to explain why ICAM-2 
does not dimerise (Reilly et al., 1995). Dimerisation of ICAM-1 enhances the 
affinity for LFA-1, but whether this is due to the ICAM-1 dimer interacting with two 
sites on the same LFA-1 molecule or with two LFA-1 molecules is unknown. 
1.2.7 Ligands for ICAM-1 
1.2.7. a LFA-1 
LFA-1, the most widely distributed member of the Leukocyte Integrin family, 
was the first receptor to be described for ICAM-1 (Marlin and Springer, 1987). It is 
also the receptor for the other members of the ICAM family. It is described in detail 
in Chapter 1.1.1. a. 
1.2.7. b Mac-1 
Another leukocyte integrin, Mac-1, also binds to ICAM-1 (Diamond et al., 
1990). Like LFA-1, the I domain of Mac-1 contains a binding site for ICAM-1 
(Diamond et al., 1993). However, LFA-1 and Mac-1 do not interact with ICAM-1 in 
the same way. Chimeric and domain deletion molecules indicate that domain 3 is 
critical for Mac-1 binding, as domains 1 and 2 can be deleted without effect 
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(Diamond et al., 1991). Asp229 in domain 3, which corresponds to G1u34 of domain 1, 
is critical for binding to Mac-1 (Diamond et al., 1991). 
The extent of N-linked glycosylation in ICAM-1 domain 3 is important in the 
regulation of Mac-1 binding. Mutation of either of the two glycosylation sites, or 
truncation of the sugars, enhances binding. fMLP-stimulated neutrophils bind to 
ICAM-1 with large carbohydrate side chains through LFA-1. However, binding to 
non-glycosylated forms, or those with simple side chains, is via Mac-1. 
Glycosylation of ICAM-1 is cell-type specific, therefore extent of glycosylation may 
be a method of controlling where and which leukocytes bind (Diamond et al., 1991). 
Like LFA-1, Mac-1 is not constitutively active for binding to ICAM-1. Upon 
neutrophil activation, e. g. by fMLP, cytokines or phorbol ester, there is a rapid 
induction of Mac-1/ICAM-1 interaction and, occurring more slowly, but maximal by 
10 minutes, a ten fold increase in cell surface expression (Miller et al., 1987). 
1.2.7. c Fibrinogen 
By binding to ICAM-1 on the endothelium, particularly stimulated 
endothelium, and either ICAM-1 or Mac-1 on the leukocyte, fibrinogen acts as a 
bridge to enhance adhesion between leukocytes and endothelium (Languino et al., 
1993), and promotes migration of the leukocytes across the endothelium (Languino 
et al., 1995). Under conditions of flow this fibrinogen bridge produces firm 
attachment of leukocytes to the endothelium (Sriramarao et al., 1996). The 
interaction of ICAM-1 with fibrinogen is mediated by residues 8-21 in domain 1 of 
ICAM-1 binding to fibrinogen y chain residues 117-133 (Altieri et at., 1995; D'Souza 
et at., 1996). In addition, two mAbs that inhibit this interaction have been mapped to 
residues Asp26 and Pro70 in ICAM-1 domain 1 (Duperray et al., 1997). 
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1.2.8 Binding of pathogens to ICAM-1 
1.2.8. a Plasmodiumfalciparum 
A crucial stage in malarial infections is the adhesion of erythrocytes infected 
with the malarial parasite Plasmodium falciparum to capillary endothelium. By this 
process, known as sequestration, the infected erythrocytes escape clearance by the 
spleen. The erythrocytes adhere to the endothelium for around 24 hours before they 
rupture and release the matured parasites into the circulation. ICAM-1 has been 
identified as an endothelial cell receptor for the infected erythrocytes (Berendt et al., 
1989). Endothelial cell ICAM-1 expression is greatly upregulated by the cytokines, 
in particular TNF, which are released as part of the inflammatory response to severe 
malarial infections. The parasite ligand for ICAM-1 is PfEMP1 (P. falciparum 
erythrocyte membrane protein 1), encoded by the var multigene family. PfEMP1 is a 
large antigenically variant protein and is expressed on the host erythrocyte surface 
(Baruch et al., 1996 ; Smith et al., 1995; Smith et al., 2000b). 
Although there is some discrepancy between the results of the two groups 
who have analysed the malaria binding sites in ICAM-1 (perhaps due to the use of 
different P. falciparum clones), two regions are implicated. These regions are Gly'a- 
Ser22 on ß-strand B and Pro36-Asn47 covering the CD loop, (3-strand D and the DE 
loop (Berendt et al., 1992; Ockenhouse et al., 1992). These residues lie on the 
opposite face of ICAM-1 from those affecting LFA-1 binding. 
1.2.8. b Rhinovirus 
Cell surface receptors for viruses serve to target the virus to specific cell 
types and promote entry of the viral genome into the cell. For human rhinoviruses 
(HRV), 90% of serotypes belong to the major group, classified with respect to their 
common cellular receptor, ICAM-1 (Greve et al., 1989; Staunton et al., 1989b). 
HRV, members of the picornavirus family, are the cause of 50% of cases of the 
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common cold. Picornaviruses are icosahedrons formed by 60 protomers around a 
single stranded RNA genome. Each protomer is composed of four capsid proteins, 
VP1, VP2, VP3 and VP4. The receptor binding site is located in the canyon found 
on each protomeric face of the virion (Olson et al., 1993). This canyon is the most 
conserved area on the surface of the virion and its size makes it inaccessible to the 
host's antibodies, therefore resistant to selective pressure from the host immune 
system. In vitro studies show that rhinovirus binding to a soluble form of ICAM-1 
causes destabilising conformational changes in the virion, spontaneous uncoating of 
the virus and release of the VP4 subunit, viral RNA and ICAM-1 (Hoover-Litty and 
Greve, 1993). 
For rhinovirus binding, the BC, DE and FG loops at the apex of ICAM-1 
domain 1 penetrate into the canyon of the rhinovirus capsid, with the short CD loop 
sitting on the rim of the canyon (Bella et al., 1998). Mutational analysis of ICAM-1 
corroborates this mode of interaction (McClelland et al., 1991; Register et al., 1991; 
Staunton et al., 1990). 
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1.3 THE ROLE OF LFA-1/ICAM-1 INTERACTIONS IN THE 
IMMUNE SYSTEM 
1.3.1 LFA-1 and ICAM-1 as adhesion molecules 
1.3.1. a Leukocyte-endothelium interactions 
Leukocyte adhesion to and transmigration across endothelium are critical 
events in lymphocyte recirculation and leukocyte emigration into inflamed tissues. 
Lymphocytes continuously circulate between the blood and lymphoid tissues to 
survey the body for foreign antigen. This process requires the lymphocytes to move 
across specialised post-capillary endothelium in the high endothelial venules (HEV) 
of peripheral lymph nodes. In inflammatory sites bacterial products and 
inflammatory cytokines cause vasodilation, increase vascular permeability, and 
induce surface expression of adhesion molecules on the endothelial cells. These 
conditions initiate leukocyte migration from the blood to the inflamed tissue. A 
cascade of leukocyte-endothelium adhesion events mediates the transmigration out 
of the blood in both lymphocyte recirculation and leukocyte emigration into inflamed 
tissues (Fig. 1.9). This process has been reviewed in (Bianchi et al., 1997; Carlos 
and Harlan, 1994; Johnson-Leger et al., 2000) and will be discussed in brief below. 
During the first step, circulating leukocytes become loosely attached to the vascular 
endothelium and begin to roll along it. This rolling is mediated by L-selectin on the 
leukocyte and E- and P-selectin on the endothelium binding to sialyl-Lexis" moieties 
on their glycosylated counter-receptors. The binding of the integrins a4ß, and a4ß, 
on the leukocyte to VCAM-1 and MAdCAM-1 on the endothelium can also support 
rolling but, in contrast to the selectin-mediated rolling, this requires stimulation. 
Chemokines, constitutively produced in lymphoid tissues or produced by cells 
stimulated by bacterial products or inflammatory cytokines, are found bound to 
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proteoglycans on the endothelium. The chemokines activate leukocytes by engaging 
specific G protein-coupled receptors. Recently, it has been shown that chemokines 
play a role in this first phase of the adhesion cascade, rather than coming into play 
subsequent to rolling as previously thought (Grabovsky et al., 2000). Surface bound 
chemokines promote u4ß, -mediated rolling of leukocytes on VCAM-1 by triggering 
extremely rapid (sub-second) clustering of a4ß1, thus increasing its avidity for 
VCAM-1 (Grabovsky et al., 2000). 
The second step is the arrest of the leukocytes. Additional chemokine signals 
combined with signalling through ligated L-selectin, activate the integrins to firmly 
adhere to their endothelial ligands. LFA-1 is one of the integrins contributing to this 
stable adhesion, with Mac-1, a413, and a4ß, also involved. The endothelial ligands 
are ICAM-1, fibrinogen, VCAM-1 and MAdCAM-1. The arrested leukocytes flatten 
and spread on the endothelium. 
The next step in the process is diapedesis. This is the crawling of the 
leukocytes through the endothelium, directed by a gradient of chemotactic factors 
from extravascular sites. Diapedesis is reported to occur preferentially at points 
where three endothelial cells contact, as the tight and adherens junctions between the 
endothelial cells are weaker at these points. It is thought that leukocyte binding to 
the endothelial cells initiates signals that result in opening of these junctions. 
Proteolytic degradation of junctional proteins may also be involved at this stage. The 
molecules responsible for migration through the junctions are less well defined than 
for the earlier steps. Platelet endothelial cell adhesion molecule-1 (PECAM-1, 
CD31) and junctional adhesion molecule (JAM), IgSF proteins with a junctional 
distribution, have been implicated at this stage, with the integrins LFA-1, Mac-1, 
a4ß, and a4137 also predicted to be involved. Finally, the leukocytes migrate through 
the basement membrane and the extravascular connective tissue to the target site. 
This requires the proteolytic degradation of extracellular matrix (ECM) components, 
potentially by matrix metalloproteases, and integrin-ECM-mediated migration. 
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1.3.1 .b Leukocyte-leukocyte interaction 
As naive lymphocytes circulate between the blood and peripheral lymph 
nodes, they bind transiently to antigen presenting cells (APC) until they encounter 
antigen. Once antigen is recognised, the T cells become activated, proliferate and 
differentiate into effector cells, which can respond rapidly upon subsequent antigen 
challenge. These effector cells are of three types: cytotoxic T cells, which kill virus 
infected cells; TH1 inflammatory T cells, which activate macrophages to kill ingested 
bacteria; TH2 cells, which activate B cells to produce antibody. The initial 
interaction of the T cell with an APC or target cell is antigen-independent and 
mediated by LFA-1 and CD2 on the T cell binding to ICAM-1 and LFA-3 on 
APC/target cell. During the initial contact phase the T cells crawl on the APC, and 
this is similar to what is observed when the T cells are plated on purified ICAM-1 
(Dustin et al., 1997; Negulescu et al., 1996). Recognition of antigen, however, 
triggers an increase in adhesion so that the T cell stops and becomes more tightly 
bound, facilitating the stable, long-lasting interaction that is required for T cell 
activation. The use of purified proteins, rather than APCs, indicates that adhesion 
during this antigen-dependent phase can be provided by LFA-1/ICAM-1 (Dustin et 
al., 1997; Negulescu et al., 1996). The firm adhesion of the cells is associated with 
an intracellular Ca2+ flux followed by Ca 21 oscillations. Thus, LFA-1 binding to 
ICAM-1 plays an important role in mediating T cell interactions with APC and target 
cells. 
1.3.2 LFA-1 and ICAM-1 as signal transduction molecules 
1.3.2. a LFA-1 mediated signalling 
Transmission of signals into the cell following ligand binding by integrins 
affects many cell processes, including migration, regulation of the actin cytoskeleton, 
gene expression, proliferation, differentiation and survival. Signalling events 
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following LFA-1 engagement are ill characterised but include stimulation of PLCy1 
(phospholipase C yl) and raised intracellular Ca2+ levels (Kanner et al., 1993), 
activation of the tyrosine kinases ZAP-70 (Soede et al., 1999), Pyk-2 and p125FAx 
(Rodriguez-Fernandez et al., 1999), and translocation of Pyk-2 (Rodriguez- 
Fernändez et al., 1999) and the ß, and S isoforms of PKC (Volkov et al., 1998) to the 
microtubule organising centre. The sequence of these events, and the consequence 
of each, is unknown. 
1.3.2. b LFA-1 as a costimulatory molecule 
Upon T cell engagement of an antigen presenting cell there is an antigen- 
dependent recruitment of LFA-1 to the contact point (Kupfer and Singer, 1989). 
With more sophisticated microscopy it has become apparent that molecules are 
segregated to specific areas in the cell-cell contact to form what has been termed the 
immunological synapse. On initial contact of the cells, a central zone of LFA-1 with 
a peripheral ring of TCR forms. Within minutes this structure reverses and the 
central area, known as the cSMAC (central supramolecular activation cluster), 
becomes occupied by the TCR associated with PKC-6 and the protein tyrosine 
kinases Fyn and Lck. This is surrounded by a peripheral area, called the pSMAC 
(peripheral supramolecular activation cluster), of LFA-1 colocalised with talin 
(Grakoui et al., 1999; Monks et al., 1998). This mature immunological synapse is 
stable for more than an hour and allows T cell activation. It is not clear what the 
precise role of LFA-1 at the contact point is. 
For efficient T cell activation and proliferation to occur in response to major 
histocompatibility complex (MHC)-peptide, a costimulatory signal is required in 
addition to signalling through the TCR. CD28 is one of the best characterised 
costimulatory molecules for TCR signalling. Binding of B7.1 (CD80) and B7.2 
(CD86) to CD28 has been shown to activate signalling pathways distinct from those 
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activated by TCR engagement (reviewed in (Rudd, 1996)). One mechanism by 
which CD28 costimulation promotes T cell activation is by recruiting lipid rafts rich 
in kinases to the site of TCR engagement (Viola et al., 1999). LFA-1 mediated 
adhesion can facilitate antigen presentation to T cells, resulting in IL-2 production 
and cell proliferation but, in contrast to CD28 costimulation, LFA-1 does not 
promote long term cell survival (Zuckerman et al., 1998). It has, however, proved 
difficult to identify signals specifically associaied with LFA-1 engagement. It has 
therefore been proposed that LFA-1 does not transduce signals, but merely acts as an 
adhesion molecule to promote cell-cell contact, thus optimising TCR signalling by 
enhancing TCR engagement by MHC-peptide (Bachmann et al., 1997). One 
argument against this is that increasing peptide/MHC density does not restore the 
defects in T cell activation which occur in LFA-1 deficient T cells or when the 
antigen presenting cell lacks ICAM-1 (Abraham et al., 1999; Shier et al., 1999). For 
example, a costimulatory signal is required for IL-2 production and proliferation 
(Abraham et al., 1999; Geginat et al., 1999). 
Prolonged LFA-1 mediated adhesion is necessary for induction of cyclin D3 
and a decrease in the cyclin dependent kinase inhibitor p27' ', which results in hyper 
phosphorylation of pRb and allows entry into the S phase of the cell cycle (Geginat 
et al., 1999). Interestingly, Jun activation domain-binding protein 1 (JAB-1), which 
functions as a negative regulator of p27K'P' by promoting its degradation (Tomoda et 
al., 1999), has recently been identified as a protein that interacts with the cytoplasmic 
tail of the LFA-1 ß2 subunit (Bianchi et al., 2000). Whether JAB-i is responsible for 
the LFA-1-induced p27KP' degradation is unknown, but LFA-1 engagement does 
induce JAB-1 translocation from the plasma membrane to the nucleus, where it 
enhances c-Jun driven transcription (Bianchi et al., 2000). 
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1.3.2. c Integrin crosstalk 
There is increasing evidence that the function of one type of integrin can be 
modulated by ligation of another. This process has been termed crosstalk. ICAM-1 
binding to LFA-1 alters the function of the ß, integrins, %01 and a5ß1 on T cells 
(Leitinger and Hogg, 2000; Porter and Hogg, 1997) and, vice versa, engagement of 
(x, O, can activate LFA-1 binding to ICAM-1 (Chan et al., 2000). The mechanism by 
which integrin crosstalk occurs remains unclear. It has been speculated that crosstalk 
may occur during transendothelial migration when leukocytes convert from a rolling 
to a firmly adherent phenotype. 
1.3.2. d ICAM-1 mediated signalling 
As well as mediating adhesion, ICAM-1 can also transmit intracellular 
signals. For leukocytes, ligation of ICAM-1 leads to an increase in MHC class II 
expression and proliferation in B cells (Gardiner and D'Souza, 1999; Holland and 
Owens, 1997), down-regulation of cell cycle protein kinase cdc2 activity in T cells 
(Chirathaworn et al., 1995), and costimulation of an oxidative burst in monocytes 
(Rothlein et al., 1994). The signalling pathways leading to these events are not well 
characterised, but involve phosphorylation of a number of proteins including the Src 
family tyrosine kinases p53/p56'" and p60s" and activation of the Raf-1/ERK-1 
MAP-kinase cascade (Gardiner and D'Souza, 1999; Holland and Owens, 1997). 
On endothelial cells, two signalling pathways initiated by ICAM-1 ligation 
converge to regulate organisation of the cytoskeleton. An early event is activation of 
PLCyl, which leads to elevation of intracellular Ca 2+ levels and activation of a Cat+- 
dependent isoform of PKC. The activation of PKC leads to phosphorylation of the 
tyrosine kinase p60s", which in turn phosphorylates the cytoskeletal protein cortactin 
and contributes to the phosphorylation of the focal adhesion associated proteins 
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paxillin and p125F"K (Etienne-Manneville et al., 2000). The activation of the small 
GTPase Rho is also necessary for paxillin and p125F"' (but not cortactin) 
phosphorylation and leads to Cas phosphorylation. Upon phosphorylation, paxillin, 
p125' and Cas form a complex. Cas and paxillin associate with the adapter protein 
Crk that then recruits the guanine nucleotide exchange factor C3G. This pathway 
eventually leads to JNK activation (Etienne et al., 1998). 
Both the Rho and PLCyI pathways regulate cytoskeletal rearrangement and 
stress fibre formation. Inhibition of either pathway prevents leukocyte migration 
(Adamson et al., 1999; Etienne-Manneville et al., 2000). JNK (c-Jun N-terminal 
kinase) is a regulator of the AP-1 transcription factor complex. AP-1 mediated 
transcription has been observed downstream of the Erk-1 MAP-kinase pathway, 
rather than downstream of the JNK pathway, upon ICAM-1 engagement in 
endothelial cells, and is responsible for the upregulation of VCAM-1 (Lawson et al., 
1999). In synovial cells, activation of AP-1 via ICAM-1 mediates transcription of 
IL-10 (Koyama et al., 1996). Thus, on endothelial cells, ICAM-1 engagement, either 
by LFA-1-mediated leukocyte adhesion or by antibodies, results in cytoskeleton 
reorganisation, which is required for leukocyte diapedesis (Adamson et al., 1999), 
and causes upregulation of inflammatory cytokines and endothelial adhesion 
molecules, all of which cooperate to enhance leukocyte transmigration. 
A consequence of fibrinogen binding to ICAM-1 on the endothelium is 
activation of the MAP kinase cascade (Pluskota and D'Souza, 2000) and 
phosphorylation of the phosphatase SHP-2, which associates with ICAM-1 
phosphorylated on Tyr 495 (Pluskota et al., 2000). These signalling pathways 
ultimately prevent endothelial cell apoptosis. 
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1.3.3 Genetic deficiencies 
1.3.3. a Leukocyte Adhesion Deficiency-1 
The physiological importance of the Leukocyte Integrins is revealed by an 
inherited syndrome known as leukocyte adhesion deficiency-1 (LAD-1). LAD-1 
occurs as a result of mutations in the ß2 subunit that disrupt association with the a 
subunits and thereby impair transport to the cell surface. Affected individuals suffer 
from recurrent life-threatening bacterial infections, but mount adequate responses to 
viral challenge. Characteristically, LAD patients have wounds without pus 
formation. LAD-1 is discussed in more detail in Chapter 6. 
1.3.3. b Knockout mice 
ICAM-1 and CD18 deficient mice have similar problems as LAD-1 patients. 
ICAM-1 deficient mice have elevated peripheral blood neutrophil counts, impaired 
neutrophil infiltration into inflamed tissue, suppressed contact hypersensitivity, and 
indicate a critical role for ICAM-1 on stimulator cells, but not on responder cells, in 
mixed lymphocyte reactions (Sligh et al., 1993). 
Mice deficient in the leukocyte integrin ß2 subunit (CD18) also exhibit 
elevated peripheral blood neutrophil counts, have splenomegaly and 
lymphadenopathy, and develop spontaneous skin lesions. Neutrophil migration into 
these lesions or to induced inflamed skin is severely impaired (Mizgerd et al., 1997; 
Scharffetter-Kochanek et al., 1998). Neutrophil extravasation in response to lung 
inflammation or peritonitis is, however, normal (Mizgerd et al., 1997). Functional 
abnormalities in T cells are also apparent. T cells from these mice do not proliferate 
in response to staphylococcal enterotoxin or MHC alloantigens (Scharffetter- 
Kochanek et al., 1998). In addition, CD18 deficient mice have almost complete 
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absence of intraepithelial lymphocytes, a subset of T cells found in intestinal 
epithelium (Huleatt and Lefranrois, 1996). 
These studies demonstrate that the leukocyte integrins are responsible for 
leukocyte migration to some sites of inflammation and play a role in some T cell 
responses. The specific contribution of each member of this family of integrins was, 
however, unclear until the development of LFA-1 and Mac-1 knockout mice. LFA-1 
deficient mice have small peripheral lymph nodes and reduced migration into lymph 
nodes (Berlin-Rufenach et al., 1999; Schmits et al., 1996), reflecting the essential 
role of LFA-1 in mediating T cell interaction with HEV of lymph nodes and Peyer's 
patches (Berlin-Rufenach et al., 1999; Warnock et al., 1998). Thus LFA-1 is 
important for lymphocyte homing. 
Lymphocytes from LFA-1 null mice fail to aggregate and have impaired 
proliferation in mixed lymphocyte reactions and in response to the mitogen 
concavalin A (Schmits et al., 1996; Shier et al., 1996). Proliferative responses in 
response to lipopolysaccharide, triggering the T cell receptor CD3 subunit, or 
activating the cells with phorbol ester and ionomycin (to activate PKC and raise 
intracellular Ca2+ concentration) were all found to be normal (Shier et al., 1996). 
CTL function in response to virus was not affected by absence of LFA-1 (Schmits et 
al., 1996). 
Surprisingly, comparison of LFA-1 and Mac-1 knockout mice demonstrated a 
dominant role for LFA-1 in neutrophil recruitment to inflammatory sites and for 
neutrophil adhesion to endothelial cells and to purified ICAM-1 (Ding et al., 1999; 
Lu et al., 1997). The specific roles of Mac-1 are revealed by the inability of Mac-1 
deficient neutrophils to phagocytose iC3b coated particles, degranulate or produce a 
respiratory burst (Lu et al., 1997). 
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1.4 Aims 
The major aim of this thesis was to increase the understanding of how the 
leukocyte integrin LFA-1 interacts with its ligands ICAM-1 and ICAM-3. On the 
ICAM side of the interaction, this involved identifying residues in ICAM-1 and 
ICAM-3 that are important for binding LFA-1. For LFA-1, the objectives were to 
discover what alterations occur to form the high affinity LFA-1 conformation and to 
understand how intracellular signalling pathways induce LFA-1 adhesion without 
increasing its affinity for ICAM-1. The opportunity arose to analyse the dysfunction 
in leukocytes from a unique patient with the characteristic symptoms of Leukocyte 
Adhesion Deficiency. 
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MATERIALS AND METHODS 
2.1 MATERIALS 
Details of companies can be found in Appendix III 
2.1.1 Stimulants , inhibitors and other reagents 
Aprotonin Sigma A 2.2 mg/ml solution. 
Store at 4°C 
BCECF-AM (2', 7'-bis- Calbiochem Stock 1 mM in dimethyl 
(2-carboxyethyl)-5- sulphoxide (DMSO). 
(and-6)- Store at -20°C 
carboxyfluorescein- 
acetoxymethyl ester) 
Calpeptin Calbiochem Stock 10 mg/ml in 
DMSO. 
Store at -20°C 
CBZ-LVG (CBZ-Leu- Sigma Stock 10 mM in DMSO. 
Val-Gly diazomethyl Store at -20°C 
ketone) 
DHR (di- Cambridge Bioscience Stock 10 mM in DMSO. 
hydrorhodamine) Store at -20°C 
fMLP (N-formyl- Sigma Stock 10 mM in ethanol. 
methionyl-leucyl- Store at -20°C 
phenylalanine) 
lonomycin Calbiochem Stock 1 mM in DMSO. 
Store at 4°C 
Jasplakinolide Molecular Probes Stock 1 mM in DMSO 
Store at -20°C 
Lactacystin Calbiochem Stock 10 mM in DMSO 
Store at -20°C 
PdBu (Phorbol-12,13- Calbiochem Stock 2 mM in DMSO. 
dibutyrate) Store at -20°C PMSF Sigma Stock 10 mg/ml in 
(Phenylmethylsulphonyl ethanol. 
fluoride) Make fresh each time. 
SKF-96365 Calbiochem Stock 50 mM in H2O 
Store at -70°C Thapsigargin Calbiochem Stock 2 mM in DMSO. 
Store at -20°C 
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2.1.2 Buffers 
2.1.2. a HEPES buffer 
20 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid]), 
140 mM NaCl, 2 mg/ml glucose, adjusted to pH 7.4 
2.1.2. b H-HBSS 
Hanks Balanced Salt Solution (HBSS; 10 x; Gibco-BRL) containing 10 mM 
HEPES (1 M; Sigma) 
2.1.2. c 0.1 M Carbonate buffer pH 9 
1.36 g/1 Na2CO3,7.35 g/1 NaHCO3 
2.1.2. d FACSwash 
Phosphate-buffered saline (PBS)-A containing 0.2% bovine serum albumin 
(BSA; Sigma) and 0.1% sodium azide 
2.1.2. e FACSfix 
PBS-A containing 2% formaldehyde 
2.1.2. f Other stock solutions 
Roosevelt Park Memorial Institute medium (RPMI 1640), Dulbecco's 
modified Eagle's medium (DMEM) and PBS-A (lx and 10x) were prepared by 
Central Cell Services, ICRF. 
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2.1.3 Antibodies 
2.1.3. a ICAM-1 mAbs 
ICAM-1 mAbs used in this study were: 15.2 (Research Monoclonal Antibody 
Services, ICRF), My13 (Curt Civin, Baltimore, USA), 7F7 (T. Schulz, Munich, 
Germany), RR1/1 and R6.5 (R. Rothlein, Ridgefield, CT, USA), WEHT-CAM-1 (A. 
Boyd, Melbourne, Australia), 7.5C2 and 8.4A6 (D. Haskard, London), CBR-IC1/11 
and CBR-1C1/12 (Leukocyte Typing V). 
2.1.3. b ICAM-3 mAbs 
ICAM-3 mAbs used in this study were: BRIC79, CG106, CBR-1C3/1, CBR- 
1C3/2, CBR-1C3/3, CBR-1C3/4, CBR-1C3/5, CBR-1C3/6, WDS 3A9, BY44, 
TPI/24, HP2/19, KS128,152-2D11,140-11,101-1D2 (all from Leukocyte Typing 
V), CH3.1, CH3.2 and CH3.3 (D. Simmons, Oxford), CG106, BY44, KS118 and 
KS 128 (D. Mason, Oxford). 
2.1.3. c Leukocyte integrin mAbs 
LFA-1, Mac-1 and p150,95 mAbs used in this study were: 38 (CD11a), 
ICRF44 (CD11b), 3.9 (CD11c), 24 (activation epitope on (32 integrins) all obtained 
from Research Monoclonal Antibody Services, ICRF. Also KIM185 (ß2 activating 
mAb; M. Robinson, Celltech, Slough), S6F1 (CD11a; C. Morrimoto, Boston, USA), 
G25.2 (CD11a; Becton Dickinson), TS2/4 (CD11a; American Type Culture 
Collection), IB4 (CD18; A. Law, Oxford) and TS1/18 (CD18; American Type 
Culture Collection). 
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2.1.3. d Other integrin mAbs 
Other integrin mAbs used were: HP2/1 (CD49d; Serotec), SAM-1 (CD49e; 
Eurogenetics), P5D2 (CD29; American Type Culture Collection), HUTS21 
(activation epitope on ßl integrins; C. Cabanas, Madrid, Spain), 15/7 (activation 
epitope on ß, integrins; T. Yednock, Elan Pharmaceuticals, San Francisco, USA) and 
TS2/16 (ß, activating mAb; C. Cabanas, Madrid, Spain) 
2.1.3. e Antibodies against cytoskeletal and signalling proteins 
The cytoskeletal and signalling protein antibodies used were against talin 
(clone 8d4), a-actinin (clone BM-75.2), vinculin (clone hVIN-1), ezrin (clone 3C12), 
all purchased from Sigma, and filamin, purchased from Chemicon. All were used at 
1/5000 for Western blotting. Also cytohesin-1 clone 10 (1/10 dilution of 
supernatant; W. Kolanus, Munich, Germany), Pyk-2 (1/5000; Santa Cruz). 
2.1.3. f Other primary mAbs 
Other antibodies used were: 52U (IgGi control), 4U (IgG2a control), UCHTI 
(CD3), DS4.20 (CD4), 14 (CD8), UCHM1 (CD14), 3G8 (CD16), BU12 (CD19), 
2D1 (CD45RA), UCHL1 (CD45RO) all from Research Monoclonal Antibody 
Services, ICRF; LAM1.3 (L-selectin; T. Tedder, Duke University, NC, USA) and 
G19.4 (CD3; Bristol-Myers Squibb, Seattle, USA) 
2.1.3. g Secondary antibodies 
Conjugated secondary antibodies: horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit immunoglobulins (Ig) (Dako) used at 1/5000 for Western blotting; 
HRP-conjugated sheep anti-mouse Ig (Amersham Pharmacia Biotech) used at 
1/50,000 for Western blotting; HRP-conjugated rabbit anti-goat IgG (Sigma) used at 
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1/5000 for Western blotting; HRP-conjugated goat anti-rat Ig (Southern 
Biotechnology Associates Inc. ) used at 1/10,000 for Western blotting; HRP- 
conjugated goat anti-mouse Ig (Dako) used at 1/500 for enzyme-linked 
immunosorbent assays (ELISA); fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse Ig (Sigma) used at 1/400 for flow cytometry; FITC-conjugated goat anti- 
mouse IgG Fc (Jackson Immunoresearch Labs. ) used at 10 µg/ml for confocal 
microscopy. 
2.1.4 Recombinant proteins 
2.1.4. a ICAM-lFc (three domain) 
A plasmid encoding the N-terminal three domains of ICAM-1 fused to the 
hinge, CH2 and CH3 domains of human IgGI was obtained from D. Simmons, 
Oxford. This construct consisted of the CDM8 vector into which the sequence 
encoding the three extracellular domains of ICAM-1 was cloned in frame with a 
human IgGI Fc sequence in which a mutation had been made to prevent di-sulphide 
bond formation. ICAM-1Fc (three domains) protein was expressed by transient 
transfection of COS-1 cells as described in Chapter 2.2.1. 
2.1.4. b ICAM-lFc (five domain) 
A plasmid encoding the five extracellular domains of ICAM-1 fused at the C- 
terminus to the hinge, CH2 and CH3 domains of human IgG, (ICAM-1Fc) was 
obtained from A. Craig, Oxford. This construct consisted of the CDM8 based 
expression vector pIGi into which a sequence encoding the leader sequence and all 
five extracellular domains of ICAM-1 was cloned in frame with the human IgG, Fc 
sequence. ICAM-1Fc (five domain) was produced by transient transfection of COS- 
1 cells with this plasmid as described in Chapter 2.2.1. 
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2.1.4. c ICAM-lFc domain 2 mutants 
Plasmids encoding mutant versions of the ICAM-lFc constructs were 
provided by P. Stanley, Leukocyte Adhesion Laboratory, ICRF. Mutations were 
introduced by site directed mutagenesis using standard protocols. Nomenclature for 
mutants identifies the wild type (wt) amino acid, its position within the protein, and a 
forward slash followed by the amino acid substitution. The mutant proteins were 
produced by transient transfection of COS-1 cells as described in Chapter 2.2.1. 
2.1.4. d K29/M ICAM-1Fc (ICAM-1K'Lf) 
A five domain version of ICAM-lFc (the five extracellular domains of 
ICAM-1 fused at the C-terminal to the Fc portion of human IgG, ) with the single 
substitution of a methionine for a lysine at position 29 (Craig et al., 2000) was 
provided by A. Craig, Oxford. 
2.1.4. e ICAM-3Fc and mutants 
ICAM-3Fc was produced by transient transfection of COS-1 cells (see 
Chapter 2.2.1) with the Fc expression vector pIGI encoding the two N-terminal 
domains of ICAM-3 (provided by D. Simmons, Oxford) (Holness et al., 1995). 
Alternatively, ICAM-3Fc and mutant forms of ICAM-3Fc were obtained as purified 
proteins from D. Simmons, Oxford. 
2.1.4. f VCAM-lFc 
VCAM-lFc, consisting of the two N-terminal domains of VCAM-1 fused to 
the Fc fragment of human IgG, was obtained from M. Robinson, Celltech, Slough as 
a purified protein. 
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2.1.4. g I-Fc 
A plasmid encoding the LFA-1 I domain fused to the Fc portion of human 
IgGI (I-Fc) was obtained from A. Randi, Leukocyte Adhesion Laboratory, ICRF. 
This consisted of the CDM8 based expression vector pIGi into which a sequence 
encoding the 25 amino acids of LFA-1 signal peptide, the first four amino acids of 
the mature subunit, amino acids G1y128-Ser321 of the I domain and the first 11 amino 
acids of domain 3 had been cloned in frame with the IgGI Fc sequence (Randi and 
Hogg, 1994). I-Fc was produced by transient transfection of COS-1 cells as 
described in Chapter 2.2.1. 
2.1.4. h I-GST 
Epicurian coli TOPP 2 transformed with the pGEX2T vector encoding the 
LFA-1 residues Leu`-Ser327, which include the predicted I domain sequence and a 
17 amino acid N-terminal extension, fused to glutathione S-transferase (GST) were 
provided by P. Stanley, Leukocyte Adhesion Laboratory, ICRF (Stanley and Hogg, 
1998). These were grown to log phase and induced with 0.1 M isopropyl-l-thio-(3- 
D-galactopyranoside (IPTG; Amersham Pharmacia Biotech) for 4 hours. The LFA-1 
I domain fused to glutathione S-transferase (I-GST) was extracted from the bacterial 
pellets using the GST purification module kit (Amersham Pharmacia Biotech) 
following manufacturer's instructions. 
2.1.5 Peptides 
Peptides spanning the LFA-1 I domain were synthesised by the Peptide 
Synthesis Service, ICRF on a model 430A Applied Biosystems solid phase 
synthesiser using 9-fluorenyl-methoxycarbonyl chemistry and characterised by 
amino acid analysis and plasma desorption spectrometry. A peak corresponding to 
the expected molecular weight was found for each peptide and in all cases contained 
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the correct sequence. Peptides were desalted using Sephadex G10 (Amersham 
Pharmacia Biotech) and stored as a lyophilised powder at room temperature (RT) 
under desiccating conditions. All peptides were tested for cytotoxic activity using a 
MTT cytotoxicity assay (see Chapter 2.2.10) and were used in experiments at 
concentrations at which they were fully soluble. 
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2.2 METHODS 
2.2.1 Transient transfection of COS-1 cells 
Transient transfection of COS-1 cells with Fc chimeric constructs was 
facilitated by either diethylaminoethyl-dextran (DEAE dextran), which is thought to 
bind to the cells and promote endocytosis of the DNA, or electroporation, which 
transiently permeabilises the cells with an electrical pulse, allowing uptake of the 
DNA. 
2.2.1. a DEAE dextran 
15 cm tissue culture dishes of confluent COS-1 cells were incubated for 4 
hours at 37°C with 20 ml DMEM containing 30 µg DNA, 400 9g/m1 DEAE dextran 
(Sigma) and 60 µg/ml chloroquine (Sigma). The plates were then rinsed with ice 
cold 10% DMSO/PBS-A and left overnight in DMEM/1O% foetal calf serum (FCS). 
The following day the cells were split 1 in 2 and 24 hours later washed into serum 
free DMEM. After 5 days the tissue culture medium was collected and the secreted 
protein purified as described in Chapter 2.2.3. 
2.2.1 .b Electroporation 
Confluent COS-1 cells were removed from 15 cm tissue culture dishes with 
trypsin/EDTA, washed in RPMI-1640 and resuspended in 500 µl RPMI-1640 
containing 30 pg DNA. These cells were placed in an electroporation cuvette with a 
4 mm electrode gap and subjected to a voltage of 250 V for 4-6 milliseconds using a 
Gene Pulser (Bio-Rad) connected to a Capacitance Extender (Bio-Rad) set at 250 µF. 
The cells were then re-plated on 15 cm tissue culture dishes in DMEM/10% FCS for 
24 hours before washing into serum free DMEM. After 5 days the tissue culture 
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medium was collected and the secreted protein purified as described in Chapter 
2.2.3. 
2.2.2 ICAM-1Fc preparation from CHO cells 
CHO cells were stably transfected with a chimeric construct composed of the 
five extracellular domains of ICAM-1 fused to the Fc tail of human IgG, (ICAM-1- 
Fc) by P. Stanley, Leukocyte Adhesion Laboratory, ICRF. These were grown in 
supplemented Glasgow minimum essential medium (GMEM-S; see Appendix II) 
with 10% FCS and selected with 100 µM methionine sulphoxamine (Sigma). The 
cells were expanded every two days until 30-40 175 cm2 flasks were obtained. On 
the day after the final expansion the cells were washed into serum free GMEM-S 
supplemented with 2 mM sodium butyrate (Sigma) to enhance protein secretion. 
After 7-10 days the cell culture supernatant was collected and the secreted protein 
purified by affinity chromatography as described in Chapter 2.2.3. 
2.2.3 Fc chimeric protein purification 
Particulate matter was removed from the cell culture supernatant by 
centrifugation at 1300 xg for 10 minutes (min) then filtration through a 0.22 gm 
filter unit (Millipore). The supernatant was then loaded onto a Protein A Sepharose 
(Amersham Pharmacia Biotech) column with a flow rate of 1 mu min. Once all the 
supernatant was loaded, the column was washed with 30 ml of PBS-A to remove 
unbound material. The Fc chimeric protein was eluted with 0.1 M citrate buffer pH 
3 and collected in 2 ml fractions, which were immediately neutralised with 500 gl of 
1M Tris pH 9. The fractions containing protein, identified by absorbance at 280 nm 
measured on an Ultraspec III (Amersham Pharmacia Biotech), were pooled, dialysed 
into PBS-A and, if necessary, concentrated using Centricon centrifugal filter devices 
(Millipore). The integrity and purity of the protein was checked by SDS-PAGE 
(sodium dodecyl sulphate polyacrylamide gel electrophoresis; see Chapter 2.2.19) 
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and the concentration estimated using the BCA Protein Assay Reagent (Pierce) as 
per manufacturers instructions. 
2.2.4 35S-methionine labelling 
Confluent COS-1 cells, grown in 6 well tissue culture plates, were incubated 
for 4 hours at 37°C with 500 µl/well DMEM containing 5 µg DNA, 400 µg/ml 
DEAE dextran (Sigma) and 60 µg/ml chloroquine (Sigma). The wells were then 
rinsed with ice cold 10% DMSOIPBS-A and left overnight in DMEM/10% FCS. 
The following day the cells were rinsed in methionine free DMEM, incubated at 
37°C for 15 min in methionine free DMEM, then incubated at 37°C for a further 5 
hours in 500 µl/well methionine free DMEM supplemented with 100 µCi 35S- 
methionine (Amersham Pharmacia Biotech). After this time the cell culture 
supernatant was collected, microfuged for 10 min at 4°C to remove particulate 
material, and 1 µg/ml aprotonin and 20 µg/ml PMSF added. The cells were lysed on 
the plates by addition of 500 µl/well of lysis buffer (50 mM Tris pH 8,1% Triton X- 
100 (t-octylphenoxypolyethoxyethanol), 1 µg/ml aprotonin and 20 µg/ml PMSF) for 
30 min on ice. The cell lysates were then microfuged for 20 min at 4°C to remove 
insoluble material. The supernatants and lysates were precleared with Sepharose 
CL4B (Amersham Pharmacia Biotech) for 3 hours at 4°C, then the Fc chimeric 
proteins were affinity purified overnight at 4°C with 200 µl of a 50% slurry of 
Protein A Sepharose (Amersham Pharmacia Biotech). The sepharose beads were 
washed four times, alternating high salt (500 mM NaCl) and low salt (150 mM 
NaCl) containing lysis buffer, and finally in lysis buffer without salt. The beads 
were boiled for 5 min in SDS-PAGE sample buffer and proteins separated by SDS- 
PAGE on 7.5% gels (see Chapter 2.2.19). 35S-methionine labelled proteins were 
detected by exposure to film. 
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2.2.5 ELISA 
Immulon-1 96 well plates (Dynex) were coated overnight at 4°C with 50 
µl/well ICAM-lFc, ICAM-3Fc (or mutated versions of these proteins), at 5 gg/ml in 
PBS-A (unless indicated otherwise). Unbound protein was removed and the plates 
blocked with 150 µl/well 2% FCS/PBS-A for 1 hour at RT. The wells were washed 
three times with PBS-A prior to addition of 50 gl/well of primary mAb for 30 min at 
RT (mAb diluted in 2% FCS/PBS-A at 10 µg/ml, unless otherwise indicated), and 
again before addition of 50 µl/well HRP-conjugated goat anti-mouse Ig (Dako) 
diluted in 2% FCS/PBS-A. Unbound antibody was removed by washing as above 
and bound antibody detected with 75 µl/well o-phenylenediamine dihydrochloride 
(OPD) detection buffer (20 ml 0.1 M NaHPO4,10 ml 0.1 M citric acid, 10 µl H202 
plus one OPD tablet (Sigma)). The reaction was stopped with 50 Al/well 3M H2SO4 
and the absorbance at 492 nm read on a Titertek Multiskan plate reader. 
2.2.6 T cell purification and culture 
Blood from a buffy coat (National Blood Service) was diluted 1 in 4 with 
RPMI-1640.60 ml of the diluted blood were layered over 30 ml of Lymphoprep 
(Nycomed) in 100ml glass tubes then centrifuged at 1380 xg for 30 min at RT. 
Peripheral blood mononuclear cells (PBMC) were removed from the 
plasma/Lymphoprep interface. The harvested cells were washed three times in 
RPMI-1640 then cultured in RPMI-1640 + 10% FCS +1 pg/ml 
phytohaemagglutinin (PHA) (Murex Biotech Ltd. ). After 3 days the cells were 
washed three times in RPMI-1640 and maintained at approximately 106 cells/ml in 
RPMI-1640 + 10% FCS + 20 ng/ml recombinant interleukin-2 (IL-2) (Chiron UK 
Ltd. ) for 7- 14 days (Cantrell and Smith, 1983). 
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2.2.7 Purification of neutrophils 
Neutrophils were isolated from EDTA or heparin anticoagulated venous 
blood as described by Dooley et al. (Dooley et al., 1982). Erythrocytes were 
sediinented by the addition of 1 ml of 6% Dextran T500 (Amersham Pharmacia 
Biotech) in 150 mM NaCl per 10 ml of blood. After 45 min at RT the leukocyte-rich 
fraction was layered onto a discontinuous 70%/80% isotonic Percoll (Amersham 
Pharmacia Biotech) gradient and centrifuged at 1000 xg for 15 min at RT. The 
neutrophil fraction was harvested from the interface between the 70% and 80% 
Percoll and washed three times in H-HBSS. 
2.2.8 T cell adhesion assays 
Immulon-1 96 well plates (Dynex) were coated overnight at 4°C with 50 
µl/well ICAM-1Fc, ICAM-3Fc (or mutated versions of these proteins), VCAM-lFc 
(all at 5 µg/ml unless indicated otherwise) or fibronectin (Sigma) at 20 µg/ml, all 
diluted in PBS-A. Unbound protein was removed and the plates blocked with 150 
p lweil 2.5% BSA/PBS-A for 1 hour at RT. The wells were washed three times with 
assay buffer. 
T cells, washed and resuspended at 4x 106/ml in HEPES buffer, were 
labelled for 30 min at 37°C with 2.5 µM BCECF-AM. Cells were then washed into 
the appropriate assay buffer and added to the coated plate at a final concentration of 
2 x105 cells/100 µl in the presence or absence of stimuli and inhibitors as indicated. 
Plates were spun at 66 xg for 1 min then incubated at 37°C for 30 min. 
Unbound cells were washed off with warm HEPES buffer containing 0.4 mM MgCI2 
and 0.4 mM CaCl2. Bound cells were quantified using a Cytofluor Multi-well Plate 
Reader Series 4000 (PerSeptive Biosystems) with an excitation wavelength of 485 
nm and an emission wavelength of 530 nm. 
83 
MATERIALS AND METHODS 
2.2.9 Neutrophil binding to fibrinogen 
A 0.5 mgJml solution of fibrinogen (Sigma) was prepared in 0.1 M carbonate 
pH 9 by incubating at 37°C for 30 min then filtering through a 0.2 µm syringe filter. 
Maxisorp 96 well Nunc-Immunoplates (Gibco-BRL) were coated overnight at 4°C 
with 50 µl/well of the fibrinogen solution. Unbound protein was removed and the 
plates blocked with 150 gl/well 2% BSA/PBS-A for 1 hour at RT. The wells were 
washed three times with H-HESS. 
Neutrophils, washed and resuspended at 2x 106/ml in H-HBSS, were labelled 
for 30 min at RT with 1 µM BCECF-AM. After washing in H-HBSS the cells were 
added to the fibrinogen coated plate at a final concentration of 105 cells/100 Al in H- 
HBSS with 1 mM MgC12 and 1 mM CaC12 together with stimulating or blocking 
agents as indicted in the figure legends. Plates were incubated at RT for 30 min. 
Unbound cells were removed by washing the plates with H-HBSS and the number of 
bound cells quantified using a Cytofluor Multi-well Plate Reader Series 4000 
(PerSeptive Biosystems) with an excitation wavelength of 485 nm and an emission 
wavelength of 530 nm. 
2.2.10 MTT cytotoxicity assay 
To test the viability of cells following treatment with peptides and inhibitors 
MTT (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) 
cytotoxicity assays were performed based on the method of Denizot and Lang 
(Denizot and Lang, 1986). This assay is based on the ability of mitochondrial 
dehydrogenase enzymes in living cells to convert the yellow water soluble substrate 
MTT into a dark blue water insoluble product. Cells were incubated with the 
relevant concentration of peptide or inhibitor plus 0.5 mg/ml MTT (Sigma) in a 96 
well plate for 3 hours at 37°C. Cells without peptide or inhibitor were included as a 
positive control and 50 pM digitonin added as a negative control. Each condition 
was performed in triplicate. The reaction was stopped by the addition of 150 µl/well 
84 
MATERIALS AND METHODS 
of 40 mM HCl in isopropanol and the plates left in the dark overnight. The 
absorbance at 570-630 nm was then read on a Titertek Multiskan plate reader. Cell 
viability was calculated as a percentage of the absorbance of untreated cells after the 
negative control had been subtracted. 
2.2.11 Flow cytometry 
5x 10' cells were incubated in 50 Al of FACSwash containing primary 
antibody (including peptides or stimulatory agents where indicated) for 30 min on 
ice, or at 37°C where indicated. The cells were then washed three times in 
FACSwash and resuspended in 50 µl of FACSwash containing a 1: 400 dilution of 
FITC-conjugated goat anti-mouse IgG (Sigma). After 30 min on ice the cells were 
washed three more times in FACSwash, resuspended in 200 µl of FACSfix and 
analysed using a FACScan (Becton Dickinson). 
2.2.12 Antibody staining for confocal microscopy 
For immunofluorescence analysis by confocal microscopy, 13 mm round 
glass coverslips were precoated with a 0.01% solution of poly-L-lysine (Sigma) for 
10 min at RT, washed twice in RPMI-1640 then left to air dry. T cells were washed 
three times in RPMI-1640 before addition onto coverslips (5x105 cells/coverslip), in 
the presence of stimulants and CD1la mAbs at 10 pgfml. Coverslips were spun at 
40 xg then incubated for 30 min at 37°C. Unbound cells were removed by gentle 
washing in warm RPMI-1640. In order to prevent antibody-induced clusters, cells 
were fixed with 1% formaldehyde in PBS-A for 10 min at RT, prior to a second 
incubation with 10 µg/ml FITC-conjugated goat anti-mouse IgG Fc (Jackson 
Immunoresearch Labs) for 25 min at 4°C. 
Cells were mounted for confocal microscopy, which was carried out using an 
MRC-600 Confocal Laser Scanning System (Bio-Rad Laboratories Ltd. ). The 
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regions of the confocal microscopy images with the highest fluorescence intensity 
(i. e. with the pixel colour intensity in the 150-255 range) were highlighted in red 
using the Segmentation utility of the IP Lab Spectrum Version 3.1 software 
(Scanalytics). 
2.2.13 Analysis of clustering 
IP Lab Spectrum Version 3.1 software was also used to quantify the levels of 
fluorescence of the images. Background fluorescence was estimated by measuring 
the signal strength in areas visibly devoid of specific staining but in close proximity 
to cells. The average of these values was then subtracted from the original image to 
give a corrected image. The areas of interest (e. g. free membrane or membrane at 
cell-cell contact points) on the corrected images were selected and the average signal 
strength calculated automatically by the computer software. A statistical assessment 
of the differences between the treatment groups and the untreated resting T cells was 
performed using the one-way ANOVA test. 
2.2.14 Measurement of intracellular calcium ([Ca2+]i) 
Cells were incubated at 107/ml in H-HBSS with 5 µM Fluo-3 (Molecular 
Probes) at 37°C for 30 min. After three washes the cells were resuspended at 2x 
106/ml in H-HBSS containing 1 mM CaCl2 and 1 mM MgC12. Cells were kept at 
37°C and 2 ml aliquots added to quartz fluorimeter cuvets (Sigma). Stimulants were 
added at the indicated time points and the samples stirred constantly. Fluorescence 
was monitored to determine [Ca2+]; using a Photon Technologies International 
fluorimeter with an excitation wavelength of 485 nm and an emission wavelength of 
530 nm. Results are represented as the emission at 530 nm. 
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2.2.15 Measurement of neutrophil respiratory burst 
The production of superoxide was measured according to the method of 
Smith and Weidemann (Smith and Weidemann, 1993). Neutrophils at 2x 106/ml 
were labelled with 1 pM DHR for 5 min at 37°C prior to exposure to stimuli. After 
30 min stimulation at 37°C the samples were transferred to ice. The generation of 
superoxide was measured by flow cytometry using a FACScan. 
2.2.16 Chemotaxis assays 
Migration assays were performed in 24 well Transwells with a 6.5 mm 
diameter and 5 µm pores (Corning Costar) that had been pre-incubated in RPMI- 
1640 for 1 hour at 37°C. The bottom well was filled with 600 µl of human stromal 
cell-derived factor (SDF)-1-a (PeproTech) at the indicated concentration in RPMI- 
1640 with 0.5% BSA and 100 pl of T cells at 5x 106/ml in RPMI-1640 with 0.5% 
BSA were placed in the top well. Migration was carried out at 37°C for 90 min after 
which the top well was discarded, the cells in the bottom well collected, and the 
wells washed with ice cold PBS-A containing 5 mM EDTA to collect any adherent 
cells. The cells were pelleted and resuspended in 200 µl of FACSwash. Cells were 
counted for 20 seconds using a FACScan, with a known number of CaliBRITE 31 
beads (Becton Dickinson) as a standard. The number of cells in the starting 
population and the number of cells which accumulated in the bottom well were 
calculated as follows: 
no. of cells counted x total no. of beads added 
no. of beads counted 
2.2.17 Preparation of detergent soluble T cell extracts 
T cells were suspended at 5x 10'/ml in ice cold lysis buffer (50 mM Tris pH8 
containing 150 mM NaCl, 2 mM MgC12,2 mM EGTA, 1 µg/ml aprotonin, 20 µg/ml 
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PMSF and 1% Triton X-100) and lysed for 20 min on ice. The lysate was then 
microfuged for 15 min to remove insoluble material. The soluble material was either 
immediately used for immunoprecipitation or mixed with an equal volume of SDS- 
PAGE sample buffer (see Chapter 2.2.19) and stored at -20°C for use as total cell 
lysate in Western blotting 
2.2.18 Immunoprecipitation 
Immunoprecipitates were prepared from the Triton X-100-soluble cell 
fraction which had been precleared for 1 hour at 4°C by rotation with 50 µl of a 50% 
slurry of Protein A Sepharose (Amersham Pharmacia Biotech) per 1 ml of lysate. 
LFA-1 was immunoprecipitated from the precleared lysates with 10 tg/ml mAb 38 
and 50 µl of 50% Protein A Sepharose by rotating overnight at 4°C. To remove non- 
specifically bound material the immunoprecipitates were washed five times in lysis 
buffer. Precipitated material was removed from the Protein A Sepharose beads by 
boiling for 5 min in SDS-PAGE sample buffer (see Chapter 2.2.19) and the beads 
were then pelleted by centrifugation and removed. 
2.2.19 SDS-PAGE 
SDS-PAGE was performed according to the method of Laemmli et al 
(Laenimli, 1970). Proteins were separated on polyacrylamide gels of the indicated 
percentage prepared from a 30% acrylamide/0.8% bis-acrylamide stock solution 
(Anachem) in 375 mM Tris pH 8.8 containing 0.1% sodium dodecyl sulphate (SDS) 
and polymerised with 0.04% ammonium persulphate (APS) and 1/500 N, N, N', N'- 
tetramethylethylenediamine (TEMED; Sigma). The separating gels were overlaid 
with a 3% polyacrylamide stacking gel prepared from the acrylamide/bis-acrylamide 
stock solution in 125 mM Tris pH 6.8 containing 0.1% SDS and polymerised with 
APS and TEMED as above. Proteins for electrophoresis were boiled for 5 min in 
sample buffer (125 mM Tris pH6.8,25% glycerol, 2% SDS, 0.02% bromophenol 
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blue), containing 1% 2-mercaptoethanol (Sigma) when reducing conditions were 
required, before loading onto the gels. Rainbow coloured protein molecular weight 
markers in the range 14.3 kDa-220 kDa (Amersham Pharmacia Biotech) were run on 
each gel as standards. Electrophoresis was carried out in Atto Dual Mini Slab 
Chamber (Genetic Research Instrumentation Ltd. ) containing electrophoresis running 
buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS) at 90 volts through the 
stacking gel and 180 volts through the separating gel. When required, proteins were 
visualised by staining with Coomassie Blue (0.5% Coomassie Blue (Bio-Rad) in 
40% ethanol and 10% glacial acetic acid) and destained with a solution of 20% 
ethanol and 10% glacial acetic acid. 
2.2.20 Western blotting 
Following separation by SDS-PAGE, proteins were transferred onto Hybond 
ECL nitrocellulose membrane (Amersham Pharmacia Biotech) in a Transblot Cell 
(Bio-Rad) using Transfer buffer (25 mM Tris base, 192 mM glycine, 20% methanol). 
Proteins were transferred for 75 min at 60 volts. Proteins were visualised, to ensure 
even transfer had taken place, by staining the membrane with 0.1% Ponceau S 
Solution (Sigma) for a few minutes. To minimise non-specific antibody binding, 
membranes were blocked overnight at 4°C in 5% milk powder in PBS-A/0.1% 
polyoxyethylenesorbitan monolaurate (Tween 20). The membranes were incubated 
for 1 hour at RT with the primary antibody diluted in PBS-A/0.1% Tween 20 
followed by a1 hour incubation at RT with the appropriate HRP-conjugated 
secondary antibody diluted in PBS-A/0.1% Tween 20. After each antibody 
incubation the membranes were washed three times for 5 min with PBS-A/0.1% 
Tween 20. Bound antibody was detected by chemiluminescence using ECL Western 
blotting detection reagents (Amersham Pharmacia Biotech) as per manufacturer's 
instructions. 
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LFA-1 BINDING SITES ON ICAM-1 AND ICAM-3 
3.1 INTRODUCTION 
The interaction of the leukocyte integrin LFA-1 with its ligands ICAM-1, 
ICAM-2 and ICAM-3 is a central feature of the immune response. Many integrins 
recognise the sequence Arg-Gly-Asp (RGD) in their ligands. The ICAMs, however, 
do not possess an RGD sequence (Fawcett et al., 1992; Staunton et al., 1989a; 
Staunton et al., 1988), and thus the manner in which they are bound by the integrins 
has been of interest. This chapter describes three projects in which I have 
participated that have contributed to the characterisation of LFA-1 binding sites in 
ICAM-1 and ICAM-3. The introduction will cover aspects of ICAM-1 and ICAM-3 
relating to these projects. 
All ICAM-1 mAbs that disrupt interaction with LFA-1 map to the two N- 
terminal domains, and a domain 1 and 2 truncated version of ICAM-1 is sufficient 
for LFA-1 binding (Berendt et at., 1992; Staunton et al., 1990). Mutation of residues 
Asp26-Leu30, Lys40, Leu43-Asn4' and Pro70-Gly72 in domain 1 of ICAM-1 all result in 
loss of function blocking mAb epitopes (Berendt et al., 1992), and LFA-1 binding is 
most severely disrupted by domain 1 mutations G1u34/Ala (on ß-strand C) and 
Gln73/His (on ß-strand G) (Staunton et at., 1990). These two residues are conserved 
in ICAM-2 (Staunton et al., 1989a) and ICAM-3 (Fawcett et al., 1992), as well as in 
murine ICAM-1 and ICAM-2 (Horley et at., 1989; Xu et al., 1992). Mutation of 
Asp26-Lys29 or Gly46-Asn48 or substitution of Lys39, Met" or Tyr66 also reduce binding 
of LFA-1 (Fisher et at., 1997; Staunton et at., 1990). These residues all lie on the 
apex and the face formed by the C, F and G ß-strands of domain 1, indicating that 
this face of ICAM-1 contains the LFA-1 binding site (see Fig. 3.1). 
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No specific function has been attributed to domain 2 of ICAM-1 other than to 
be a spacer to extend domain 1 away from the cell surface. As domain 1 and 2 are 
structurally inter-dependent, it has not been possible to test either domain for 
function independently of the other. However, four mAbs that block LFA-1 
interaction have been mapped to domain 2 of ICAM-1, suggesting that domain 2 
may be involved in LFA-1 binding (Berendt et al., 1992; Duperray et al., 1997; 
Staunton et al., 1990). The epitopes for these mAbs are located at the top of domain 
2. Therefore, rather than their epitopes being sites important for LFA-1 binding, the 
mAbs may simply be sterically hindering LFA-1 binding to domain 1. For vascular 
cell adhesion molecule-1 (VCAM-1) and mucosal addressin cell adhesion molecule- 
1 (MAdCAM-1), the most homologous members of the IgSF to the ICAMs, residues 
in domain 2 contribute to their binding to the integrins a431 and a4ß, (Newham et al., 
1997). More extensive mutational analysis of domain 2 of ICAM-1 must be carried 
out before its role is clear. 
As for ICAM-1, the two most N-terminal domains of ICAM-3 are sufficient 
to support LFA-1 binding (Fawcett et al., 1992). ICAM-3 has 47% identity with 
ICAM-1, with 37% in domain 1 and 77% in domain 2. Although residues G1u34 and 
G1n73 of ICAM-1, which are critical for binding to LFA-1, are conserved in ICAM-3 
(Fawcett et al., 1992), there is evidence that ICAM-1 and ICAM-3 bind to LFA-1 
differently. Two mAbs that recognise the LFA-1 I domain inhibit T cell binding to 
ICAM-3 but not to ICAM-1, and a third I domain mAb activates T cell binding to 
ICAM-1 but not to ICAM-3 (Landis et al., 1994). In addition, peptide studies 
indicate that the ICAM-1 and ICAM-3 binding sites in the I domain differ (see 
Chapter 4.2.9). 
As well as binding LFA-1, ICAM-1 acts as a receptor for Plasmodium 
falciparum infected erythrocytes, mediating their adhesion to capillary endothelium, 
a critical step in the life cycle of the parasite (Berendt et al., 1989). P. falciparum 
causes the most severe form of malaria. Although only a minority of infected 
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individuals develop life-threatening complications, such as cerebral malaria, it is 
estimated that as many as 2-3 million deaths each year can be attributed to P. 
falciparum infection. It has been acknowledged for many years that malaria exerts a 
selective pressure on the human genome, and there is now a growing list of gene 
polymorphisms that have been recognised to influence the severity of P. falciparum 
infection. Since ICAM-1 is important for the pathogenesis of cerebral malaria, it 
was considered possible that evolutionary selection by malaria may have resulted in 
polymorphisms in ICAM-1 that are protective against severe disease. This 
hypothesis was tested by sequencing the ICAM-1 gene from people living in Kilifi, 
Kenya, an area of endemic malaria transmission. This study revealed that 14% of the 
population are homozygous for a single nucleotide substitution that results in the 
mutation Lys29IMet in domain 1 of ICAM-1 (termed ICAM-1""). Unexpectedly, 
however, this polymorphism was found to be associated with increased susceptibility 
to cerebral malaria (Fernandez-Reyes et al., 1997). Since the polymorphism is found 
at high frequency despite being linked to such a disadvantageous outcome, it is 
speculated that it must be maintained by some compensatory selective pressure. The 
advantage of the Lys29/Met mutation in ICAM-1 to ICAM-1-dependent functions is 
therefore of interest. 
In the past few years I have been involved in a number of collaborations that 
have had the aim of defining LFA-1 binding sites on the intercellular adhesion 
molecules ICAM-1 and ICAM-3. My contributions to these studies are described in 
this chapter. In brief, these pieces of work investigate (1) whether ICAM-1 domain 
2 has a role in directly binding to LFA-1, (2) binding sites for LFA-1 in ICAM-3, 
and (3) the effect of the ICAM-1"'''E' polymorphism on binding of LFA-1. 
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3.2 RESULTS - THE ROLE OF ICAM-1 DOMAIN 2 IN BINDING LFA-1 
3.2.1 Mutations in domain 2 of a three domain ICAM-1Fc construct result in 
protein which is produced at low levels and which has a severely 
disrupted structure 
Studies I have been involved in previously have shown that four mAbs that 
recognise epitopes in domain 2 of ICAM-1 are able to inhibit T cell binding to 
ICAM-1, providing evidence that domain 2 of ICAM-1 has a role in binding to LFA- 
1 (Berendt et al., 1992; Duperray et al., 1997). It was decided to further investigate 
this possibility by making mutations in domain 2 of an ICAM-1Fc construct. This 
project was carried out in collaboration with P. Stanley and J. Brashaw, Leukocyte 
Adhesion Laboratory, ICRF and with P. Bates, Biomolecular Modelling Laboratory, 
ICRF. 
As hydrophilic, and therefore exposed, residues are likely binding sites, 
domains 1 and 2 of ICAM-1 were analysed using a Kyte and Doolittle 
hydrophobicity plot (Kyte and Doolittle, 1982) (data not shown). The CC' and EF 
loops in domain 2 were found to be the most hydrophilic. Arg'ZSG1yGlu, the only 
residues in the CC' loop, and His'SZHisGly, the most hydrophilic residues in the EF 
loop, were mutated to alanines (referred to as R125GE/AAA ICAM-1Fc and 
H152HG/AAA ICAM-1Fc, respectively). The positions of these loops are indicated 
in Figure 3.1. Preliminary studies using peptides from these loops had indicated that 
residues on either side of His'52HisGly might be important in binding LFA-1 (J. 
Brashaw - unpublished results). Two further mutants were therefore made, 
R '49RD/AAA and N"/A. Mutated ICAM-1Fc chimeric proteins were produced by 
transient transfection of COS-1 cells followed by purification of the secreted protein 
from the culture supernatant by Protein A Sepharose affinity chromatography. 
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Figure 3.1 Structure of domains 1 and 2 of ICAM-1 
In domain 1 G1u34 and G1n73, which are essential for LFA-1 binding (Staunton et al., 
1990), are indicated. Lys29 in domain 1 and Arg'2G1yGlu and His' 52 HisGly in 
domain 2, which are mutated in this study, are also shown. This figure is adapted 
from Casasnovas et al., 1998b. 
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Initially the mutations were made in a three domain version of ICAM-1Fc 
(i. e. the three N-terminal domains of ICAM-1 fused to human IgGI Fc). The yield of 
most of the mutant proteins was low compared to the yield of wild type (wt) protein. 
Typically 80-100 µg of wt protein was produced from each 15 cm culture dish of 
transfected COS-1 cells, whereas only 20% of this amount of mutant proteins 
R125GE/AAA, R149RD/AAA and H152HG/AAA ICAM-1Fc were obtained. The 
N1S6/A ICAM-117c mutant was produced at similar levels to the wt. It was decided to 
investigate at what stage of the protein preparation the problem that resulted in low 
yield of the mutant proteins lay. COS-1 cells transfected with wt ICAM-1Fc cDNA 
or with cDNA of one of the low yield mutants, R"GE/AAA ICAM-117c, were 
labelled with 35S-methionine and the amount of labelled ICAM-117c in the cell lysates 
and secreted into the culture medium compared. Following transfection with both 1 
µg and 5 gg of cDNA, wt ICAM-117c could be detected as an approximately 80 kDa 
band both within the cell and secreted in the cell culture supernatant (Fig. 3.2 A 
lanes 1 and 2). No equivalent band could be detected in mock transfected cells (Fig. 
3.2 A lane 5). Very little secreted R'25GE/AAA ICAM-1Fc could be detected, even 
when 5 µg of cDNA were transfected (Fig. 3.2 A lanes 3 and 4). The amount of 
R11GE/AAA ICAM-1Fc detected within the cell was also reduced compared to wt 
(Fig. 3.2 A lanes 3 and 4). Therefore, either there is a defect in synthesis and 
secretion of R1 GE/AAA ICAM-117c or R'uGE/AAA ICAM-117c is easily degraded, 
thus resulting in low protein yield. 
The small amounts of R'25GE/AAA, R149RD/AAA and H'S2HG/AAA ICAM- 
1Fc protein that were obtained were tested by ELISA for binding of a panel of mAbs 
that recognise different epitopes in domains 1 and 2 of ICAM-1 (Berendt et al., 
1992). When compared to an equal amount of wt ICAM-IFc, all three mutant 
proteins showed reduced binding, or lack of binding, of many of the mAbs (Fig. 3.2 
B), indicating that the structure of these mutants was severely disrupted. N156/A 
ICAM-1Fc, however, which was produced at similar levels to wt, bound all 
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Figure 3.2 Three domain ICAM-lFc with mutation R"GE/AAA is synthesised 
at reduced level, is poorly secreted, and does not have an intact structure. 
A: Protein A Sepharose affinity purified proteins from the cell lysate and cell growth 
medium of 35S-methionine labelled COS-1 cells transfected with I µg wt ICAM-IFc 
(lane 1), 5 µg wt ICAM-1 Fc (lane 2), 1 µg R'2GE/AAA ICAM-1 Fc (lane 3), 5 µg 
R125GE1AAA ICAM-1Fc (lane 4), or mock transfected (lane 5). The open arrow 
indicates the expected position of the ICAM- l Fc proteins. B: An ELISA to test the 
binding of a panel of ICAM-1 mAbs (used as neat supernatant, 1/100 ascites or 10 
µg/ml purified mAb) to wt and mutated ICAM-lFc (all at 10 tg/ml). The mAbs 
used are 38 (1), My 13 (2), 7F7 (3), RR 1/ 1 (4), WEHI-CAM-1 (5), 7.5C2 (6), 15.2 
(7), 8.4A6 (8) and R6.5 (9). These mAbs recognise domain 1 (0) or domain 2 ( ) of 
ICAM- I except the negative control mAb (0) which recognises CD 11 a. Data are 
from representative experiments (n=2). 
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the mAbs at a similar level to wt ICAM-1Fc, with the exception of R6.5, which 
recognises residues Glu'-Ala' 4 at the top of domain 2 (Staunton et al., 1990). 
Therefore, as the majority of the three domain constructs appeared to be unstable, 
they could not be used for further studies. 
3.2.2 A five domain version of R12GEIAAA ICAM-lFc is produced as a 
secreted protein by COS-1 cells 
Attempts to improve the protein yield were made to disprove the possibility 
that, rather than the mutations disrupting the structure, it was the extra manipulations 
required for production of low yield proteins, for example concentration, which were 
responsible for the loss of structure. Two approaches were tested: electroporation 
was tried as an alternative to DEAE dextran to facilitate transfection of COS-1 cells; 
and the mutant proteins were made as five domain constructs (i. e. the five N-terminal 
domain of ICAM-1 1 fused to human IgG, Fc). Electroporation did not prove any 
better than DEAE dextran as again very little R"'GE/AAA ICAM-117c was secreted 
(Fig. 3.3 A lane 3), but N`sb/A ICAM-lFc was secreted into the medium at similar 
levels to wt (Fig. 3.3 A lane 1 and 2). 
The five domain version of the ICAM-lFc construct has a different Fc 
portion to the three domain construct and is able to dimerise, thus the five domain 
proteins run on SDS-PAGE under non-reducing conditions as an approximately 200 
kDa band. 35S-methionine labelling of COS-1 cells transfected with cDNA for five 
domain R12SGE/AAA ICAM-117c showed that this form of the protein could be 
secreted (Fig 3.3 B lane 2), whereas, as seen previously, two different cDNA clones 
of the three domain version were not secreted (Fig. 3.3 B lanes 3 and 4). The five 
domain constructs were therefore used in all further experiments. 
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Figure 3.3 Three domain ICAM-1Fc with mutation R'2`GE/AAA is synthesised 
at reduced level and poorly secreted from electroporated cells, however a five 
domain version is secreted. 
Protein A Sepharose affinity purified proteins from the cell lysate and cell growth 
medium of 35S-methionine labelled COS-1 cells transfected A: by electroporation 
with three domain versions of wt ICAM- l Fc (lane 1), N' -"/A ICAM-1 Fc (lane 2), 
R'uGE/AAA ICAM-lFc (lane 3), or mock transfected (lane 4) or B: by DEAE 
dextran with three domain wt ICAM-lFc (lane 1), five domain R'1SGE/AAA ICAM- 
lFc (lane 2), three domain R''SGE/AAA ICAM-lFc clone I (lane 3), three domain 
R' GF/AAA ICAM- l Fc clone 2 (lane 4), or mock transfected (lane 5). The 
expected positions of the 3 domain and five domain ICAM-lFc proteins are 
indicated by the black open arrows and the red open arrow respectively. 
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3.2.3 Mutation H152HG/AAA in domain 2 of a five domain ICAM-lFc 
construct reduces T cell binding 
T cell binding to ICAM-1 is mediated by LFA-1. Therefore, to assess the 
effect of mutations in domain 2 of ICAM-1 on binding to LFA-1, the five domain 
versions of wt, R'2 GE/AAA, R149RD/AAA, H'52HG/AAA and N156/A ICAM-1Fc 
proteins were titrated onto Immulon-1 plates and tested for their ability to support 
adhesion of T cells. Mutation H152HG/AAA had the greatest effect on T cell 
adhesion, showing reduced ability to support T cell binding compared to wt ICAM- 
1Fc (Fig. 3.4 A). At saturating concentrations the other mutants supported similar 
levels of T cell adhesion to wt ICAM-lFc, although binding to all the mutants was 
reduced to some extent at sub-saturating concentrations (Fig. 3.4 B). To ensure that 
these results were due to the H'SZHG/AAA mutation affecting LFA-1 binding and not 
due to a gross defect in the structure of the molecule, the integrity of the protein was 
checked by SDS-PAGE and the binding of a panel of ICAM-1 antibodies was tested. 
SDS-PAGE showed that all the mutants and wt ICAM-1Fc run as one band of 
approximately 200 kDa under non-reducing conditions (data not shown). Wt and 
H152HG/AAA ICAM-1Fc, when compared at equal concentrations, showed similar 
levels of binding of a panel of ICAM-1 mAbs (Fig. 3.4 C), thus indicating that the 
structure of H'52HG/AAA ICAM-1Fc was intact. Therefore, residues His1S2HisGly, 
which lie in the EF loop at the bottom of domain 2 of ICAM-1, have a role in 
ICAM-1 binding to LFA-1. 
When the T cell binding assays were performed with the ICAM-1Fc proteins 
captured on plates coated with an antibody against the Fc portion of human IgG, the 
same pattern of results were seen as when the ICAM-lFc proteins were coated directly 
on plastic (data not shown). These results dismiss the possibility that the reduced T cell 
binding to HHG/AAA ICAM-lFc was due to lower coating density on the plates. 
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Figure 3.4 Mutation H152HG/AAA in ICAM-1Fc disrupts T cell binding. 
T cell binding stimulated by 2 mM MgCI, /1 mM EGTA to 0-10 µg/ml A: wt ICAM- 
1Fc ( ) and H`S2HG/AAA ICAM-IFc (A) and B: wt ICAM-IFc (0), R'25GEJAAA 
ICAM-1Fc (A), R'49RD/AAA ICAM-lFc (") and N"`'/A ICAM-IFc ("). Data 
(mean of triplicates ± S. D. ) from one representative experiment (n=4) are shown. C: 
An ELISA to test the binding of a panel of ICAM-1 mAbs (used as neat supernatant, 
1/100 ascites or 10 µg/ml purified mAb) to 10 µg/ml wt ICAM- l Fc ( ) and 
H'52HG/AAA ICAM-lFc (O). Data from one representative experiment (n=3) are 
shown. 
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3.3 DISCUSSION - THE ROLE OF ICAM-1 DOMAIN 2 IN BINDING 
LFA-1 
The first part of this work has established that domain 2 of ICAM-1 has a role 
in binding to LFA-1. In particular, the residues His152HisGly, which lie in the EF 
loop at the bottom of domain 2, prove to be important. It was not clear from this 
work, however, whether residues His152HisGly directly bind LFA-1, or whether their 
mutation indirectly affects the LFA-1 binding site in domain 1. These possibilities 
were investigated by P. Stanley in the laboratory (Stanley et al., 2000). She showed 
that mutation of His'SZHisGly prevented binding to the isolated I domain of LFA-1. 
Mutation of Glu34 in domain 1 of ICAM-1 has already been shown to prevent 
binding to the I domain (Stanley and Hogg, 1998), in keeping with the hypothesis 
that G1u34 coordinates the divalent cation bound to the I domain (Lee et al., 1995b). 
Although the two N-terminal domains of ICAM-1 contain a similar number of 
residues as the I domain, the I domain is a much more compact structure, being 
approximately 25 A in diameter compared to the 38 A diameter of domain 1 of 
ICAM-1. The size of the I domain relative to an Ig-like domain makes it impossible 
for the I domain to bind to G1u34 in domain 1 and to His'SZHisGly in domain 2 at the 
same time. Further evidence against His'SZHisGly directly binding to the I domain 
comes from the crystal structure of ICAM-1, which reveals that His'SZHisGly and 
G1u34 are on opposite sides of the molecule (see Fig. 3.1) (Casasnovas et al., 1998b). 
In support of an indirect effect by His'SZHisGly on I domain binding, the I domain 
was unable to bind to a chimeric protein in which domain 1 of ICAM-1 was replaced 
with domain 1 of VCAM-1. Using this construct it was also shown that the ICAM-1 
domain 2 mAbs, which had been shown to inhibit interaction with LFA-1, do this 
indirectly (Stanley et al., 2000). Therefore domain 2 of ICAM-1 appears to have a 
critical role in binding to LFA-1, but does not bind directly. 
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It was unexpected that a three domain ICAM-lFc construct was misfolded 
and poorly synthesised upon mutation of some residues in domain 2, but that these 
problems were not encountered when the same mutations were made in a five 
domain ICAM-1Fc construct. The five domain constructs differ from the three 
domain constructs in that they have a Fc portion that allows dimerisation. Whether 
dimerisation or the presence of all five domains contributes to the stability of the 
protein is unclear. Proper folding of domain 1 of ICAM-1 is dependent on domain 2 
(Stanley et al., 2000; Staunton et al., 1990), therefore it is possible that mutation of 
domain 2 could affect the structure of domain 1. Another study has found that 
folding at the bottom of domain 2 affects binding of rhinovirus to domain 1 
(Casasnovas et al., 1998a), providing evidence that alterations in structure in one 
domain can be transmitted through the molecule to affect the structure of another 
domain. 
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3.4 RESULTS - BINDING SITES IN ICAM-3 FOR LFA-1 
3.4.1 Identification of ICAM-3 mAbs that inhibit interaction with LFA-1 
As domain 1 and 2 of ICAM-3 had been shown to contain the LFA-1 binding 
site (Fawcett et al., 1992), it was decided to further localise the binding site by a 
combination of mutagenesis of these two domains and mapping of function blocking 
mAbs. This work was done in collaboration with C. Holness and D. Simmons, Cell 
Adhesion Laboratory, ICRF, Oxford and P. Bates Biomolecular Modelling 
Laboratory, ICRF. 
First, to identify function-blocking mAbs, a panel of 16 ICAM-3 mAbs, 
obtained from Leukocyte Typing V, was tested for ability to block T cell binding to 
ICAM-3Fc immobilised on Immulon-1 plates. Although this interaction was 
completely inhibited by LFA-1 mAb 38, all the ICAM-3 mAbs (at 10 . tg/ml or 1/100 
dilution of ascites) failed to affect T cell adhesion (Fig. 3.5). Four ICAM-3 mAbs 
that were not submitted to the Leukocyte Typing Workshop, CH3.1, CH3.2, CH3.3 
and KS 118, were tested separately and showed no effect on T cell binding to ICAM- 
3 (data not shown). These four mAbs were only available in the form of tissue 
culture supernatant and, therefore, may not have been tested at optimum 
concentration. In conclusion, these experiments failed to identify any function- 
blocking ICAM-3 mAbs. 
3.4.2 Structural integrity of ICAM-3Fc mutants and mapping of ICAM-3 
mAbs 
Based on the results of ICAM-1 mutagenesis, residues predicted to be 
exposed on the CFG face of ICAM-3 domain 1 were substituted in an ICAM-3Fc 
construct containing domains 1 and 2 of ICAM-3 (see Fig. 3.6). Connecting loops 
between ß-strands in domain 2 were also mutated (see Fig. 3.6). The ICAM-3 mAbs 
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Figure 3.5 Effect of ICAM-3 mAbs on T cell binding to ICAM-3 
T cell binding to ICAM-3Fc stimulated by 2 mM MgCI2/1 mM EGTA/50 nM PdBu 
in the presence of the indicated mAbs (1/100 dilution). Data (mean of triplicates ± 
S. D. ) from one representative experiment (n=3) are shown. 
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Figure 3.6 A model of domains 1 and 2 of ICAM-3 
This model of domains I and 2 of ICAM-3 was produced by P. Bates, Biomolecular 
Modelling Laboratory, ICRF. The locations of residues subjected to site-directed 
mutagenesis are shown. 
105 
LFA-1 BINDING SITES ON ICAM-1 AND ICAM-3 
that were in most abundant supply were tested for reactivity with wt and mutated 
ICAM-3Fc. The aim of this experiment was to check the structural integrity of the 
mutant proteins and also to map the epitopes of the mAbs. None of the mutations 
disrupted the binding of more than one mAb (Fig 3.7 B-H), indicating that the 
structure of the mutant proteins was intact. A control mAb did not react with any of 
the proteins (Fig. 3.7 A). All the ICAM-3 mAbs reacted with wt ICAM-3Fc 
domains 1 and 2 (Fig. 3.7). A construct in which murine ICAM-1 domain 1 was 
fused to human ICAM-3 domains 2 and 3 (mlh2-3 ICAM-3Fc) was used to identify 
mAbs that recognise epitopes in domain 2. Only KS 128 recognised this construct 
(Fig. 3.7 H). Binding of this mAb was reduced by mutations R127/A and D 166/A in 
domain 2 (Fig. 3.7 H). Binding of mAbs CH3.1, CH3.2 and CH3.3 was not affected 
by any of the mutations (Fig. 3.7 B-D). CG106 recognised an epitope affected by 
mutation E37/A (Fig. 3.7 E), whereas BY44 recognised an epitope affected by 
mutation S681K (Fig. 3.7 F). KS 118 showed reduced binding to a number of the 
mutant proteins, in particular domain 2 mutations R127WE/AAA, R127/A and D166/A, 
although KS118 does not recognise the m1h2-3 ICAM-3Fc, indicating that its 
epitope is not solely contained in domain 2 (Fig. 3.7 G). 
3.4.3 Effect of mutations in ICAM-3 on binding to LFA-1 
T cell binding assays were used to assess the effect of the mutations in 
ICAM-3 on LFA-1 binding and to determine whether the ICAM-3 binding site for 
LFA-1 is similar to the ICAM-1 site. T cell binding was totally abolished by 
mutations E37/A, L66/K, S68/K, Q's/A and Q75/H (Fig. 3.8 A and B). The domain 2 
mutations E"3/A, P'58/A and D166/A had little effect. T cell binding to domain 1 
mutant E43/A and the domain 2 mutants R127/A and R'27WE/AAA was consistently 
lower than to wt. 
Similar results were obtained when the ICAM-3Fc proteins were captured on 
plates coated with an antibody against the Fc portion of human IgG (data not shown). 
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Figure 3.7 Mapping of ICAM-3 mAbs 
An ELISA to test the binding of a panel of ICAM-3 mAbs to wt ICAM-3Fc (1), 
mlh2-3 ICAM-3Fc (2), or ICAM-3Fc with mutation E37/A (3), E43/A (4), 06 /K (5), 
S'/K (6), Q'S/A (7), Q /H (8), R"WE/AAA (9), Eiaa/A (10), D'66 /A (11), Ri27/A 
(12), P'-"'8/A (13). A: ICAM-1 mAb 15.2 was used as a negative control. The ICAM- 
3 mAbs used are B: CH3.1, C: CH3.2, D: CH3.3, E: CG106, F: BY44, G: KS118, 
and H: KS 128. All proteins were tested at 10 µg/m1 and all mAbs were used as neat 
supernatant. Data from one representative experiment (n=3) are shown. 
107 
123456789 10 11 12 13 
0 
123456789 10 11 12 13 
0 
123456789 10 11 12 13 123456799 10 11 12 13 
0 
123456789 10 11 12 13 
0 
123456789 10 11 12 13 
0 
123456789 10 11 12 13 
0 
123456789 10 11 12 13 
LFA-1 BINDING SITES ON ICAM-1 AND ICAM-3 
A 50 
40 
30 
a., 0 
9 20 
"o 
.5 
10 
01 
0. 
B 
0 
0 
60 
r 
50 
Z 
V 
40 
4. + 
30 
b0 
5 -0 
v 10 
E4 
1 l0 
Protein concentration (µg/ml) 
Figure 3.8 Effect of mutations in ICAM-3 domains 1 and 2 on T ceR binding 
2 mM MgC12/1 mM EGTA/50 nM PdBu stimulated T cell binding to 0-20 [ug/ml A: 
wt ICAM-3Fc (U) or ICAM-3Fc with mutation E3'/A (A), E43/A ("), Q75/A ("), 
Q75/H (Q), P'-58/A (h), and B: wt ICAM-3Fc ( ), or ICAM-3Fc with mutation 
RIVWFJAAA (A), R"/A (0), LI)`'/K ("), S`'H/K (Q), E'43/A (A), D"/A (0). Data 
(mean of triplicates ± S. D. ) from one representative experiment (n=5) are shown. 
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3.5 DISCUSSION - BMING SITES IN ICAM-3 FOR LFA-1 
Mutagenesis suggests that the residues in ICAM-1, ICAM-2 and ICAM-3 
that mediate binding to LFA-1 are similar but not identical. In this study residues 
G1u37 and G1n75 in domain 1 of ICAM-3 were shown to be essential for binding to 
LFA-1 and these results have been confirmed in other studies (Klickstein et al., 
1996; Sadhu et al., 1994). These two residues correspond to G1u34 and G1n73 of 
ICAM-1 and Glu" and G1n75 of ICAM-2, which have also been shown to be essential 
for binding to LFA-1 (Staunton et al., 1990; Casasnovas et al., 1999). These residues 
are not conserved in ICAM-4, but are replaced by ArgS2 and Thr91, mutation of which 
has no effect on binding to LFA-1 (Hermand et al., 2000). In ICAM-5, G1u40 is the 
equivalent of G1u37, but Thr79 occupies the equivalent of the second position. 
However, information is not yet available on the role of these residues in binding to 
LFA-1. Mutation of GIu34 in ICAM-1 prevents binding to a recombinant form of the 
LFA-1 I domain (Stanley and Hogg, 1998), and it is proposed that this residue 
coordinates Mg2+ bound to the I domain (Lee et al., 1995b). 
The crystal structure of ICAM-3 is not yet available but it is predicted that, as 
for ICAM-1 and ICAM-2, G1u37 lies in strand C and Gln75 in strand G. Other 
residues on the CFG face were shown to be important for binding to LFA-1, namely 
Leu66 and Ser68. In other studies G1u32, Lys33, Thr38, Lys42, Phe" and Arg" of 
ICAM-3 have all been shown to play a role in the binding site for LFA-1 (Bell et al., 
1998; Klickstein et al., 1996; Sadhu et al., 1994). Four positions, corresponding to 
G1u37, Phe 54, Ser68 and Gln75 in ICAM-3, are also important in ICAM-1 and 2 
(Casasnovas et al., 1999). Binding to the Lys42 ICAM-3 mutant was consistently 
reduced compared to binding to wt, but was not severely disrupted. The 
corresponding residue in ICAM-1 and ICAM-2 is essential for binding (Casasnovas 
et al., 1999; Fisher et al., 1997), and for ICAM-3 it has been shown to be necessary 
for binding when activation is not optimum (Holness et al., 1995). It has been 
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suggested that the role of this residue in ICAM-2 may be to orientate the side chain 
of the critical residue G1u37 (Casasnovas et al., 1999). For ICAM-1 and ICAM-2, the 
LFA-1 binding site is rectangular in shape and is present on a long flat ridge on 
domain 1. In contrast to the LFA-1 binding sites on ICAM-1 and ICAM-2, there is 
evidence that the LFA-1 binding site on ICAM-3 may also include residues on the 
BED face (Bell et al., 1998; Klickstein et al., 1996). 
Unlike for ICAM-1, domain 1 of ICAM-3 can be expressed independently of 
domain 2 (Klickstein et al., 1996). Experiments with domain deletion mutants of 
ICAM-3 indicate that domain 1 is sufficient for binding LFA-1 and that domains 2 
and 3 do not contribute to the binding site (Klickstein et al., 1996). Others, however, 
report that mutations in domain 2 of ICAM-3 can diminish LFA-1 binding, including 
His" and Gly1S6, which correspond to His'53 and Gly'S4 in ICAM-1 (Bell et al., 1998; 
Holness et al., 1995). Whether the role of these residues is indirect, as has been 
shown here for ICAM-1, was not investigated. None of the mutations made in 
domain 2 were found to have a severe effect on LFA-1 binding. Mutation of R' 27 
and R127WE in the CC' loop of domain 2 did reduce T cell binding, and in another 
study, using LFA-1 transfectants, it was shown that the effect of these mutations is 
more pronounced when activation of LFA-1 is not optimum (Holness et al., 1995). 
The equivalent residues in ICAM-1 are R125GE, which are shown here not to play a 
role in LFA-1 binding (see Fig. 3.4). 
The ICAM-3 mAb CG106 was mapped to an epitope including G1u37, and 
binding of BY44 was diminished by mutation of Ser68. These two mutations 
completely prevented LFA-1 binding, therefore it was surprising to find that CG106 
and BY44 did not inhibit T cell binding to ICAM-3. Another study has confirmed 
the mapping of CG106 to G1u37 and shown that the BY44 epitope also includes G1n75. 
They find, however, that these two mAbs, as well as several others in the Leukocyte 
Typing V panel, are inhibitory for LFA-1 binding to ICAM-3 (Klickstein et al., 
1996). The discrepancy in results remains unexplained but different assays were 
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used and the mAbs should have been titrated. KS128 maps to domain 2, however it 
has been reported that its epitope also encompasses residues in domain 1 (Klickstein 
et al., 1996). 
3.6 RESULTS - LFA-1 BINDING TO ICAM-1 WITH THE ICAM-1`111 
POLYMORPHISM 
3.6.1 Effect of the ICAM-11{i1i' polymorphism on structural integrity of the 
protein 
In collaboration with A. Craig, Oxford and D. Altieri, Yale University, USA, 
the mechanism by which the ICAM-1K'"f' polymorphism is maintained, despite being 
associated with susceptibility to cerebral malaria, was investigated. The mutation 
K29/M was introduced into a five domain version ICAM-1Fc (K29/M ICAM-1Fc). 
Before using this protein in functional assays it was important to ensure that the 
structure was intact. ELISAs were performed to compare the binding of a panel of 
ICAM-1 mAbs to equal amounts of wt ICAM-1Fc and K29/M ICAM-1Fc. The 
results demonstrate that the epitopes for all the mAbs, with the exception of BBA4, 
are present on K29/M ICAM-1Fc at the same level as on wt ICAM-lFc (Fig. 3.9 A). 
Binding of BBA4 has previously been shown to be destroyed by the K29/M mutation 
(Fernandez-Reyes et al., 1997). 
3.6.2 Effect of the ICAM-1"'''n polymorphism on T cell binding 
Having verified the structural integrity of the K29/M ICAM-lFc protein, it 
was tested for ability to support LFA-1-mediated T cell adhesion. LFA-1 binding to 
ICAM-1 is critical for many functions in the immune system, therefore alteration of 
this interaction could have immunomodulatory effects that provide a compensatory 
selective advantage for individuals with the ICAM-1K'''f' gene. At protein 
concentrations that supported maximal T cell binding, similar numbers of cells 
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Figure 3.9 Effect of ICAM-1'`"M polymorphism on structural integrity and T 
cell binding 
A: An ELISA to test the binding of a panel of ICAM-1 mAbs (at 5 µg/ml) to 10 
µg/ml ICAM-lFc (") and ICAM-1'"f'fi (U). MSP2 is used as a negative control 
mAb. Data are from a representative experiment (n=4). B: T cell binding to 0-40 
µg/ml ICAM-IFc (A) and ICAM-1'K"" ( ) stimulated by 50 nM PdBu. Data (mean 
of triplicates ± S. D. ) are from a representative experiment (n=3). 
6E6 15.2 BBA4 14C II 
112 
LFA-1 BINDING SITES ON ICAM-1 AND ICAM-3 
bound to K29/M ICAM-lFc and wt ICAM-lFc. At sub-saturating conditions, 
however, binding to K29/M ICAM-1Fc was reduced compared to binding to wt 
ICAM-1Fc (Fig. 3.9 B). This result shows that at low concentrations K29/M ICAM- 
1Fc is compromised in its ability to bind LFA-1. 
3.7 DISCUSSION - LFA-1 BINDING TO ICAM-1 WITH TILE 
ICAM-1"POLYMORPHISM 
To recognise the functional basis by which the ICAM-iK1if polymorphism is 
maintained despite an association with cerebral malaria, an ICAM-lFc construct 
with the mutation K29/M was made and compared with wt ICAM-1Fc for the ability 
to support a number of ICAM-1 functions. As demonstrated in this chapter, K29/M 
ICAM-1Fc has reduced affinity for LFA-1. LFA-1 binding to ICAM-1 plays a 
crucial role in the immune system, mediating leukocyte-leukocyte and leukocyte- 
endothelial interactions. The interaction of ICAM-1 with fibrinogen also mediates 
leukocyte-endothelial interaction, with fibrinogen acting as a bridge between ICAM- 
1 on the endothelium and Mac-1 on the leukocyte (Languino et al., 1993). D. Altieri 
and colleagues found that the binding of K29/M ICAM-1Fc to fibrinogen was 
severely impaired (Craig et al., 2000). Thus, by reducing leukocyte adhesion, the 
polymorphism could have beneficial effects, for instance by limiting the leukocyte 
mediated tissue damage that occurs in response to infection. 
Rhinovirus is likely to have an impact on childhood mortality in areas of 
malarial transmission, if not directly then through secondary bacterial infection. The 
adherence of rhinovirus to K29/M ICAM-1Fc is one crucial ICAM-1 function that we 
were unable to investigate in this study. Lys29 lies at the end of the B to C loop in 
domain 1 of ICAM-1 (see Fig. 3.1). Mutation of residues Asp26-Lys29 in this loop 
has been shown to reduce rhinovirus binding to 13% of the level of binding to wt 
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ICAM-1 (Staunton et al., 1990), suggesting that the ICAM-l"' polymorphism could 
be protective against rhinovirus infection. 
Susceptibility to malaria is determined by a complex evolutionary interplay 
between host and parasite genetics. Therefore, as well as human gene 
polymorphisms, variants of P. falciparum also occur. In previous studies, mutation 
of Lys29 had no effect on infected erythrocyte binding to ICAM-1 (Berendt et al., 
1992; Ockenhouse et al., 1992). However, when two different laboratory isolates of 
P. falciparum were tested for adherence to K29/M ICAM-lFc it was found by A. 
Craig and colleagues that binding of one was disrupted but the other not (Craig et al., 
2000). These results are likely to reflect a variation in the parasite protein that 
mediates adhesion to ICAM-1. Geographical variation in P. falciparum populations 
may explain why the ICAM-1K'''f polymorphism predisposes to cerebral malaria in 
Kenya (Fernandez-Reyes et al., 1997), but shows no association in The Gambia, an 
area of low malaria transmission (Bellamy et al., 1998). 
3.8 CONCLUSION 
In conclusion, the work in this chapter demonstrates that for ICAM-3 similar 
residues to ICAM-1 and ICAM-2 are involved in binding LFA-1. The main LFA-1 
binding site lies on the face of domain 1 of the ICAMs formed by the C, F and G 0- 
strands and the CD edge. Evidence is also provided that, in addition to domain 1, 
domain 2 of both ICAM-1 and ICAM-3 plays a role in binding LFA-1. Finally, it is 
shown that the ICAM-1' polymorphism reduces the affinity of ICAM-1 for LFA-1 
and we speculate that this may have an immuno-modulatory effect that could provide 
an evolutionary selective advantage. 
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A ROLE FOR THE LFA-1 I DOMAIN IN HIGH AFFINITY 
BINDING TO ICAM-1 
4.1 INTRODUCTION 
In this laboratory, two methods have been used to induce LFA-1 on T cells to 
bind to its ligands. The characteristics of the active LFA-1, however, differ 
depending on the method of stimulation. The first method is PKC activation by the 
phorbol ester PdBu, which is thought to mimic signalling following engagement of 
the T cell receptor or chemokine receptors. PdBu does not induce a detectable 
increase in LFA-1 affinity, but enhances the avidity of adhesion through a pathway 
dependent on PKC, intracellular Ca2+ and the actin cytoskeleton (Stewart et al., 
1996). Further details of this form of adhesion are investigated in Chapter 5. The 
second method is addition of the divalent cation Mg2+ with the simultaneous 
chelation of Ca2+ using EGTA. It is thought that Mg2+ binds to the MIDAS motif in 
the I domain and induces a change in the conformation of LFA-1 that allows ligand 
binding. Activation with Mg2+ increases the affinity of LFA-1 for its ligands, as 
detected by its increased ability to bind ICAM-1 in solution (Stewart et al., 1996). 
Expression of the epitope recognised by mAb 24 is dependent on temperature and 
Mg 2+ or Mn", and is a distinctive feature of this high affinity LFA-1 (Dransfield and 
Hogg, 1989; Stewart et al., 1996). 
It is not known whether LFA-1 uses different sites to bind ligand depending 
on the method of activation. Sites involved in ligand binding have been identified in 
both the LFA-1 a subunit N-terminal repeats (Stanley et al., 1994) and in the ß 
subunit (Bajt et al., 1995). A third putative site was initially identified when cloning 
of the LFA-1 a subunit revealed an insertion of approximately 200 amino acids 
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between repeats II and III in the N-terminus (Larson et al., 1989). It was noted that 
this domain is homologous to domains in von Willebrand Factor that had been 
shown to interact with ligand (Larson et al., 1989). This region was termed the "I" 
(inserted/interactive) domain. A number of pieces of evidence demonstrate that the 
LFA-1 I domain is indeed a major binding site for ICAM-1: anti-LFA-1 a chain 
antibodies that block ligand binding map to the I domain (Champe et al., 1995; 
Edwards et al., 1998; Randi and Hogg, 1994); the isolated I domain can bind directly 
to ligand (Randi and Hogg, 1994); LFA-1 in which the I domain is replaced with the 
murine sequence, or from which the I domain has been removed, does not bind 
ligand (Edwards et al., 1995; Leitinger and Hogg, 2000). 
In this chapter, recombinant I domain and constituent peptides have been 
used to investigate how the LFA-1 I domain participates in Mgt/EGTA- and PdBu- 
stimulated T cell adhesion to ICAM-1 and ICAM-3. 
4.2 RESULTS 
4.2.1 The LFA-1 I domain inhibits Mgt+/EGTA- but not PdBu-induced 
adhesion of T cells to ICAM-1 
To investigate the role of the LFA-1 I domain in T cell adhesion to 
immobilised ICAM-1, a recombinant chimeric protein composed of the I domain 
residues Gly'Z$-Ser327 connected to the Fc portion of human IgG, (I-Fc) was tested for 
its effect on Mgt+/EGTA- and PdBu-stimulated adhesion. I-Fc inhibited 
Mgt+/EGTA-stimulated adhesion in a dose dependent manner, but had no effect on 
PdBu-stimulated adhesion (Fig. 4.1 A). Both forms of adhesion were completely 
blocked by mAbs against LFA-1 (Fig. 4.1 A). I-Fc with the mutation Asp239/Ala, 
which has been shown to be non-functional (Edwards et al., 1995; Kamata et al., 
1995), did not interfere with Mgt+/EGTA-stimulated adhesion (Fig. 4.1 B), 
suggesting that the inhibitory effect of I-Fc was specific. 
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Figure 4.1 The effect of the I domain on T cell adhesion to ICAM-1 
A: T cell binding to immobilised ICAM-lFc stimulated by Mgt /EGTA (") or PdBu 
(I) in the presence of 0-50 µg/ml I-Fc. Anti-LFA-1 mAb 38 at 10 µg/ml (0) totally 
inhibits adhesion. B: Mgt+/EGTA stimulated T cell adhesion to ICAM-lFc in the 
presence of 0-50 µg/ml wild type I-Fc (") or D2-9/A l-Fc (A). Data (mean of 
triplicates ± S. D. ) from one representative experiment (n=3) are shown. 
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The I domain with an amino-terminal extension of 17 amino acids (residues 
Leu"'-Ser327) was made as a GST fusion protein (I-GST) (Stanley and Hogg, 1998) 
and proved to be more stable and more effective than I-Fc. I-GST was similar to I- 
Fc in its effect on adhesion, inhibiting Mgt/EGTA-stimulated adhesion but having 
no effect when adhesion was induced by PdBu (see Fig. 1 of McDowall et al., 1998), 
and was therefore used in all subsequent experiments. 
4.2.2 The strengths of Mgt+/EGTA- and PdBu-stimulated T cell adhesion to 
ICAM-1 are similar 
The failure of the I domain to inhibit PdBu-stimulated adhesion could be 
explained if the overall strength of PdBu-induced adhesion was stronger, and 
therefore less easily inhibited, than that stimulated by Mgt/EGTA. This possibility 
was investigated by titrating the ICAM-1 function blocking mAb 15.2 in PdBu- and 
Mgt+/EGTA-activated T cell adhesion to ICAM-1 (Fig. 4.2). Both forms of adhesion 
were equally inhibited by this mAb, indicating that the overall strengths of PdBu- 
and Mgt/EGTA-stimulated adhesion are similar and that there must be an alternative 
explanation for the effects of the I domain being dependent on the stimulus for 
adhesion. 
4.2.3 The LFA-1 I domain inhibits expression of the mAb 24 activation epitope 
on T cell LFA-1 
Another mechanism by which the recombinant I domain could exert an 
inhibitory effect on adhesion stimulated by Mgt+/EGTA, but not on PdBu-stimulated 
adhesion, could be by preventing a conformational change necessary for the 
formation of the Mgt+/EGTA-induced high affinity form of LFA-1. To investigate 
this potential mechanism, the effect of the I domain on the binding of mAb 24 was 
tested. The epitope for this antibody is exposed upon Mgt+/EGTA activation of 
LFA-1, but not upon PdBu activation, and is thought to reflect a conformational 
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Figure 4.2 Titration of an anti-ICAM-1 mAb to compare the strength of 
Mgt+/EGTA- and PdBu-stimulated adhesion 
T cell binding to immobilised ICAM-lFc stimulated by Mg`+/EGTA (") or PdBu 
( ) in the presence of 0-10 µg/ml anti-ICAM-1 mAb 15.2. Data (mean of triplicates 
± S. D. ) from one representative experiment (n=4) are shown. 
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change which leads to the high affinity form of the integrin (Stewart et al., 1996). I- 
GST inhibited the expression of the mAb 24 epitope in a dose dependent manner 
(Fig. 4.3 A and B). Two other anti-LFA-1 a subunit mAbs which, like 24, do not 
bind to the I domain are S6F1 and G25.2 (Leitinger and Hogg, 2000; Randi and 
Hogg, 1994). These two mAbs have been shown to recognise different epitopes in 
the putative ß-propeller domain (Huang and Springer, 1995). I-GST did not affect 
the binding of either of these antibodies (Fig. 4.3 C and D). These data show that 
the I domain specifically interferes with expression of the activation dependent 
epitope recognised by mAb 24. This result implies that the I domain inhibits 
Mgt+/EGTA-stimulated T cell binding to ICAM-1 by interacting with LFA-1 on the 
T cells, thereby preventing conversion to the high affinity conformation of the 
integrin. 
4.2.4 LFA-1 interaction with ICAM-1 is not necessary for expression of the 
activation epitope 24 
If mAb 24 recognises a ligand induced binding site (LIBS) on LFA-1, then 
the I domain could inhibit expression of the mAb 24 epitope by binding to ICAM-1, 
thereby blocking the interaction of ICAM-1 with LFA-1 necessary for triggering 
formation of the LIBS. Alternatively, although it has been shown that both I-Fc and 
I-GST bind to ICAM-1Fc in cell free assays (Randi and Hogg, 1994; Stanley and 
Hogg, 1998), in the T cell adhesion assay the I domain may bind to LFA-1 on the T 
cells, thus preventing a conformational change necessary for the epitope for mAb 24 
to be revealed. Blocking LFA-1 interaction with ICAM-1, either with ICAM-1 
mAbs 15.2 or RR1I1 or with LFA-1 mAb 38, does not alter 24 expression (Fig. 4.4), 
suggesting that LFA-1 interaction with ICAM-1 is not required for expression of the 
mAb 24 epitope. These findings imply that the I domain inhibits T cell binding by 
interacting with LFA-1 on the T cell and preventing a conformational change 
necessary for formation of high affinity LFA- 1. 
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Figure 4.3 The effect of the I domain on binding of mAbs 24, S6F1 and G25.2 to 
T cells stimulated by Mgt+/EGTA 
A: Mean fluorescence of mAb 24 on T cells incubated at 37°C in Mg2/EGTA in the 
presence of 0-6 µM I-GST ("). The background binding of mAb 24 to T cells 
incubated in Mg2/EGTA at 4°C ( ). Data from one representative experiment (n=3) 
are shown. B: The binding of mAb 24 to T cells incubated in Mgt /EGTA at 4°C 
at 37°C (-) and at 37°C with 4 µM I-GST (-). Data from one representative 
experiment (n=4) are shown. The binding of C: mAb S6F1 and D: mAb G25.2 to T 
cells incubated in Mg2/EGTA at 37°C (-) and at 37°C with 4 µM I-GST (-). Data 
from one representative experiment (n=2) are shown. 
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Figure 4.4 The effect of inhibiting LFA-1 interaction with ICAM-1 on binding 
of mAb 24 
The binding of mAb 24 to T cells incubated at 37°C in Mg2/EGTA alone ( ), or in 
the presence of 10 µg/m1 anti-LFA-1 mAb 38 (-), or anti-ICAM- l mAbs 15.2 (-) 
or RR1/1 (-). Data from one representative experiment (n=3) are shown. 
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4.2.5 Peptides 1(217-233) and 1(238-254) inhibit Mgt+/EGTA- but not PdBu- 
stimulated T cell binding to ICAM-1 
To determine the regions within the I domain specifically required for 
Mgt+/EGTA-stimulated adhesion, peptides spanning the I domain (Table 4.1) were 
tested for their effect on T cell binding to ICAM-1. When adhesion was activated by 
Mgt+/EGTA only peptides 1(217-233) and 1(238-254) consistently blocked LFA-1 
binding to ICAM-1 (Fig. 4.5 A). The average level of inhibition with 2 mM peptide 
was 50% with 1(217-233) and 72% with 1(238-254) (n=13). When adhesion was 
induced with PdBu none of the peptides tested had an inhibitory effect (Fig. 4.5 B). 
These results indicate that residues Thr2"-Va1233 and Thr238-Ile214 of the I domain are 
specifically involved in Mgt/EGTA-induced LFA-1 binding to ICAM-1. 
4.2.6 Subpeptides of 1(217-233) and 1(238-254) also inhibit Mgt/EGTA- 
stimulated T cell binding to ICAM-1 
To further define the residues of the I domain critical for Mgt+/EGTA- 
stimulated LFA-1 binding to ICAM-1 overlapping peptides covering the region 
Thr2 7-Ile1S4 were made (Table 4.1 - second series). 1(238-246), 1(242-254) and 
1(247-258), sub-peptides of 1(238-254), the most inhibitory peptide in the first series, 
all blocked Mgt+/EGTA-stimulated T cell binding to ICAM-1 in a dose dependent 
manner equivalent to the parent peptide (Fig. 4.6 A). The control peptide 1(256-275) 
had no effect at the same concentrations (Fig. 4.6 A). 1(223-233) also had an 
inhibitory effect on adhesion (Fig. 4.6 B) which corresponded to the levels of 
inhibition with the parent peptide 1(217-233) (data not shown). Unfortunately 1(210- 
223) could not be tested due to its limited solubility. 
Scrambled versions of 1(223-233) and 1(238-254) were made (Table 4.1 ) and 
these controls did not affect T cell binding to ICAM-1, indicating that the dose- 
dependent inhibition seen with 1(223-233) and 1(238-254) was specific (Fig. 4.6 B). 
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Peptide Amino acid sequence 
1(130-159) VDLVFLFDGS. MSLQPDEFQK . ILDFMKDVMK 
1(193-202) DALLKHVKHN 
1(217-233) TEVFREELGA. RPDATKV 
1(238-254) TDGEATDSGN. IDAAKDI 
1(256-275) RYIIGIGKHF. QTKESQETLH 
1(276-295) KFASKPASEF. VKILDTFEKL 
I(296-312) KDLFTELQKK. IYVIEGT 
Second series 
1(223-233) ELGARPDATK. V 
1(238-246) TDGEATDSG 
1(242-254) ATDSGNIDAA. KDI 
1(247-258) NIDAAKDIIR. YI 
Scrambled controls 
1(223-233) VKLETAGADR. P 
1(238-254) DIDTKAEGAD. TAINSDG 
Table 4.1 LFA-1 I Domain Peptides and Amino Acid Sequences 
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Figure 4.5 The effect of LFA-1 I domain peptides on T cell adhesion to 
ICAM-1. 
The effect of LFA-1 peptides (2 mM) on T cell binding to ICAM-lFc 
following stimulation with A: Mgt+/EGTA or B: PdBu. Data (mean of 
triplicates ± S. D. ) from one experiment (n=13) are shown. 
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Figure 4.6 Mgt/EGTA stimulated T cell adhesion to ICAM-1 with a titration of 
inhibitory LFA-11 domain peptides and control peptides 
Mgt+/EGTA stimulated T cell binding to ICAM-IFc with A: titration of 1(238-254) 
("), overlapping peptides 1(238-246) ( ), 1(242-254) ("), I(247-258) (A) and 
control peptide 1(256-275) ( ) and B: titration of 1(223-233) (0), its scrambled 
control (D), 1(238-254) (") and its scrambled control (0). Data (mean of triplicates 
± S. D. ) from one representative experiment (n=3) are shown. 
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4.2.7 Peptide 1(238-254) inhibits 24 expression 
To test whether the peptide inhibition of T cell binding to ICAM-1 occurs by 
the same mechanism as the soluble I domain inhibition, the effect of peptide I(238- 
254) on mAb 24 expression was analysed. 1(238-254), but not its scrambled control, 
inhibited 24 expression (Fig. 4.7). The average level of inhibition of 24 expression 
e 
was 55% (n=4). These results suggest that 1(238-254) and the I domain interact with 
T cells in a similar manner. 
4.2.8 The position of 1(223-233) and 1(242-254) on the LFA-1 I domain crystal 
structure 
When the two function blocking peptides, 1(223-233) and 1(242-254), are 
superimposed on the crystal structure of the LFA-1 I domain (Qu and Leahy, 1995) 
they span two adjacent areas. The sequence Glu223-Va1233 corresponds to the loop 
after the a4 helix which terminates in the ß3 strand and Ala242-Ileu4 corresponds to 
the ß3 to a5 loop and continues as far as the end of the a5 helix (Fig. 4.8). 
4.2.9 Peptide 1(256-275) inhibits Mg2*/EGTA-stimulated binding to ICAM-3 
but not to ICAM-1 
The first series of peptides (Table 4.1) were also tested for their effect on 
Mgt+/EGTA-stimulated T cell adhesion to ICAM-3. As for ICAM-1, peptides 1(217- 
233) and 1(238-254) inhibited adhesion but, interestingly, 1(256-275) also had an 
inhibitory effect (Fig. 4.9). The average level of adhesion in the presence of 1(256- 
275) was 30% to ICAM-3 (n=4) and 119% to ICAM-1 (n=4). This result supports 
the idea that LFA-1 binds to ICAM-1 and ICAM-3 in a similar, but not identical, 
manner. 
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Figure 4.7 The effect of peptide 1(238-254) on the expression of the mAb 24 
epitope 
The expression of the mAb 24 epitope on T cells incubated at 37°C in Mg2/EGTA 
either without peptide ( ), or with 2 mM 1(238-254) (-) or its scrambled control 
(-). Data from one representative experiment (n=4) are shown. 
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Figure 4.8 The LFA-1 I domain crystal structure indicating the position of the 
peptides that inhibit LFA-1 interaction with ICAM-1 
A ribbon diagram of the LFA-1 I domain with the sequence corresponding to the 
1(223-233) peptide indicated in yellow and 1(242-254) in red. The metal ion bound 
to the MIDAS motif is shown in pink and the water molecules in white. This figure 
was generated by P. Bates, Biomolecular Modelling Laboratory, ICRF using 
coordinates obtained from the Brookhaven Data Bank. 
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Figure 4.9 The effect of LFA-1 I domain peptides on Mgt+/EGTA stimulated T 
cell adhesion to ICAM-3 
T cell binding to ICAM-3Fc stimulated by Mgt+/EGTA in the presence of LFA-1 I 
domain peptides (2 mM). Data (mean of triplicates ± S. D. ) from one experiment (n=4) 
are shown. 
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4.2.10 PdBu-stimulated T cell adhesion to ICAM-1 is more sensitive to 
inhibition by anti-CD18 mAbs than Mgt+/EGTA-stimulated adhesion 
A panel of anti-CD18 (LFA-1 ß2 subunit) mAbs were tested for their effect 
on T cell adhesion to ICAM-1. It was found that some CD18 mAbs are more potent 
inhibitors of PdBu-stimulated binding than of Mgt+/EGTA-stimulated binding (Fig. 
4.10 A). A number of the mAbs were titrated. Although the LFA-1 a subunit mAb 
38 inhibited Mgt"/EGTA- and PdBu-stimulated binding to a similar extent at all 
concentrations (Fig. 4.10 B), it was found that the ß2 subunit mAbs TS 1/18 and 
GRF1 inhibited PdBu-stimulated binding to a greater extent than Mgt+/EGTA- 
stimulated binding (Fig. 4.10 D and E). This effect was not seen with all ß2 subunit 
mAbs, however, as the mAb 6.5E had similar effects on both forms of adhesion (Fig. 
4.10 Q. These results suggest that the LFA-1 ß subunit has a more prominent role 
in PdBu-stimulated adhesion than in the high affinity Mgt+/EGTA-induced LFA-1 
adhesion. 
4.3 DisCUSSioN 
The finding that recombinant LFA-1 I domain interfered with Mgt+/EGTA- 
activated, but not PdBu-activated, T cell adhesion to ICAM-1 implies that the I 
domain has a distinct role in high affinity LFA-1 adhesion. An alternative 
explanation for this result was that Mgt+/EGTA-stimulated adhesion was stronger, 
and therefore less easily inhibited, than PdBu-stimulated adhesion. Both forms of 
adhesion were equally inhibited by an anti-ICAM-1 mAb, however. To further 
discount this possibility, quantitative centrifugal removal assays were performed in 
which the number of cells remaining bound to ICAM-1 following subjection to 
increasing relative centrifugal forces was measured. The number of cells was equal 
for both forms of adhesion (McDowall et al., 1998), therefore, together these data 
confirm that the overall strengths of Mgt/EGTA- and PdBu-stimulated adhesion are 
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Figure 4.10 The effect of CD18 mAbs on T cell binding to ICAM-1. 
A: T cell binding to ICAM-1Fc stimulated by 50 nM PdBu (0) or 2 mM Mg=+/1 mM 
EGTA (R) in the presence of of the indicated mAbs at 5 ltg/ml or 1/100 ascites for 
GRF 1 and CLB54 (n=3). T cell binding to ICAM- l Fc stimulated by 50 nM PdBu 
( ) or 2 mM Mg2+/1 mM EGTA (") in the presence of B: 0-10 lug/ml CDl la mAb 
38 (n=4), C: 0-10 [ug/ml CD 18 mAb 6.5E (n=3), D: 0-20 µg/ml TS 1/ 18 (n=5), E: 
1/100-1/16400 dilution of CD18 mAb GRF1 (n=3). Data (mean of triplicates ± S. D. ) 
from one representative experiment are shown. 
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similar. As low levels of Mg2' are essential for PdBu-stimulated adhesion (Stewart 
et al., 1996), the possibility that the selective inhibition of Mgt+/EGTA-stimulated 
adhesion by the recombinant I domain was due to chelation of Mg2+ by the I domain 
was discounted. 
With the use of mAb 24 it was determined that the inhibitory effect of the I 
domain occurs via interaction with T cell LFA-1 rather than with the immobilised 
ICAM-1. The expression of the epitope recognised by mAb 24 is one feature which 
distinguishes the Mgt+/EGTA-induced form of LFA-1 from the resting and PdBu- 
induced forms (Stewart et al., 1996). Exposure of this epitope is thought to reflect a 
conformational change induced by Mg2+ binding to LFA-1. The inhibition of 24 
expression by the recombinant I domain therefore suggests that the recombinant I 
domain is interfering with a conformational change within LFA-1 required for 
formation of the high affinity form of the integrin. It is known that the 24 epitope is 
somewhere on the LFA-1 a subunit other than the I domain (Dransfield and Hogg, 
1989; Leitinger and Hogg, 2000; Randi and Hogg, 1994). This suggests that what is 
being measured by 24 expression is not a conformational change in the I domain 
itself, although recent evidence shows this does occur (Emsley et al., 2000; Oxvig et 
al., 1999; Shimaoka et at., 2000), but an interdomain movement involving the I 
domain. 
Peptides covering a region of the I domain including the a4 to ß3 loop, the ß3- 
a5 loop and the a5 helix mimicked the behaviour of recombinant I domain in 
preventing Mgt+/EGTA-stimulated adhesion, and for 1(238-254) in preventing mAb 
24 expression. The I domain crystal structure shows that these two regions lie on the 
same face of the domain (see Fig. 4.8). Evidence suggests that ligand binds to the 
MIDAS face of I domains (Edwards et al., 1998; Huang and Springer, 1995; Käpylä 
et al., 2000; Rieu et al., 1996; Smith et al., 2000a; Zhang and Plow, 1997). The 
sequences corresponding to the peptides 1(223-233) and 1(242-254) lie on the side 
and towards the opposite end of the domain to the MIDAS face. It therefore seems 
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unlikely that the inhibitory effect of these two peptides is due to direct blocking of 
ligand binding. Lovastatin, a fungal metabolite, is an inhibitor of LFA-1/ICAM-1 
interaction (Kallen et al., 1999). It binds to a pocket formed by the a, and a7 helices 
and the ß4 and (35 strands on the opposite face of the I domain to the MIDAS, and is 
therefore thought to inhibit by an indirect mechanism. It is proposed that this pocket 
is a regulatory site for LFA-1 activation and that lovastatin binding locks LFA-1 in 
an inactive form, thereby allosterically interfering with ligand binding (Kallen et al., 
1999). The peptides 1(223-233) and 1(242-254) lie close to this pocket, therefore 
may inhibit interaction with ICAM-1 by a mechanism similar to that proposed for 
lovastatin. 
The seven N-terminal repeat sequences of a typical integrin a subunit have 
been modelled as aß propeller fold homologous to the heterotrimeric G protein ß 
subunit (Sondek et al., 1996; Springer, 1997). The I domain, which is structurally 
homologous to the G protein a subunit, can be positioned on the upper surface of the 
n-propeller, to one side of the central axis, mimicking the relationship between the G 
protein a and ß subunits (Lambright et al., 1996; Springer, 1997). Looking down on 
the central axis of the ß-propeller (see Fig. 4.11), the Ala"-Ile" sequence protrudes 
over the central cavity, and, potentially, the G1u223-Val" sequence makes contact 
with the ß-propeller domain. One speculation is that the conformational change in 
LFA-1 that occurs upon Mg2+ activation involves movement between the I domain 
and the ß-propeller. Therefore, recombinant I domain and peptides representing the 
a4 and a5 loop regions could compete with cellular I domain in intact LFA-1 for 
binding to the ß-propeller domain, thereby physically blocking activation. 
It was of interest that peptide 1(256-275) interfered with LFA-1 binding to 
ICAM-3 without having an effect on binding to ICAM-1. This peptide covers the ßa 
strand, the ß4 to a6 loop and most of the a6 helix. These regions are indicated in 
Figure 4.8 and lie close in the structure to the sequences represented by 1(223-233) 
and 1(242-254). Whether this peptide inhibits 24 expression remains to be tested, 
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Figure 4.11 A model of the association between the LFA-1 I domain and a 
propeller domain 
A ribbon diagram of the LFA-1 I domain (blue) and the ß-propeller domain of the 
heterotrimeric G protein transducin (green) in the same relative orientation as the a 
and ß subunits of transducin (Lambright et at., 1996). The sequence corresponding 
to the I domain peptide 1(223-233) is indicated in yellow and 1(242-254) in red. 
The arrow points to the MIDAS motif. This model was generated by P. Bates, 
Biomolecular Modelling Laboratory, ICRF using coordinates taken from the 
Brookhaven Data Bank. 
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therefore at present the mechanism by which this peptide inhibits binding to ICAM-3 
cannot be ascertained. There is evidence from the use of anti-LFA-1 I domain mAbs 
that ICAM-1 and ICAM-3 bind the I domain at distinct sites (Landis et at., 1994). 
Point mutation of LFA-1 residues Lys 12' and Asn129 abrogates adhesion to ICAM-3, 
without affecting binding to ICAM-1 (van Kooyk et al., 1996). Although shorter 
peptides covering these residues have no effect, a peptide spanning residues Gly"s- 
G1y138 inhibits LFA-1 binding to ICAM-3 but not to ICAM-1 (van Kooyk et al., 
. 
1996), indicating that the sequences surrounding Lys'27 and Asn129 are important for 
the effect of the peptide. Residues Gly"s-G1y138 start N-terminal to the I domain and 
extend to the end of the ßl strand, therefore are not in close proximity to residues 
covered by peptide 1(256-275). Unfortunately the Gly"s-Gly138 peptide proved to be 
insoluble in our hands, therefore could not be tested. 
The fact that recombinant I domain does not block LFA-1 activation by PdBu 
implies that PdBu stimulation does not involve a conformational change involving 
the I domain. This is in keeping with the fact that PdBu does not cause an affinity 
alteration or a detectable conformational change in LFA-1 (Stewart et al., 1996). 
This does not preclude the involvement of the I domain of intact LFA-1 in ligand 
binding following PdBu stimulation. It was intriguing to find that PdBu-stimulated 
adhesion was more sensitive than Mgt+/EGTA-stimulated adhesion to inhibition by 
mAbs against the LFA-1 ß subunit. The expression of these mAbs is not influenced 
by the state of LFA-1 activation (data not shown), therefore other explanations for 
these results should be explored. These mAbs might prevent a conformational 
change required for PdBu-stimulated adhesion, although, as mentioned above, such a 
change has not been detected. A second possibility is that the mAbs could block a 
ligand binding site used by the PdBu-stimulated form only, however, as discussed 
earlier, there is no evidence for the different forms of LFA-1 having different binding 
sites on ICAM-1. Finally, the mAbs might inhibit the clustering that is required for 
PdBu-stimulated adhesion (see Chapter 5). The epitopes for most of the LFA-1 0 
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subunit mAbs tested in this study have been mapped (Huang et al., 1997). All the 
mAbs that were most effective at inhibiting PdBu-stimulated binding map to the first 
and last cc-helices in the ß2 subunit I-like domain. These helices are predicted to be 
neighbouring. 6.5E, L130 and MAY. 017 bind elsewhere in the ß2 subunit I-like 
domain and all appeared to inhibit both forms of adhesion equally. L130 and 
MAY. 017 have yet to be titrated, however. KIM127, KIM185, CBRLFA-1/2 and 
MEM-48 map to the cysteine rich region at the C-terminal of the 12 subunit 
extracellular domain and activate LFA-1 binding to ICAM-1 (data not shown), in 
agreement with other studies (Andrew et al., 1993; Huang et al., 1997; Huang et al., 
2000; Petruzzelli et al., 1995; Stephens et al., 1995). CBRLFA-1/7, which had no 
effect on LFA-1 adhesion, also maps to this region (Huang et al., 2000). 
From this study it can be concluded that the addition of recombinant I domain 
or peptides interferes with interdomain movements or alterations in intersubunit 
associations and thereby prevents changes in the quaternary structure of LFA-1. The 
results give rise to the idea that activation of LFA-1 to a high affinity form involves 
interdomain movement that alters the association of the I domain with the 0- 
propeller domain or ß subunit and in this way leads to structural changes that 
increase the affinity for ligand. Preliminary evidence is also provided to suggest that 
LFA-1 interaction with ICAM-1 and ICAM-3 differs, and that the LFA-1 ß subunit 
plays different roles in adhesion depending on the method of activation. 
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LFA-1 MEDIATED T CELL ADHESION IS REGULATED 
BY THE PROTEASE CALPAIN 
5.1 INTRODUCTION 
The divalent cation Ca2+ is a second messenger involved in many cellular 
processes. In resting cells, the intracellular Ca2+ concentration ([Ca2*]; ) is maintained 
at 10-100 nM by Ca 2+ pumps, which transport Ca2+ into the endoplasmic reticulum 
(ER) or out of the cell. Cell activation can increase the [Ca2+]; to 500-1000 nM. 
Stimulation through G protein coupled receptors and receptor tyrosine kinases 
activates phospholipase C, which hydrolyses phosphatidylinositol 4,5, bisphosphate 
(PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses 
rapidly from the plasma membrane to interact with an ion channel on the ER, thus 
causing channel activation and release of stored Ca' into the cytosol to generate the 
initial Ca2'' signal. The depletion of Ca2+ from the ER triggers an influx of Ca 2+ 
across the plasma membrane. This second phase of the Ca 2+ signal, termed 
capacitative calcium entry, replenishes the intracellular stores and produces a more 
sustained elevation of [Ca2+] ; (reviewed in (Clapham, 1995)). The mechanism by 
which the plasma membrane Ca2+ channels are activated in response to a fall in the 
Ca'+ concentration in the ER has yet to be established, although two alternative 
mechanisms have been proposed: release of a chemical messenger from the ER or 
physical interaction between the ER and the plasma membrane (reviewed in (Putney, 
1999)). 
In T cells, increases in [Ca2+]; occur upon T cell receptor (TCR) signalling 
(reviewed in (van Leeuwen and Samelson, 1999)) and chemokine receptor signalling 
(reviewed in (Ward et al., 1998)). The raised [Ca2+]; has many downstream effects 
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that ultimately lead to control of gene expression. As both TCR and chemokine 
receptor signalling induce LFA-1 adhesion to ICAM-1 (Campbell et al., 1998; 
Dustin and Springer, 1989; Lloyd et al., 1996) it was of interest to examine the 
contribution of changes in [Ca2+]; to the activation of LFA-1. 
5.2 RESULTS 
5.2.1 Agents that mobilise intracellular Ca2+ induce LFA-1 mediated T cell 
adhesion to ICAM-1 
Ionomycin and thapsigargin are agents which can be used to directly raise 
[Ca2+];, bypassing the initial signalling events. Ionomycin is an ionophore which 
complexes with Ca2+ and directly transports it out of the ER, whereas thapsigargin 
inhibits the 100 kDa isoform of the ATP-dependent Ca"* pumps that transport Ca 2+ 
from the cytosol into the ER (Papp et al., 1993). Both compounds cause emptying of 
the intracellular Ca2+ stores and a resultant Ca 2+ influx across the plasma membrane 
via capacitative entry. To gain insight into the role of intracellular Ca 2+ in the 
signalling pathways that activate LFA-1, these two compounds were tested for their 
ability to activate T cell adhesion to ICAM-1. Ionomycin and thapsigargin both 
stimulated LFA-1 mediated T cell adhesion to immobilised ICAM-1 in a dose 
dependent manner (Fig. 5.1). Peak adhesion was achieved with approximately 1 µM 
ionomycin and 5 µM thapsigargin. These results demonstrate a role for intracellular 
Cat+in the activation of LFA-1 mediated T cell adhesion to ICAM-1. 
5.2.2 An influx of extracellular Ca2+ is required for LFA-1 mediated T cell 
adhesion induced by intracellular Ca2+ mobilisation 
Ionomycin and thapsigargin raise [Ca2+]; by capacitative entry across the 
plasma membrane as well as by inducing release from intracellular stores. The 
compound SKF-96365, which inhibits capacitative Ca2+ entry (Chung et al., 1994), 
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Figure 5.1 The intracellular Ca2+ mobilisers ionomycin and thapsigargin induce 
LFA-1 mediated T cell adhesion to ICAM-1 
Stimulation of T cell binding to ICAM-1 with 0-10 pM ionomycin (") or 0-50 µM 
thapsigargin ( ) for 30 min at 37°C. Thapsigargin stimulated adhesion is inhibited 
with 5 µg/ml LFA-1 mAb 38 (A). Data (mean of triplicates ± S. D. ) from one 
representative experiment (n=2) are shown. 
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was used to determine whether the initial rise in [Ca2+];, which results from release 
from intracellular stores, is sufficient for activation of LFA-1 by inside-out 
signalling, or whether Cat+influx across the plasma membrane is also necessary. 
Adhesion stimulated by ionomycin and thapsigargin was inhibited by SKF-96365 at 
concentrations greater than 25 tM (Fig. 5.2 A). Adhesion stimulated by ionomycin, 
thapsigargin, through the TCR-CD3 complex, or by PdBu was inhibited by SKF- 
96365 (Fig. 5.2 B). As expected, T cell adhesion stimulated by Mgt+/EGTA was 
unaffected by this compound (Stewart et al., 1996), even at a concentration of 100 
µM (Fig. 5.2 B). Thus LFA-1 mediated T cell adhesion stimulated by different 
intracellular signalling pathways requires an influx of extracellular Ca". 
5.2.3 Expression of the epitope for mAb 24 is low on ionomycin or 
thapsigargin treated T cells. 
The characteristics of ionomycin and thapsigargin stimulated LFA-1 were 
investigated with the use of mAb 24. Expression of the epitope recognised by this 
mAb correlates with the high affinity LFA-1 binding to ICAM-1, which occurs upon 
Mgt+/EGTA stimulation but not upon PdBu stimulation, and is therefore thought to 
reflect generation of the high affinity conformation of LFA-1 (Stewart et al., 1996). 
The level of binding of 24 to T cells treated with the Ca2+ mobilising agents was 
similar to that induced by PdBu and very low in comparison to Mgt+/EGTA 
stimulated binding (Fig. 5.3). It can be concluded that ionomycin and thapsigargin 
resemble the PdBu model of adhesion by being poor inducers of the high affinity 
conformation of LFA-1. 
5.2.4 Thapsigargin stimulates redistribution of LFA-1 into clusters 
The low binding of mAb 24 indicated that the mechanism of ionomycin and 
thapsigargin stimulated T cell adhesion to ICAM-1 was unlikely to be via 
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Figure 5.2 Titration of SKF-96365 and its effect on T cell adhesion to ICAM-1 
The effect on binding to ICAM-lFc of preincubation of T cells for 30 min at 37°C 
A: with 0-125 µM SKF-96365 followed by stimulation with 0.7 µM ionomycin (") 
or 5 p. M thapsigargin (A) for 30 min at 37°C. B: with ( ) or without ( ) 100 µM 
SKF-96365 followed by stimulation with 5 mM Mg'+/l mM EGTA, 0.7 µM 
ionomycin, 5 µM thapsigargin, 50 nM PdBu or 5 p. g/ml anti CD3 for 30 min at 37°C. 
Data (mean of triplicates ± S. D. ) from one representative experiment (n=3) are 
shown. 
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Figure 5.3 The expression of the mAb 24 epitope on T cells following activation 
of LFA-1 
T cells incubated with mAb 24 at 10 µg/ml for 30 min at 37°C in the presence of 5 
mM Mg2+/1 mM EGTA, 50 µM Mn2+550 nM PdBu, 5 µM thapsigargin or 0.7 µM 
ionomycin. Data (mean of triplicates ± S. D. ) from one representative experiment 
(n=3) are shown. 
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conversion to a higher affinity form of LFA-1. An alternative mechanism was that 
the membrane distribution of LFA-1 was altered in a manner facilitating adhesion, 
therefore corifocal microscopy was used to investigate this possibility. In order to 
analyse LFA-1 distribution, the confocal images were highlighted such that the 
membrane regions with the highest LFA-1 fluorescence (i. e. in the pixel intensity 
range 150-250, where 250 is the highest possible value) are depicted in red and all 
others in white (Fig. 5.4). Unstimulated cells (Fig. 5.4 A) and Mgt+/EGTA 
stimulated cells (Fig. 5.4 B) have very little high intensity LFA-1 fluorescence (red) 
in comparison to that on thapsigargin stimulated cells (Fig. 5.4 Q. These 
observations were confirmed by quantifying (see Chapter 2.2.13) the levels of 
fluorescence for each sample on regions of the membrane where there was no 
contact between cells (Table 5.1: Free Membrane). Statistical analysis (one way 
ANOVA) of these measurements confirmed that the level of fluorescence on the 
thapsigargin stimulated cells, but not on the Mg2+/EGTA stimulated T cells, was 
significantly increased compared to the level on the resting T cells (Table 5.1: 
Significance Levels). This increase in the intensity of LFA-1 fluorescence upon 
thapsigargin stimulation was detected with three distinct CD11a mAbs, 38, F110.22 
and G25.2 (data not shown), therefore does not represent the exposure of a particular 
epitope. These results suggested that thapsigargin might stimulate an increase in the 
cell surface expression of LFA-1. When measured by flow cytometry, however, 
results revealed that the level of LFA-1 expression following thapsigargin 
stimulation did not differ from LFA-1 expression on the resting or Mgt+/EGTA 
treated cells (Fig. 5.5). This suggested that the increase in signal strength observed 
by confocal microscopy upon thapsigargin stimulation reflects increased clustering 
which creates higher LFA-1 fluorescence intensity. 
It was observed that some of the brightest LFA-1 fluorescence was to be 
found where cells were in contact with each other and, therefore, the level of 
fluorescence in these regions was quantified (Table 5.1: Contact Zone) to determine 
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Figure 5.4 Thapsigargin stimulates LFA-1 clustering on T cells 
Confocal microscopy images showing the expression of LFA-1 on T cells which 
were A: unstimulated or treated with B: 5 mM Mg`+/ 1 mM EGTA or C: 5 µM 
thapsigargin for 30 min at 37°C. Fluorescence intensity exceeding a preset pixel 
value (see Chapter 2.2.12) is coloured red. This setting remained constant in all 
samples. Bar represents 10 µm. 
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Figure 5.5 The effect of thapsigargin on LFA-1 expression on T cells 
The expression of LFA-1 detected by mAb 38 (10 µg/ml) on unstimulated T cells 
() or on T cells stimulated with 5 mM Mg 2+/l mM EGTA () or 5 µM 
thapsigargin (-) for 30 min at 37°C. Data from one representative experiment 
(n=3) are shown. 
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whether this high fluorescence reflected a redistribution of LFA-1 to cell: cell 
contacts or was merely the additive value of the two cell membrane measurements. 
As the ratio of the average fluorescence intensity at cell contact areas to that of free 
membrane was approximately 2 (Table 5.1: Contact/Free) it can be concluded that 
there is no large scale redistribution of LFA-1 to points of cell contact upon 
thapsigargin treatment. In summary, the confocal microscopy results revealed that 
upon thapsigargin stimulation LFA-1 becomes locally clustered, but does not change 
its distribution to regions of the cell membrane in contact with other cells. Similar 
results were obtained with the other Ca"' mobilising agents as well as PdBu (data not 
shown) and by crosslinking the TCR/CD3 (see Fig. 5.11), suggesting that local LFA- 
1 clustering may be a general feature of several T cell adhesion activating protocols. 
5.2.5 Thapsigargin induced clustering of LFA-1 is inhibited by Jasplakinolide 
The implication of the above confocal experiments was that the Cat+- 
mobilisers promoted LFA-1 clustering. To assess the role of the cytoskeleton in 
LFA-1 clustering the cell-permeant peptide jasplakinolide, which is isolated from 
marine sponge, was tested for its effect on the distribution of LFA-1 on thapsigargin 
treated cells. Jasplakinolide stabilises actin filaments, prevents actin filament 
disassembly and, with longer treatment, promotes actin polymerisation (Bubb et al., 
1994; Cramer, 1999). As seen in Figure 5.6, jasplakinolide diminished the 
fluorescence levels of LFA-1 detected by confocal microscopy (i. e. there is less 
fluorescence highlighted in red in Fig. 5.6 B than in Fig. 5.6 A). Identical levels of 
LFA-1 expression were detected by flow cytometry before and after jasplakinolide 
treatment (Fig. 5.7), indicating that the inhibitor prevented LFA-1 clustering rather 
than caused receptor loss. It can therefore be concluded that actin reorganisation is 
necessary for LFA-1 to become clustered on the cell membrane. 
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Figure 5.6 The effect of jasplakinolide on thapsigargin induced clustering of 
LFA-1 on T cells 
Confocal microscopy images showing the expression of LFA-1 on T cells which 
were A: treated with 5 µM thapsigargin for 30 min at 37°C or B: preincubated with 
I ttM jasplakinolide for 30 min at 37 °C before treatment as in A. Fluorescence 
intensity exceeding a preset pixel value (see Chapter 2.2.12) is coloured red. This 
setting remained constant in all samples. Bar represents 10 µm. 
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Figure 5.7 The effect of jasplakinollide on LFA-1 expression 
The expression of LFA-1 detected with mAb 38 (10 µg/ml) on T cells incubated at 
37°C for 30 min in the presence of 5 µM thapsigargin ( ), or 5 µM thapsigargin +I 
µM jasplakinolide (-). Data from one representative experiment (n=3) are shown. 
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5.2.6 Thapsigargin stimulated T cell adhesion to ICAM-1 is inhibited by 
Jasplakinolide 
The effect of jasplakinolide on T cell adhesion to ICAM-1 was also tested to 
determine whether disassembly of the actin cytoskeleton and clustering of LFA-1 are 
requirements for adhesion. Jasplakinolide inhibited LFA-1 mediated T cell adhesion 
to ICAM-1 in a dose dependent manner (Fig. 5.8). Thus LFA-1 clustering, which is 
dependent on disassembly of the actin cytoskeleton, is a critical feature of 
thapsigargin stimulated T cell adhesion to ICAM-1. 
5.2.7 The calpain inhibitors CBZ-LVG and calpeptin prevent LFA-1 adhesion 
to ICAM-1 
In an attempt to understand the molecular mechanism by which Ca2+ induces 
LFA-1 clustering, the effect of inhibitors and mAbs specific for several major Cat+- 
utilising enzymes which have a link with adhesion were investigated in this 
laboratory (Stewart et al., 1998). Among the inhibitors tested were CBZ-LVG and 
calpeptin, membrane permeable inhibitors of the cytosolic cysteine protease calpain. 
Activation of calpain requires intracellular Ca 2+ levels much higher than those found 
in resting cells (5 µM to 1 mM depending on the isoform) (Johnson and Guttmann, 
1997). T cell adhesion to ICAM-1 induced by thapsigargin and PdBu was inhibited 
by CBZ-LVG in a dose dependent manner, but no effect on Mgt+/EGTA stimulated 
adhesion was seen (Fig. 5.9 A). A variety of stimuli were tested for sensitivity to 
calpeptin. T cell adhesion stimulated with thapsigargin, PdBu, or through CD3 was 
inhibited with 100 gg/ml (280 µM) calpeptin but, as with CBZ-LVG, there was no 
effect on Mgt+BGTA stimulated adhesion (Fig. 5.9 B). There was no alteration in 
cell viability at concentrations at which these inhibitors were maximally active (data 
not shown). 
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Figure 5.8 The effect of jasplakinolide on LFA-1 mediated T cell adhesion to 
ICAM-1 
The effect on binding to ICAM-1176 of preincubation of T cells for 1 hour at 37°C 
with 0-2 µM jasplakinolide followed by stimulation with 5 µM thapsigargin for 30 
min at 37°C. Data (mean of triplicates ± S. D. ) from one experiment (n=3) are 
shown. 
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Figure 5.9 The effect of calpain inhibitors on LFA-1 mediated T cell adhesion 
to ICAM-1 
The effect on binding to ICAM-1 Fc of preincubation of T cells for 30 min at 37°C 
A: with 0-400 µM CBZ-LVG followed by stimulation with 5 mM Mg2+/ l mM 
EGTA (A), 50 nM PdBu ( ) or 5 µM thapsigargin (") for 30 min at 37°C. B: with 
( ) or without ( ) 280 µM calpeptin followed by stimulation with 5 mM Mg''/1 
mM EGTA, 50 nM PdBu, 5 µM thapsigargin or 5 tg/ml anti-CD3 for 30 min at 
37°C. Data (mean of triplicates ± S. D. ) from one representative experiment (n=2 for 
A; n=4 for B) are shown. 
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The calpain inhibitors used in this study are not entirely specific for calpain, 
but also inhibit lysosomal cathepsins and proteasome activity. To rule out the 
involvement of the proteasome, the highly specific proteasome inhibitor lactacystin 
was tested for its effect on thapsigargin and Mgt+/EGTA stimulated T cell adhesion 
to ICAM-1. Although antigen presentation was inhibited by 20 . tM lactacystin 
(Isabel Correa and John Trowsdale- personal communication) T cell adhesion was 
unaffected by concentrations as high as 200 µM (Fig. 5.10). Furthermore, T cells 
lack lysosomal cathepsins, which are also susceptible to the calpain inhibitors. These 
results indicate that calpain, or a calpain-like enzyme, is involved in thapsigargin 
stimulated T cell adhesion to ICAM-1. 
5.2.8 Calpeptin inhibits LFA-1 clustering 
When examined by confocal microscopy it was found that the levels of 
clustered LFA-1 detected following treatment with thapsigargin (Fig. 5.11 A) or by 
crosslinking CD3 (Fig. 5.11 B) were diminished by calpeptin treatment (Fig. 5.11 C 
and D) (i. e. there is less fluorescence highlighted in red in Fig. 5.11 C and D than in 
Fig. 5.11 A and B) to levels similar to those on resting T cells (Table 5.1: Free 
Membrane). Therefore, in conclusion, raising intracellular Ca2+ levels in T cells 
promotes LFA-1 mediated adhesion to ICAM-1 by inducing LFA-1 clustering on the 
plasma membrane. It would appear that both the clustering and adhesion are 
dependent upon the actin cytoskeleton and the activity of the Ca 2'-dependent 
protease calpain. 
5.2.9 Talin can be cleaved by calpain but does not coprecipitate with LFA-1 
Based on these findings it was decided to analyse whether the cytoskeletal 
associations of LFA-1 alter to allow clustering and ligand binding, with the hope of 
identifying a calpain dependent step. The following experiments were therefore 
undertaken to establish which cytoskeletal proteins associate with LFA-1, whether 
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Figure 5.10 The proteasome inhibitor lactacystin has no effect on T cell 
adhesion to ICAM-1 
Binding to ICAM-1 of T cells preincubated for 2 hours at 37°C with 0-200 µM 
lactacystin then stimulated for 30 min at 37°C with 5 mM Mg2+/ l mM EGTA (") or 
5 µM thapsigargin ( ). Data from one representative experiment (n=2) are shown. 
155 
CALPAIN REGULATES LFA-1 ADHESION 
Figure 5.11 LFA-1 clustering induced by thapsigargin and anti-CD3 is 
inhibited by calpeptin 
Confocal microscopy images showing the expression of LFA-1 on T cells which 
were stimulated with A and C: 5 pM thapsigargin or B and D: CD3 mAb G19.4 at 
10 µg/ml for 30 min at 37°C. Cells in C and D were preincubated for 30 min at 
37°C with 100 dug/ml calpeptin. Fluorescence intensity exceeding a preset pixel value 
(see Chapter 2.2.12) is coloured red. This setting remained constant in all samples. 
Bar represents 10 µm. 
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these associations are regulated by activation or ligand binding of LFA-1, and 
whether any of the proteins are cleaved by calpain. 
Talin is a 225 kDa cytoskeletal protein that links the plasma membrane and 
the actin cytoskeleton. Talin co-localises with LFA-1 in the T cell contact zone with 
an antigen presenting cell (Kupfer and Singer, 1989; Monks et al., 1998). This 
polarisation apparently occurs in response to LFA-1 engagement by ICAM-1 
(Sedwick et al., 1999). Whether talin binds directly to LFA-1 is unclear as opposing 
results have been obtained from studies of the interaction of purified talin with aß2 
cytoplasmic tail peptide (Sampath et al., 1998; Sharma et al., 1995). Despite this 
evidence for at least an indirect association of talin with LFA-1, talin was never 
found to coprecipitate with LFA-1 from resting or activated T cells (Fig. 5.12 A) or 
upon T cell adhesion to ICAM-1 (data not shown). Calpain cleaves talin into two 
fragments with apparent masses of 190 kDa and 47 kDa (Rees et al., 1990), however 
in only 5 out of 15 experiments was a proteolytic fragment of talin detected. On the 
occasions on which talin was cleaved, this process proved to be activation dependent, 
occurring in response to T cell stimulation with PdBu, thapsigargin and crosslinking 
CD3 with mAb UCHT1, but not in unstimulated cells or Mgt+/EGTA treated cells 
(Fig. 5.12 B). The 190 kDa form of talin was not detected when the cells were pre- 
incubated with the calpain inhibitor calpeptin (Fig. 5.12 B). 
5.2.10 Filamin and a-actinin can coprecipitate with LFA-1 but are not cleaved 
by calpain 
Non-muscle filamin, also known as filamin-1 or actin binding protein 280 
(ABP-280), cross-links actin filaments and promotes their high angle branching 
(Gorlin et al., 1990), as well as mediating the connection of actin with the plasma 
membrane. There is evidence that filamin binds directly to the integrin ß2 subunit 
cytoplasmic tail (Sharma et al., 1995). Filamin is a homodimer, each subunit being 
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Figure 5.12 Talin does not coprecipitate with LFA-1 but can be cleaved by 
A: Talin was detected by western blotting of cell lysates post immunoprecipitation 
and LFA-1 immunoprecipitates (IP) from unstimulated T cells (lane 1) and T cells 
stimulated with 2 mM Mg`+/ 1 mM EGTA (lane 2), 50 nM PdBu (lane 3), or 5 mM 
thapsigargin (lane 4). In the same samples the LFA-1 a subunit (CD11a) was 
detected at similar levels in all IPs. B: Talin was detected by western blotting of cell 
lysates from T cells which had (+) or had not (-) been treated for 30 min with 280 
µM calpeptin prior to being unstimulated (lanes 1) or stimulated with 50 nM PdBu 
(lanes 2), 2.5. tg/m1 UCHT-1 (lanes 3), 2 mM Mg2+/1 mM EGTA (lanes 4), 5 µM 
thapsigargin (lanes 5), or 1 µM ionomycin (lanes 6) for 30 min at 37°C. 
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280 kDa. The elongated rod-like backbone of filamin is composed of 23 repeat 
motifs, with a 25 amino acid insertion between repeats 15 and 16 containing the 
calpain cleavage site (Gorlin et al., 1990). 
a-actinin is a 105 kDa protein that forms an anti-parallel rod shaped 
homodimer, with each end of the rod having an actin binding site (Djinovic-Carugo 
et a)., 1999). Not only does a-actinin cross-link actin filaments, but it also interacts 
with many cytoskeletal and membrane proteins, potentially including the integrin ßZ 
subunit (Sampath et al., 1998; Sharma et al., 1995). 
On some occasions filamin (7 of 13 experiments) and a-actinin (7 of 17 
experiments) were found to coprecipitate with LFA-1. These interactions were not 
dependent on activation of the cells (Fig. 5.13 A and B- IP lanes), and under no 
conditions tested were the calpain-generated 200,100 or 91 kDa fragments of 
filamin or the 80 kDa fragment of ct-actinin observed (Fig. 5.13 A and B- Lysate 
lanes). 
5.2.11 Ezrin, vinculin, cytohesin-1 and Pyk-2 do not coprecipitate with LFA-1 
and are not cleaved by calpain 
Other proteins associated with cytoskeletal organisation were also tested for 
interaction with LFA-1 and calpain-dependent cleavage. The ERM family of 
proteins, ezrin, radixin and moesin, link the plasma membrane to the actin 
cytoskeleton by binding directly or indirectly to the plasma membrane at their N- 
terminal and to F-actin at their C-terminal. In lymphocytes stimulated with phorbol 
ester and ionomycin, ezrin is reported to be cleaved from 80 kDa to 55 kDa by 
calpain (Shcherbina et al., 1999). Vinculin is a 117 kDa cytoskeletal protein that 
localises to cell-cell and cell-extracellular matrix contacts. It is composed of a 
trilobular head connected by a hinge region to a long flexible tail. Binding sites for 
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Figure 5.13 Filamin and a-actinin are not cleaved by calpain but can co- 
precipitate with LFA-1 
Western blots of cell lysates and LFA-1 immunoprecipitates (IP) from unstimulated 
T cells (lane 1) and T cells stimulated with 2 mM Mg2+/1 mM EGTA (lane 2), 50 nM 
PdBu (lane 3), or 5 mM thapsigargin (lane 4) probed for A: Eilamin and B: a- 
actinin. In the same samples the LFA-1 a subunit (CD11a) was detected at equal 
levels in all IPs (data not shown). Arrows indicate the position of the molecular 
weight markers. 
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talin and a-actinin are located in the head region whereas paxillin and F-actin bind to 
the tail. There is evidence that vinculin is a component of a complex that interacts 
with the integrin ß2 subunit, but that it does not bind directly to the ß2 cytoplasmic 
tail (Sharma et al., 1995). A 95 kDa fragment of vinculin is generated by calpain 
proteolysis (Reid et al., 1993). Neither ezrin nor vinculin coprecipitated with LFA-1 
from T cell lysates or were cleaved by calpain (Fig. 5.14). 
Cytohesin-1, a 47 kDa guanine-nucleotide exchange factor (GEF) for ARF 
GTPases, activates LFA-1 adhesion to ICAM-1 and induces cell spreading by its 
ARF-GEF activity in Jurkat cells (Geiger et al., 2000). It is composed of a SECT 
domain, which can bind to the ß2 cytoplasmic tail, and a PH domain, which 
associates with the plasma membrane (Kolanus et al., 1996). Cytohesin-1, however, 
was not found to coprecipitate with LFA-1 in cultured primary T cells under any of 
the conditions tested (Fig. 5.14). 
LFA-1 mediated T cell binding to ICAM-1 has been shown to result in 
phosphorylation of the non-receptor tyrosine kinase Pyk-2 and its colocalisation with 
the microtubule organising centre (Rodriguez-Fernandez et al., 1999). In agreement 
with these results a band with an apparent molecular weight higher than that seen in 
unstimulated cells was detected in phorbol ester stimulated cells, probably reflecting 
the phosphorylated form. In Mgt+/EGTA stimulated cells both the higher and lower 
molecular weight forms of Pyk-2 could be detected (Fig. 5.14). Stimulation of 
platelets induces rapid phosphorylation of Pyk-2 and upon platelet aggregation Pyk-2 
is then cleaved by calpain, from 125 kDa to two fragments of 80 and 75 kDa (Raja et 
al., 1997). No cleavage of Pyk-2 was detected in T cells (Fig. 5.14). 
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Figure 5.14 Ezrin, vinculin, cytohesin-1 and Pyk-2 do not coprecipitate with 
LFA-1 and are not cleaved by calpain 
Western blots of LFA-1 immunoprecipitates (IP) and cell lysates from unstimulated 
T cells (lane 1), T cells in suspension stimulated with 2 mM Mg`+/ 1 mM EGTA (lane 
2), T cells on ICAM-1 coated plates stimulated by 2 mM Mg2+/1 mM EGTA (lane 3), 
T cells in suspension stimulated with 50 nM PdBu (lane 4), T cells on ICAM-1 
coated plates stimulated with 50 nM PdBu (lane 5). All stimulations were performed 
at 37°C for 30 min. The blots are immunostained with antibodies to the LFA-1 a 
subunit (CD 11 a), the cytoskeletal proteins ezrin and vinculin, the guanine-nucleotide 
exchange factor cytohesin-1 and the non-receptor tyrosine kinase Pyk-2. 
Representative blots are shown (n >_ 3 for each blot). 
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5.3 DisCUSSioN 
In this study, the role of intracellular Ca 2+ in the induction of LFA-1 mediated 
T cell adhesion to ICAM-1 was investigated. Two agents which mobilise 
intracellular Cat; were found to stimulate LFA-1 binding to ICAM-1. In a more 
physiological manner, signalling through chemokine receptors and triggering of the 
TCR by MHC/peptide on an antigen presenting cell cause Ca 2+ fluxes in T cells 
(Campbell et al., 1998; Dustin and Springer, 1989; Lloyd et al., 1996). There is also 
evidence that engagement of LFA-1 itself can induce intracellular Ca2+ mobilisation 
(Kanner et al., 1993). 
In a similar manner to PdBu stimulated LFA-1 adhesion (Stewart et al., 
1998), raising intracellular Ca2+ levels does not cause a detectable increase in LFA-1 
affinity for soluble ICAM-1 or induce a change to the high affinity conformation 
recognised by mAb 24. Instead, LFA-1 becomes clustered in the membrane and thus 
the avidity of interaction with ICAM-1 is increased. In a model of oc4p, adhesion, 
integrin clustering is driven by ligand (Yauch et al., 1997). It is unlikely that the 
LFA-1 clusters detected in this study are driven by ligand as they are observed 
uniformly over the entire cell surface, not only at cell-cell contacts, and can be 
detected by both non-function blocking and function blocking mAbs (data not 
shown). 
The use of inhibitors implicated calpain in the clustering and adhesion of 
LFA-1. Calpains are a family of intracellular neutral cysteine proteases that are 
activated by local Ca2+ fluxes and are widely expressed in mammalian cells 
(reviewed in (Johnson and Guttmann, 1997; Sorimachi et al., 1997)). Calpains are 
highly expressed in T cells and are increased at mRNA and protein levels by phorbol 
ester, calcium ionophore and anti-CD3 treatments, all agents that can induce LFA-1 
adhesion (Deshpande et al., 1995). In platelets, addition of the agonist thrombin 
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induces a relocation of calpain to the cell periphery where it is subsequently 
activated by binding of ligand to the integrin aßß3 (Fox et al., 1993). LFA-1 
engagement can also result in calpain activation (Soede et al., 1999) but, as discussed 
above, it is unlikely that ligand is participating in the calpain dependent clustering of 
LFA-1. However, this does not preclude further action of calpain after ICAM-1 
binding of T cells. 
There are a number of possibilities to explain how calpain could be acting. 
Calpain may be activated to cleave a key protein, physically releasing LFA-1 from 
its cytoskeletal restraint and allowing movement in the membrane as has been 
observed by single particle tracking (Kucik et al., 1996). Proteins that have been 
identified as calpain targets include talin (Rees et al., 1990), filamin (Collier and 
Wang, 1982) and a-actinin (Selliah et al., 1996), all of which have been reported to 
associate with integrins (reviewed in (Critchley, 2000)). In resting neutrophils the 
integrin ß2 subunit is associated with the intact form of talin, but upon neutrophil 
activation talin is cleaved by calpain, dissociates from the integrin, and is replaced by 
cc-actinin (Sampath et al., 1998). Whether a similar process occurs in T cells was 
investigated. Although talin proteolysis by calpain was seen at times, this result was 
not consistent and at no point was talin seen to coprecipitate with LFA-1. a-actinin 
did associate with LFA-1 on some occasions, however this interaction was not 
dependent on the activation state of the cell. These discrepancies with the neutrophil 
results may reflect a cell specificity to the interactions. For T cells it is upon 
activation, not in resting conditions, that LFA-1 and talin colocalise in the 
immunological synapse (Monks et al., 1998) and activation of freshly isolated T cells 
results in a-actinin, not talin, being cleaved by calpain (Selliah et al., 1996). The 
cytoskeletal proteins filamin, vinculin and ezrin also did not coprecipitate with LFA- 
1 or undergo proteolysis by calpain. Another possibility is that calpain cleaves a 
protein involved in the signalling pathways leading to integrin activation. Cytohesin- 
1, Pyk-2, p125F"x and protein tyrosine phosphatase 1B are candidates, as all but 
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cytohesin-1 are known targets of calpain proteolysis (Cooray et al., 1996; Raja et al., 
1997; Rock et at., 1997) and all are involved in integrin signalling (Arregui et al., 
1998; Kolanus et al., 1996; Lipfert et al., 1992; Rodriguez-Fernandez et al., 1999). 
Some integrin ß subunit cytoplasmic tails can be cleaved by calpain (Du et al., 1995; 
Potts et al., 1994), including the (32 subunit (Pfaff et al., 1999), however this 
possibility remains to be investigated. 
It should be noted that problems were encountered with the co-precipitation 
experiments. In attempts to obtain consistent results, lysis buffers were tried 
containing a range of concentrations of the non-ionic detergents Triton X 100 or Brij 
96 (polyoxyethylene 10 oleyl ether) or the zwitterionic detergent CHAPS (3-[(3- 
cholamidopropyl)dimethylammonio]-1-propanesulphonate). The lysis buffer was 
also varied to include MgC12 and sucrose to stabilise F-actin. The cells were allowed 
to adhere to ICAM-1 to discover whether this would stabilise interactions, and also 
various immunoprecipitating antibodies tested and added before cell lysis or to the 
precleared lysate. None of these conditions improved the reproducibility of the 
results (data not shown). The coprecipitation results should therefore be viewed with 
scepticism. Experiments are required to verify that when coprecipitation of a-actinin 
and filamin with LFA-1 is seen it is real and not just non-specific binding to the 
sepharose beads or antibody. The lysates were precleared to minimise this 
possibility and the immunoprecipitates thoroughly washed in the presence of salt. 
However, it remains a possibility, until controls are performed, that a-actinin and 
Eilamin are stickier than the other proteins tested, or that they are in a sticky complex 
that binds to the beads. 
Other studies have also demonstrated a role for calpain in integrin-mediated 
events. Cell motility is mediated by integrins and can be dissected into four phases: 
extension of lamellipodia, formation of new focal adhesions at the leading edge, 
detachment at the trailing edge and translocation of the cell mass. Failure of any of 
these processes prevents motility. Calpain has a vital role in cell migration, probably 
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by facilitating constant reorganisation of focal adhesions and other cell-substratum 
contacts that are required for motility. Inhibition of calpain can prevent fibroblast 
spreading and actin cytoskeletal reorganisation (Potter et al., 1998), and this is 
thought to reflect a role for calpain upstream of Rac and Rho (Kulkarni et al., 1999). 
Motile fibroblasts in which calpain is inhibited form stable focal adhesions and 
cannot break the contacts at the rear of the cell, resulting in restrained motility 
(Huttenlocher et al., 1997). Recently, it has been shown that fibroblast de-adhesion 
and motility induced by epidermal growth factor (EGF) occurs as a result of m- 
calpain activation downstream of ERK/MAP kinase signalling (Glading et al., 2000). 
Increases in intracellular cAMP levels, for instance upon chemokine binding to 
CXCR3, prevent this EGF stimulated motility by preventing m-calpain activation in 
a protein kinase A dependent manner (Shiraha et al., 1999). It is interesting that in 
fibroblasts calpain inhibitors are not reported to decrease the number of adherent 
cells. This is in contrast to the results with T cells presented here. This apparent 
discrepancy requires further examination: are there different roles for calpain in 
different cell types, or does calpain inhibition reduce the number of cells that adhere 
and prevent migration of those cells that do adhere, no matter the cell type? 
Many of these results have been demonstrated using calpeptin, one of the 
more soluble and membrane permeable calpain inhibitors available, but have also 
been supported by more specific means such as dominant negative calpain mutants, 
calpain antisense oligonucleotides and by overexpression of the natural calpain 
inhibitor calpastatin. It remains a possibility that the effect of calpeptin on T cell 
adhesion to ICAM-1 is not due to inhibition of calpain. Primary T cells, however, 
are difficult to transfect and microinject, therefore these methods of introducing the 
more specific inhibitors of calpain into the cell were not attempted. Instead a 
calpastatin-antennapedia peptide was synthesised. This peptide consisted of a 27 
amino acid sequence associated with the inhibitory activity of the endogenous 
calpain inhibitor protein, calpastatin (Maki et al., 1989) attached to a 16 amino acid 
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peptide from the third helix of the Antennapedia homeodomain protein to act as an 
internalisation vector (Hall et al., 1996). This peptide had no effect on T cell 
adhesion to ICAM-1 (data not shown) and was not further pursued. No conclusion 
can be drawn from this result without proving that the peptide entered the cell. 
Caution should be employed in interpreting results obtained with inhibitors 
when no other means of substantiating the results is used. For example, calpain 
inhibitors may also inhibit proteosome activity, however the possibility that this was 
the case was dismissed by demonstrating that a specific proteasome inhibitor had no 
effect. Recently, it has been suggested that calpeptin can inhibit a membrane 
associated tyrosine phosphatase upstream of Rho (Schoenwaelder and Burridge, 
1999). In these experiments calpeptin treatment, rather than inhibiting actin 
remodelling, lead to Rho mediated stress fibre formation. It would be interesting to 
test whether activation of Rho can be detected upon calpeptin treatment of T cells to 
rule out the possibility that we are looking at protein tyrosine phosphatase activity. 
However, our results require intracellular Ca2+ whereas Schoenwaelder et al. can 
chelate Ca2+ without any effect in their model. In addition, our laboratory has been 
unable to see any effect of C3 exoenzyme, a Rho inhibitor, on T cell adhesion to 
ICAM-1 (Mairi Stewart and Jo Porter - unpublished results). 
Recently, Patterson et al. have shown that treatment of smooth muscle cell 
lines with 3 µM jasplakinolide for one hour causes redistribution of F-actin into a 
tight layer around the plasma membrane and that this prevents the coupling of the ER 
and plasma membrane Ca2+ channels which they show is necessary for capacitative 
Cat; entry in theses cells (Patterson et al., 1999). Although the concentration of 
jasplakinolide used in Figure 5.6 and Figure 5.8 is reported not to disrupt actin- 
cytoskeleton organisation (Cramer, 1999), the ability of the T cells to flux Ca2+ 
following treatment with jasplakinolide should be tested to establish that the 
jasplakinolide effects are not due to inhibition of the Ca2+ flux. Calpeptin should also 
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be tested in this way to ensure that it inhibits events downstream of the rise in [Ca2; ]; 
and is not having its effect on adhesion by preventing the rise in [Ca2+];. 
In summary, this work shows that Ca2+ regulated activation of calpain (or a 
calpeptin sensitive protein) causes clustering of LFA-1. When T cells contact 
antigen presenting cells (APC), the T cells initially migrate on the APC, but convert 
to being stably adherent upon Ca2+ flux (Negulescu et al., 1996), and LFA-1 is 
localised to the T cell-APC contact (Monks et al., 1998). The work described in this 
chapter would fit in with the prediction that an initial Ca2+ flux, initiated by T cell 
contact with an APC, activates calpain. This would allow local clustering of LFA-1, 
possibly by cleaving an as yet unidentified cytoskeletal or signalling protein. It will 
be interesting to test whether, as in fibroblasts, calpain also has a role in LFA-1- 
mediated T cell migration. 
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CHAPTER 6 
CHARACTERISATION OF LEUKOCYTES FROM A 
PATIENT WITH A NOVEL FORM OF INTEGRIN 
DYSFUNCTION 
6.1 INTRODUCTION 
Leukocyte Adhesion Deficiency-1 (LAD-1) and Glanzmann's 
Thrombasthenia are rare, inherited, immune disorders affecting integrin function 
(reviewed in (Anderson et al., 1994; George et al., 1990; Hogg and Bates, 2000)). 
Mutation of the gene encoding the integrin ß2 subunit is responsible for LAD-1. The 
majority of mutations are in the ß I-like domain and prevent association with the a 
subunit. The lack of aß heterodimer formation results in deficient transport of the 
integrin to the cell surface and absence of expression of all the ß2 integrins (Wardlaw 
et al., 1990). Mutations in the (32 subunit that allow expression but not function of 
the 02 integrins have also been described (Hogg et al., 1999). LAD-1 is characterised 
by delayed umbilical cord separation, granulocytosis, reduced emigration of 
phagocytic cells to inflamed tissue, impaired phagocytosis and pus formation, 
recurrent or progressive infections of soft tissue and susceptibility to recurring, life 
threatening, bacterial infections. Delayed-type hypersensitivity reactions are normal, 
there are no problems with viral infections and antibody production is usually present 
to some extent. Severely affected people often die of infection in childhood or early 
adulthood. Bone marrow transplantation is the only curative treatment available at 
present. 
Glanzmann's Thrombasthenia is a bleeding disorder caused by mutations in 
either the a or ß subunit of the platelet integrin c 1,03. As for LAD-I, the majority of 
mutations in the 0 subunit occur in the I-like domain. For the aub subunit, most of 
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the mutations are located in the putative ß-propeller domain (reviewed in (Hogg and 
Bates, 2000)). The mutations result in absence of cell surface expression or 
expression of abnormal integrin that is unable to bind to fibrinogen. Thus the 
platelets fail to aggregate and form a clot in response to physiological agonists that 
are released at sites of vascular injury, such as thrombin, ADP and thrombospondin. 
Glanzmann's patients therefore suffer from irregular bleeding and easy bruising. 
Occasionally, severe gastrointestinal and intracranial bleeding occurs, which can lead 
to death. Patients with severe bleeding are given platelet transfusions but eventually 
become refractory to these. 
Patient FM is an 18 month old girl from Malta with clinical features of both 
LAD-1 and Glanzmann's Thrombasthenia: she has a history of bleeding problems, 
recurrent bacterial infections, non-healing skin lesions and raised leukocyte numbers. 
She first presented only 6 hours after birth with cerebral bleeding. She had a sibling 
who died of a cerebral bleed and has one other sibling who is now 5 or 6 years old 
and healthy. As far as can be ascertained her parents are not related. 
This chapter describes the defects in the function of leukocytes from this 
patient. The results suggest that she has a novel form of integrin dysfunction in 
which the ß,, ß2 and ß3 integrins are expressed on the cell surface at normal levels 
but cannot be stimulated to bind ligand by intracellular signalling pathways. Due to 
the small amount of blood that can be obtained from such a young child and her 
infrequent visits to hospital in this country, some of the results presented in this 
chapter, particularly those with neutrophils, are preliminary. 
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6.2 RESULTS 
6.2.1 Analysis of Patient FM Leukocyte Subsets 
The number of leukocytes obtained from a heparinised sample of Patient 
FM's blood, after erythrocytes were depleted by dextran sedimentation, was 32 x 
106/ml, four times the number obtained from an equal volume of blood from an age 
matched healthy donor (Control). This was accounted for by a two fold increase in 
the neutrophil numbers and an approximately ten fold increase in the number of 
peripheral blood mononuclear cells (PBMC) (Table 6.1). 
Neutrophils were separated from peripheral blood mononuclear cells (PBMC) 
on a Percoll gradient and the two fractions analysed for leukocyte populations by 
flow cytometry. In particular we were interested in discovering whether any specific 
PBMC population was responsible for the markedly elevated numbers of PBMC or 
whether all populations were expanded. T cells were identified by staining for CD3. 
The proportion of T cells in the patient's PBMC fraction was decreased compared to 
control, but had a normal CD4: CD8 ratio (Table 6.2 and data not shown). The 
CD14 positive monocyte population formed a similar proportion of the PBMCs in 
the patient and control. Of note, the CD19 positive B cell population formed 20% of 
the patient's PBMCs but only 6% of the control's PBMCs, and the patient also had 
an increased proportion of CD16 positive PBMCs, probably NK cells (Table 6.2). 
6.2.2 Patient FM has normal levels off 2 integrin expression 
Because the patient suffered from symptoms indicative of LAD-1, the cell 
surface expression of the (32 integrins was investigated by flow cytometry. As can be 
seen by the overlapping profiles in Figure 6.1, normal levels of LFA-l, Mac-1 and 
p150,95 were detected on T cells from Patient FM. The expression of aX and ß2 on 
Patient FM's neutrophils were similar to the control levels. Although it appears from 
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CONTROL PATIENT FM 
Total leukocytes 8x 106/m1 32 x 106/ml 
PBMC 1.1 x 106/m1 15 x 106/ml 
Granulocytes 6x 106/m1 12 x 106/ml 
Table 6.1 Control and Patient FM Leukocyte numbers 
The number of leukocytes, peripheral blood mononuclear cells (PBMC) and 
granulocyes found per ml of blood from Patient FM and a control donor (n=2). 
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CONTROL PATIENT FM 
CD3 64 35 
CD14 14 19 
CD19 6 20 
CD16 12 25 
Table 6.2 Control and Patient FM PBMC subsets 
The percentage of control and Patient FM PBMCs expressing CD3 (UCHT1), CD14 
(UCHM1), CD19 (BU12) and CD16 (3G8). Representative results are shown (n=2). 
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Figure 6.1 Expression of the ß2 integrins on T cells and neutrophils 
Expression of a,. (mAb 38), aM (ICRF44), aX (3.9) and ßz (TS 1/ 18) on control 
and Patient FM () T cells and neutrophils. The negative control is indicated 
Data from one experiment are shown (n=2 for T cells; n=1 for neutrophils). 
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this initial experiment that the levels of LFA-1 and Mac-1 are reduced on the 
patient's neutrophils, in a second experiment levels were normal (D. Imwold - 
personal communication). When further blood samples are available, this requires 
repeating. These initial results indicate that transport of the f2 integrins to the cell 
surface and protein stability are not affected in this patient. 
The expression of other cell surface adhesion molecules on T cells from the 
patient and a control were also compared. ICAM-1 and ICAM-3, two ligands of 
LFA-1, were expressed at equal levels, however L-selectin levels were decreased on 
Patient FM's T cells compared to the control's (Fig. 6.2). 
6.23 Patient FM has defective Mac-1 function on neutrophils 
Although Patient FM had normal cell surface expression of the (32 integrins, it 
was possible that the LAD-1 symptoms were due to the inability of these integrins to 
bind ligand. Function of the (32 integrin Mac-1 was assessed by neutrophil binding to 
plates coated with the ligand fibrinogen. A variety of stimuli were used and all 
induced neutrophils from a control donor to bind to fibrinogen in a 02 integrin- 
dependent manner (Fig. 6.3). The only stimulus to induce Patient FM neutrophils to 
bind, however, was the ß2 activating mAb KIM185. Therefore, the ability of Mac-1 
on Patient FM's neutrophils to bind to fibrinogen was impaired. 
6.2.4 Patient FM has defective LFA-1 function on T cells 
The function of LFA-1, another ß2 integrin, was tested by T cell adhesion to 
plates coated with the LFA-1 ligands ICAM-1 and ICAM-3. All the stimuli tested 
induced LFA-1-mediated T cell binding to both ICAM-1 and ICAM-3 when cells 
from a control donor were used (Fig. 6.4 A and B). When T cells from Patient FM 
were tested, however, only Mgt/EGTA induced adhesion to ICAM-1 (Fig. 6.4 A), 
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Figure 6.2 Expression of other cell surface molecules on T cells 
Expression of ICAM-1 (15.2), ICAM-3 (CH3.1) and L-selectin (LAM 1.3) on control 
() and Patient FM () T cells . Data are from one experiment (n=2). 
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Figure 6.3 Neutrophil binding to fibrinogen 
The ability of neutrophils from Patient FM (M)and from a control donor ( ) to bind 
to fibrinogen coated plates when stimulated with 100 nM fMLP, 50 nM PdBu, 0.5 
mM MnC1-,, or 5 mM MgC12/ 1 mM EGTA for 30 min RT. The presence of CD 18 
mAb 1134 at 10 µg/ml inhibits adhesion of Patient FM (Q) and control (Q) cells. 
Data (mean of triplicates ± S. D. ) from one representative experiment (n=2) are 
shown. 
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Figure 6.4 T cell binding to ICAM-1 and ICAM-3 
The ability of T cells from Patient FM (U) and from a control donor (0) to bind to 
A: ICAM-1 and B: ICAM-3 when stimulated with 50 nM PdBu, 5 µM thapsigargin, 
1 µM ionomycin, 10 µg/ml UCHT-1,10 µg/ml KIM185,5 mM Mg2+/1 mM EGTA 
or 0.5 mM Mn 2+ for 30 min at 37°C. The presence of anti-LFA-1 mAb 38 at 10 
µg /ml inhibits adhesion of Patient FM (D) and control (0) cells. Data (mean of 
triplicates ± S. D. ) from one representative experiment (n=3) are shown. 
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while Mgt; /EGTA, Mn'* and the activating ß2 mAb KIM185 induced adhesion to 
ICAM-3 (Fig. 6.4 B). 
6.2.5 Expression of the ß2 integrin activation epitope recognised by mAb 24 is 
normal on Patient FM T cells 
The results from the adhesion assays suggest that the (32 integrins on Patient 
FM's cells cannot be activated by intracellular signalling pathways, but can be 
activated from outside the cell by the divalent cations Mg2+ and Mn" and by the (32 
integrin activating mAb KIM185. These latter forms of stimulation all activate 
LFA-1 by directly binding to the integrin ectodomain and inducing a structural 
change to a higher affinity conformation that is recognised by mAb 24. The 
expression of the mAb 24 epitope on T cells was investigated by flow cytometry. 
The presence of Mn2+ at 37°C induced equivalent levels of 24 binding on T cells 
from a control donor and from Patient FM (Fig. 6.5). Therefore, as the adhesion 
assays suggest, stimulation from outside the cell can induce the high affinity 
conformation of the ß2 integrins on Patient FM's cells. 
6.2.6 Patient FM has defective a4ß1 and 45(31 function on T cells 
As a control, the function of the (31 integrins on T cells was examined. It was 
a surprise to find that, whereas all the stimuli tested induced adhesion of control T 
cells, Patient FM's T cells only adhered to VCAM-1 when stimulated by Mgt+, Mn2+ 
or the ß, activating mAb TS2/16 (Fig. 6.6 A). These activating agents all act on the 
integrin ectodomain. T cell adhesion to VCAM-1 is mediated by a4 p, and therefore, 
in a similar manner to the (32 integrins, intracellular signalling pathways fail to 
activate a4ß1. 
To test whether this defect in intracellular signalling also affected a5ß, 
function, T cell binding to fibronectin, which is mediated by a combination of a4$3, 
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Figure 6.5 Expression of the mAb 24 epitope on T cells 
Control () and Patient FM (-) T cells incubated with mAb 24 at 10 µg/ml for 30 
min at 37°C in the presence of 500 µM MnCI2. Control T cells incubated with mAb 
24 at 4°C in the presence of 1 mM EGTA( ) are shown as a negative control. Data 
are from a representative experiment (n=3). 
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Figure 6.6 T cell binding to VCAM-1 and fibronectin 
The ability of T cells from Patient FM ( ) and from a control donor ( ) to bind to 
A: VCAM-1 and B: fibronectin when stimulated with 50 nM PdBu, 5 µM 
thapsigargin, 1 [tM ionomycin, 10 µg/ml UCHT-1,10 µg/m1 TS2/16,5 mM Mg2+/ 
1 mM EGTA or 0.5 mM Mn 2+ for 30 min at 37°C. Binding of Patient FM (13) and 
control (Q) cells is inhibited by anti-a4 mAb HP2/1 at 10 Vg/ml for VCAM-1 and a 
combination of anti-a4 mAb HPI/2 and anti-a5 mAb SAM-1 for fibronectin. Data 
(mean of triplicates ± S. D. ) from one representative experiment (n=3) are shown. 
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and c f3,, was performed. Again, stimulation through intracellular signalling 
pathways failed to activate adhesion of the patient's cells, whereas the outside-in 
stimuli induced similar levels of adhesion to those obtained with control T cells (Fig 
6.6 B). 
6.2.7 Patient FM has normal levels of ß, integrin expression 
The expression of f integrins was measured by flow cytometry. Identical 
levels of a4, a5 and ß, were seen on T cells from both the patient and control (Fig. 
6.7). This confirms that the impaired ß, integrin function seen in the adhesion assays 
was not due to a difference in the level of ft integrin expression, but is more likely to 
be due to a defect in the signalling pathway that leads to integrin activation. 
6.2.8 Patient FM's neutrophils are able to flux Cat+, shed L-selectin, 
upregulate Mac-i and produce a superoxide burst in response to fMLP 
To verify that the lack of integrin activation on Patient FM's leukocytes was 
not due to a gross signalling defect, some preliminary experiments were carried out 
to test neutrophil responses to fMLP. One of the early events common to many 
signalling pathways is the mobilisation of intracellular Cat+. The patient's 
neutrophils were able to elevate [Ca2+]; in response to fMLP (Fig. 6.8 A), and in 
response to the Ca2+ mobilising agent thapsigargin (Fig. 6.8 B). 
Other responses that are characteristic of neutrophil activation by fMLP were 
also tested. L-selectin shedding (Fig. 6.9 A), the upregulation of Mac-1 (Fig. 6.9 B) 
and superoxide burst (Fig. 6.9 C) were found to occur at a similar extent in 
neutrophils from Patient FM and from a control. Therefore, despite the fact that 
fMLP cannot stimulate Patient FM's neutrophils to bind to fibrinogen (Fig. 6.3), 
these preliminary experiments (n=l) indicate that fMLP does activate the patient's 
neutrophils. 
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Figure 6.7 Expression of the ß, integrins on T cells 
Expression of a4 (HP1/2), as (SAM-1) and P, (P5D2) on control () and Patient FM 
() T cells. Data are from one experiment (n=2). 
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Figure 6.8 Intracellular Ca 2+ mobilisation in response to fMLP and 
thapsigargin stimulation of neutrophils from Patient FM 
Intracellular Ca 2+ flux in Fluo-3 labelled neutrophils from Patient FM stimulated with 
A: 0.1 pM fMLP and B: 5 µM thapsigargin at the times indicated by the arrows. 
Increases in [Ca 2+1i were detected by an increase in fluorescence of Fluo-3 and are 
represented by arbitrary units. This is a preliminary experiment (n=1). 
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Figure 6.9 The effect of fMLP on L-selectin shedding, Mac-1 upregulation and 
superoxide burst in neutrophils 
Control and Patient FM neutrophils were incubated for 30 min at 37°C without 
stimulation (-) or with 0.1M fMLP (-) and tested for A: expression of L-selectin 
(mAb LAM 1.3), B: expression of Mac-1 (mAb ICRF44) and C: superoxide burst. 
Increases in superoxide were detected by an increase in fluorescence of 
dihydrorhodamine. This is a preliminary experiment (n=1). 
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6.2.9 Patient FM's T cells are able to migrate in response to SDF-la 
Stromal derived factor (SDF)-la is a CXC chemokine produced in secondary 
lymphoid organs, which binds to the chemokine receptor CXCR4. SDF-la is a 
highly efficacious lymphocyte chemoattractant (Bleul et al., 1996), capable of 
inducing integrin mediated adhesion (Campbell et al., 1998). To test whether 
signalling through chemokine receptors is functioning in Patient FM's cells, the 
response of T cells to various concentrations of SDF-la was measured using a 
Transwell system, with the cells in the top well and SDF-1a in the bottom well (Fig. 
6.10). Patient FM's T cells were able to respond to SDF-1a. However, whereas 
approximately 70% of control input cells had migrated within 90 min toward 10 nM 
SDF-la, only approximately 35% of Patient FM's cells had migrated. The 
spontaneous migration without stimulus was consistently lower for Patient FM's 
cells than for the control's. 
6.2.10 Patient FM has normal expression of a number of cytoskeletal proteins 
reported to associate with integrins 
The link between integrins and the cytoskeleton is critical for their function 
and it is therefore possible that the dysfunction of integrins on Patient FM's 
leukocytes is due to a defect in a cytoskeletal protein. A number of cytoskeletal 
proteins have been reported to associate with integrins. Many of these interactions 
are probably not direct, are likely to be integrin and cell type specific, and may also 
depend on the activation state of both the cell and integrin. The cytoskeletal 
associations of integrins on leukocytes are therefore ill-defined. As an initial attempt 
to address whether any of these associations are defective in Patient FM's T cells, 
lysates were blotted for some of the most commonly reported integrin-associated 
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Figure 6.10 T cell migration in response to SDF-la 
T cells from Patient FM (A) and from a control donor ( ) were placed in the upper 
well of a Transwell plate and allowed to migrate for 90 min at 37°C in response to 0- 
10 nM SDF-la in the lower chamber. Data (mean of triplicates ± S. D. ) from one 
representative experiment (n=3) are shown. 
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cytoskeletal proteins. As can be seen in Figure 6.11, filamin, talin, a-actinin, 
vinculin, ezrin and actin are all present in the patient's lysate and are expressed at 
equivalent levels in the control lysate. This was also the case for the LFA-1 alpha 
subunit. Migration on SDS-PAGE of all the proteins tested was as expected and the 
same for both lysates, indicating that none of these proteins had been cleaved or had 
differences in post-trancriptional modification (Fig. 6.11). 
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Figure 6.11 Western blots of T cell lysates from a control donor and Patient FM 
immunostained for cytoskeletal proteins 
T cell lysates from a control donor (C) and Patient FM were blotted for the 
cytoskeletal proteins indicated and also for the LFA-1 a subunit (n=2). 
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6.3 DISCUSSION 
This chapter reports a patient with a novel form of inherited integrin 
dysfunction in which the ß, and ß2 integrins are expressed on the leukocyte cell 
surface at normal levels but cannot be stimulated to bind ligand by intracellular 
signalling pathways. It appears that the defect also affects the platelet integrin aßß3, 
as the patient's platelets cannot be induced to bind fibrinogen, or to express the aßß3 
activation epitope recognised by PAC-1, and fail to aggregate in response to agonists 
such as ADP (David Imwold and Nigel Klein - personal communication). Clinical 
tests showed that total immunoglobulin levels, tetanus and influenza haemagglutinin 
antibody titres, the nitro blue tetrazolium test of oxidative burst and responses to 
Candida and PPD were all within the normal range. The response to PHA was 
suboptimal, however the response to a combination of PHA and IL-2 was enhanced 
(David Imwold and Nigel Klein - personal communication). 
As the functions of at least three integrin families are affected in this patient it 
is unlikely that the dysfunction is due to mutations in the integrin a or 0 subunits 
themselves. It is more probable that the faulty gene encodes a protein that is critical 
for integrin function and that expression of this protein is restricted to haematopoietic 
cells. This latter conjecture is based on evidence from knockout mice which shows 
that integrins are essential for embryo survival: for instance both the a4 and ß, 
integrin knockouts are embryonic lethal (Fassler and Meyer, 1995; Yang et al., 
1995). It would therefore be expected that the patient would not have survived if the 
functions of ß, integrins on all cells were affected. 
Three other patients with non-classical forms of LAD-1 have been described. 
The first expressed -60% of the normal levels of (32 integrins, but despite this had no 
(32 integrin function. This patient was a compound heterozygote with a mutation in 
one allele that prevented expression and a mutation in the other allele that prevented 
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ligand binding (Hogg et al., 1999). The second case had the clinical indicators of 
LAD-1 and the (32 integrins were non-functional, but no abnormalities in the (i2 gene 
were detected. With time, defects in ß3 integrin function also became apparent, but, 
in contrast to Patient FM, 03, integrins were not affected (Kuijpers et al., 1997). It 
was speculated that the problem lay in an integrin-associated protein rather than in 
the integrins themselves. In the third case, the clinical features of LAD-1 were found 
to be due to a mutation in the gene encoding the haematopoietic cell-specific small 
GTPase Rac2, which resulted in it being unable to bind GTP (Ambruso et al., 2000; 
Williams et al., 2000). Patient FM has elevated numbers of lymphocytes and an 
intact superoxide burst, distinguishing her from the Rac2 defective patient. For the 
Rac2 defective patient, and also for the Rac2 knockout mouse (Roberts et al., 1999), 
the dysfunctions described are restricted to neutrophils. 
The signalling and cytoskeletal changes leading to integrin activation on 
leukocytes are not well defined. Although intracellular signalling could not activate 
the integrins on Patient FM's leukocytes and platelets, other functions were still 
intact. For example, fMLP did not stimulate neutrophil binding to fibrinogen but in 
preliminary experiments did induce upregulation of Mac-1 expression, L-selectin 
shedding and superoxide burst. This suggests that the defect is in a protein that is 
proximal to the integrin. A number of cytoskeletal proteins that have been reported 
to be associated with integrins (see Chapter Five) were present at normal levels in 
Patient FM T cells. This result indicates that the dysfunction is not due to lack of 
expression of one of these proteins, but does not preclude the possibility that a 
mutation in one of these proteins is disrupting its function. One obvious candidate 
for the abnormal protein is the guanine nucleotide exchange factor cytohesin-1. 
Cytohesin-1 is prevalently expressed in immune cells and interacts with the 02 
subunit cytoplasmic tail to control LFA-1 function in Jurkat cells (Kolanus et al., 
1996). However, cytohesin-1 does not interact with the ß, subunit and has no affect 
on ß, integrin function in the Jurkat T cell line (Kolanus et al., 1996), which 
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therefore diminishes the likelihood of it being implicated. The small GTPase Rap-1 
has also been demonstrated to lie in the signalling pathway leading to LFA-1, and 
also Mac-1, activation (Caron et al., 2000; Katagiri et al., 2000; Reedquist et al., 
2000), however Rap-1 is ubiquitously expressed. 
The ß, and (32 integrins play an important role in the extravasation of 
leukocytes to sites of injury or infection and in the homing of lymphocytes to tissues, 
particularly the secondary lymphoid organs. Leukocyte recruitment from the 
circulation to tissue, across vascular endothelium (or high endothelial venules of 
secondary lymphoid organs) involves a cascade of events (see Figure 1.9). First, 
leukocytes roll along the endothelium mediated by L-selectin on the leukocyte and P- 
and E-selectin on the endothelium. Next, chemokines bound to the endothelium 
activate their receptors on leukocytes resulting in L-selectin shedding, integrin 
activation, and thus integrin-mediated firm adhesion of the leukocytes to the 
endothelium. Finally, integrins mediate diapedesis of the leukocytes between the 
endothelial cells to the extravascular space (reviewed in (Carlos and Harlan, 1994; 
Springer, 1994)). Typically, LAD-1 patients have elevated numbers of circulating 
neutrophils, as these cells fail to adhere or to migrate across the endothelium. This 
results in the failure of LAD-1 patients to clear bacterial infections. With the 
additional defect of lack of ß, function, it would be expected that Patient FM would 
have further problems. In experiments with knockout mice, lack of 02 integrins can 
be somewhat compensated for by the (31 integrins (Berlin-Rufenach et al., 1999). 
Without both families of integrins it would be expected that lymphocyte trafficking 
would be severely impaired. This may partially explain why Patient FM has a vastly 
elevated number of circulating lymphocytes, a feature that is not so prominent in 
classic LAD-1 patients. Additionally, lack of integrin function may also affect 
haematopoiesis. The regulation of haematopoiesis is not well understood but 
requires both soluble factors and interaction of the stem cells/progenitors with the 
stromal cells in the bone marrow and thymus. The integrins are one of the families 
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of adhesion molecules predicted to be involved in the homing of progenitors to the 
bone marrow and the retention of progenitors in the bone marrow. Indeed, in mice 
with conditional a4 null B cells, these cells exit the bone marrow prematurely, before 
full differentiation and proliferation has taken place (Arroyo et al., 1996). Signalling 
through the integrins may also affect cell proliferation and cell survival. However 
whether increased generation, increased lifespan, increased proliferation or decreased 
migration of mature cells creates the elevated lymphocyte numbers remains to be 
investigated. 
The potential to correct inherited genetic disorders of blood cells by 
introducing a normal copy of the faulty gene into haematopoietic stem cells has been 
discussed for some years. Unfortunately human stem cell gene therapy trials have 
proved disappointing as the efficiency of gene transfer has been low and of short 
duration. Development of techniques for stem cell gene transfer involving the use of 
a fragment of fibronectin to aid co-localisation of the retroviral vector and the target 
stem cell are improving transduction levels (Abonour et al., 2000). A recent report 
of the successful use of stem cell gene therapy to treat two children with Severe 
Combined Immunodeficiency (SCID) used this protocol (Cavazzana-Calvo et al., 
2000). Although it is too early to determine whether this therapy will give long term 
alleviation from SCID, the results are encouraging and the patients have been able to 
leave sterile isolation. A potential problem of using gene therapy to correct integrin 
dysfunction is that integrins do not function normally when transfected into cells. It 
has been reported, however, that retroviral mediated transfer of the CD18 gene 
allowed LAD-1 stem cells to gain CD18 dependent functions ex vivo (Bauer et al., 
1998). Recently, the integrin $33 gene under the control of the ate, promoter was 
introduced into CD34+ peripheral blood stem cells from patients with Glanzmann's 
Thrombasthenia in order to drive megakaryocyte-targeted expression of the normal 
ß3 subunit. The transduced megakaryocytes were able to retract a fibrin clot, 
demonstrating aßß, function (Wilcox et al., 2000). These promising developments 
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in gene therapy intensify the importance of identifying the molecular basis behind 
inherited diseases. Currently, bone marrow transplantation is the only curative 
treatment for LAD-1. 
In summary, a defect in the signalling pathway which leads to integrin 
activation on leukocytes and platelets, rather than a defect in the integrins 
themselves, appears to be responsible for the LAD-1- and Glanzmann's 
Thrombasthenia-like symptoms of Patient FM. Patient FM therefore has a non- 
classical form of integrin dysfunction. The affected pathway is probably restricted to 
cells of haematopoietic origin and it is likely that events proximal to the integrin are 
affected. The defects described here demonstrate that detection of integrins on the 
cell surface does not necessarily exclude a diagnosis of LAD-1 or Glanzmann's 
Thrombasthenia. 
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SUMMARY AND FUTURE DIRECTIONS 
7.1 SUMMARY 
Integrins facilitate many leukocyte interactions in the immune system. For 
example, they are involved in leukocyte migration to peripheral lymph nodes and 
inflammatory sites, antigen presentation and cytotoxic killing. To prevent 
inappropriate induction of these processes, it is crucial that the interaction of the 
integrins with their ligands is tightly controlled. Under normal conditions, the 
integrins on leukocytes are inactive, but engagement of the T and B cell receptors, 
exposure to cytokines and chemokines, and cross talk from other cell surface 
adhesion molecules, all result in rapid integrin activation. However, little has been 
known about the detailed molecular mechanisms that regulate integrin activation on 
leukocytes. The findings of this thesis contribute to the understanding of the 
processes of integrin activation and ligand interaction. Specifically, the activation of 
the leukocyte integrin LFA-1 on T cells and its interaction with its ligands ICAM-1 
and ICAM-3 were investigated. 
7.1.1 LFA-1 binding to the ICAMs 
ICAM-1, ICAM-2 and ICAM-3 are closely related members of the 
immunoglobulin superfamily and all are ligands for LFA-1. Recently, the structures 
of domains 1 and 2 of ICAM-1 and ICAM-2 have been solved (Casasnovas et al., 
1997; Casasnovas et al., 1998b). These domains are Ig-like, each composed of two ß 
sheets, one containing the A', C, F and G strands, the other the A, B, D and E 
strands. The C and D strands form an edge to the domain. Residues G1u34, Met`4, 
Tyr66 and GIn73 of ICAM-1 are essential for interaction with LFA-1 (Staunton et al., 
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1990). Glu34 is the last residue in the C strand in domain 1 of ICAM-1, Met" and 
Tyr66 are in strand F and G1n73 lies in strand G. Thus, the CFG face of domain 1 of 
ICAM-1 is a binding site for LFA-1. In Chapter 3, the binding site for LFA-1 on 
ICAM-3 was characterised. The results demonstrate that GIu37, Leu66, Ser68 and 
Gln75 in domain 1 of ICAM-3 are critical for this interaction. The structure of 
ICAM-3 has not yet been determined, but is predicted to be similar to that of ICAM- 
1. Thus, the results in Chapter 3 indicate that LFA-1 makes contact with residues 
on the CFG face of ICAM-3, in a similar position to those on ICAM-1. Extensive 
mutagenesis has recently defined the LFA-1 binding site in ICAM-2 (Casasnovas et 
al., 1999). It is oblong in shape and extends diagonally across the CFG face and CD 
edge. The pattern that has emerged from all these results is that LFA-1 has a similar 
binding footprints on all three ICAMs. 
It is predicted that G1u34 of ICAM-1, or G1u31 in ICAM-2 and ICAM-3, is 
central to the interaction with LFA-1. G1u34 of ICAM-1 is essential for binding to the 
LFA-1 I domain (Stanley and Hogg, 1998), and it has been proposed that it 
coordinates the metal ion bound to the MIDAS motif (Lee et al., 1995b). The 
MIDAS face of the I domain would thus make contact with the CFG face of domain 
1 of ICAM-1. From the results in Chapter 3, it is predicted that ICAM-3 would 
bind to the LFA-1 I domain in a similar manner to ICAM-1, with G1u31 coordinating 
the metal ion. In Chapter 4, a peptide from the I domain inhibited T cell binding to 
ICAM-3 without affecting binding to ICAM-1. This indicates that there may be 
some selectivity to the interaction of the I domain with different ligands. We await 
co-crystals of the LFA-1 I domain with its various ICAM ligands to confirm these 
predictions. 
It has been questioned whether LFA-1 binding sites exist in ICAM-1 other 
than the CFG face of domain 1. In Chapter 3, mutagenesis of H'SZHG in the EF 
loop in domain 2 of ICAM-1 disrupted binding to LFA-1. It has subsequently been 
demonstrated that this mutation prevents binding of the isolated LFA-1 I domain, but 
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that the I domain does not bind directly to domain 2 (Stanley et al., 2000). We have 
therefore concluded that ICAM-1 domain 2 plays an important role in binding to 
LFA-1 but that it is not a direct binding site. 
In addition to binding the leukocyte integrins, ICAM-1 serves as a receptor 
for erythrocytes infected with the malarial parasite, P. falciparum . In Kilifi, Kenya 
a K29/M polymorphism in ICAM-1 was found to be associated with increased 
susceptibility to cerebral malaria. This was an unexpected finding. How could a 
polymorphism with such an undesirable consequence have arisen? In Chapter 3, 
ICAM-1 with the K29/M mutation (ICAM-1") was shown to support LFA-1- 
mediated T cell adhesion, but with a lower affinity than wt ICAM-1. It would be 
interesting to test whether the K291M mutation has a more severe effect on T cell 
binding under flow conditions, more accurately mimicking the in vivo situation. Our 
collaborator, D. Altieri, found that binding of ICAM-1K'''f to fibrinogen was severely 
impaired compared to wt ICAM-1 binding. By binding to ICAM-1 on the 
endothelium and Mac-1 on the leukocyte, fibrinogen functions as a bridge for 
leukocyte-endothelial interactions. Thus, by reducing the affinity of LFA-1 binding 
and diminishing fibrinogen binding, the ICAM-1"''' polymorphism could limit 
leukocyte transmigration. This could, perhaps, be advantageous when subjected to 
continuous microbial infection. 
7.1.2 LFA-1 affinity regulation 
Binding of the divalent cation Mg2+ to the LFA-1 ectodomain induces a high 
affinity form of LFA-1, without requirement for intracellular signalling. This form 
of LFA-1 is characterised by its ability to bind soluble ICAM-1 and by expression of 
the epitope recognised by mAb 24 (Stewart et al., 1996). In Chapter 4, it was 
shown that formation of this high affinity form of LFA-1 requires interdomain 
movement involving the I domain. A peptide corresponding to the ß3 to a5 loop and 
a5 helix of the I domain inhibited transition to the high affinity conformation, 
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suggesting this region of the domain alters its associations within the molecule 
allowing higher affinity binding to ligand. 
The in vivo relevance of regulation of integrin affinity has been questioned. 
Is this merely an experimental manipulation or are there physiological situations in 
which the affinity of integrins is altered? Until recently, evidence has been lacking 
that inside-out signalling can switch LFA-1 from a low affinity to a high affinity 
conformation. However, two publications in the last year have demonstrated that 
activation of LFA-1 through a Rap-l-dependent pathway results in increased LFA-1 
affinity, as detected by soluble ICAM-1 binding and expression of the mAb 24 
epitope (Katagiri et al., 2000; Reedquist et al., 2000). There may also be situations, 
such as wound healing, where alterations in Mg"' and Ca 2+ concentration occur that 
could influence LFA-1 affinity (Grzesiak and Pierschbacher, 1995). 
7.1.3 LFA-1 avidity 
LFA-1 can be activated to bind its ligands by intracellular signalling initiated 
by engagement of cell surface molecules, e. g. the TCR. Raising [Ca2+); by treatment 
with ionomycin or thapsigargin, or activating PKC with phorbol ester, has a similar 
effect. How these signals induce LFA-1 adhesion has been unclear. No increase in 
LFA-1 affinity can be detected and there is no evidence for a conformational change. 
In Chapter 4, it was shown that this form of adhesion was more sensitive than 
Mgt+/EGTA-stimulated adhesion to inhibition by mAbs that recognise the first and 
last helices of the ß I-like domain. It is interesting that in the a subunit I domain the 
first and last helices lie close together at the bottom of the domain and have been 
implicated in allosteric control of ligand binding (Kallen et al., 1999). 
The process by which raising [Ca2+]; regulates LFA-1 mediated T cell 
binding, was investigated in Chapter 5. This process requires the influx of 
extracellular Cat+, is susceptible to inhibitors of cytoskeletal reorganisation and 
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involves the Cat+-dependent protease calpain. Confocal microscopy revealed that 
upon treatment of T cells with Ca2+ mobilising agents, LFA-1 becomes clustered. It 
is believed that-this clustering enhances the avidity of ligand binding. 
There is evidence that restraint by the cytoskeleton maintains LFA-1 in an 
inactive state (Kucik et al., 1996; Tan et al., 2000; van Kooyk et al., 1999). These 
results were supported by the use of jasplakinolide, an agent which prevents 
reorganisation of the actin cytoskeleton. Jasplakinolide prevented LFA-1 clustering 
and adhesion to ICAM-1. As many cytoskeletal proteins are targets of calpain, we 
formed a working hypothesis in which (1) in resting cells LFA-1 is tethered to the 
cytoskeleton, (2) raised [Ca-']; activates calpain, (3) this protease then cleaves an 
LFA-1-associated cytoskeletal protein, (4) the LFA-1 released from restraint by the 
cytoskeleton is free to move in the membrane and redistribute into clusters, and (5) 
these clusters strengthen binding to ICAM-1. It therefore seemed pertinent to 
investigate LFA-1 association with the cytoskeleton. These experiments proved to 
be technically difficult, however, so conclusive results were not obtained. Attempts 
were also made to identify the specific target of calpain, but this remains elusive. 
7.1.4 A model for LFA-1 activation 
The results in Chapters 4 and 5 lead to three possible models for how 
changes in LFA-1 affinity and avidity could integrate to lead to ligand binding (Fig. 
7.1). The first option (Fig. 7.1 A) is that (1) LFA-1 exists in a low affinity, 
unclustered form on resting cells, (2) intracellular signalling events lead to clustering 
of LFA-1, (3) interaction with ligand induces a conformational change in LFA-1, 
which increases the affinity of ligand binding. In the second model (Fig. 7.1 B), (1) 
LFA-1 exists in a low affinity, unclustered form on resting cells, (2) intracellular 
signalling events lead to both LFA-1 clustering and a change to the higher affinity 
LFA-1 conformation, (3) ligand binding occurs through LFA-1 clusters containing a 
combination of low and high affinity LFA-1. The third possibility (Fig. 7.1 C) is 
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Resting Signalling Ligand 
binding 
A 
B ý- 
Figure 7.1 Three models for how changes in LFA-1 affinity and avidity could 
integrate to lead to ligand binding 
A: LFA-1 exists in a low affinity conformation (green) and is not clustered on resting 
cells. Intracellular signalling leads to clustering of LFA-1. Interaction with ligand 
induces the high affinity conformation of LFA-1 (red). B LFA-1 exists in a low 
affinity conformation (green) and is not clustered on resting cells. Intracellular 
signalling leads to both LFA-1 clustering and a change to the higher affinity LFA-1 
conformation (red). Ligand binding occurs through LFA-1 clusters containing a 
combination of low and high affinity LFA-1. C: On resting cells LFA-1 exists in an 
equilibrium of low (green) and high affinity (red) conformations. Intracellular 
signalling leads to LFA-1 clustering, then interaction with ligand stabilises the high 
affinity conformation of LFA-1. 
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that (1) on resting cells LFA-1 exists in an equilibrium of low and high affinity 
conformations, (2) intracellular signalling leads to LFA-1 clustering, (3) interaction 
with ligand stabilises the high affinity conformation of LFA-1. It has been difficult 
to distinguish between these three options. At present the model in Figure 7.1 B 
seems least likely because, as described in this thesis, most inside-out activators of 
LFA-1 adhesion cause clustering but not a detectable affinity alteration. 
7.1.5 Integrin Dysfunction 
Chapter 6 describes the characterisation of leukocytes from a patient who 
first presented with symptoms characteristic of Glanzmann's Thrombasthenia, a 
bleeding disorder due to mutation of the genes encoding the platelet integrin aß 03. 
Subsequently, indications of Leukocyte Adhesion Deficiency-1 became apparent. 
This disease is due to mutations in the leukocyte integrin (32 gene that prevent 
function and/or expression of LFA-1 , Mac-1 and p150,95. Typically, LAD-1 
patients have reduced emigration of leukocytes to inflammatory sites resulting in 
granulocytosis and susceptibility to bacterial infections. Leukocytes from this 
patient have normal levels of integrin expression. However, these integrins do not 
function properly. Inside-out stimuli failed to induce LFA-1-dependent T cell 
adhesion to ICAM-1 or ICAM-3 or Mac-1-mediated neutrophil adhesion to 
fibrinogen. Unexpectedly, cc4(3! -dependent T cell adhesion to VCAM-1 and a431- 
and a5ß1-dependent T cell adhesion to fibronectin were also found to be affected. 
All these integrins did bind their ligands when stimulated with divalent cations or 
with activating mAbs. In addition, our collaborators found that aß, ß3 mediated 
platelet adhesion to fibrinogen was defective. As at least three families of integrins 
could not be activated by intracellular signalling pathways, we concluded that this 
patient has a novel form of integrin dysfunction. We reasoned that the defect is 
unlikely to be in the integrin genes, but may be in a gene encoding a signalling 
protein or an integrin-associated protein required for activation. 
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7.2 FUTURE DIRECTIONS 
In the immediate future, I will concentrate on further characterisation of 
leukocytes from the patient with integrin dysfunction. In cell of non-haematopoietic 
origin, integrins are constituents of complexes including multiple signalling 
molecules, cytoskeletal components and adapter molecules. These complexes are 
not well characterised in leukocytes. Identification of the lesion responsible for the 
integrin dysfunction could provide an insight into the molecular mechanisms 
responsible for signal transduction and integrin activation in haematopoietic cells. 
At the protein level, the initial approaches to identify this protein will be to run three 
dimensional gels to compare cell lysates from the patient and a control donor for any 
abnormal spots. Some clue to the identity of the defective protein may be gained 
from comparing the pattern of protein phosphorylation in lysates from activated cells 
from Patient FM and a control donor. If these methods do not yield any conclusive 
results, then the possibility of identifying differentially expressed genes could be 
explored. Either RNA from the patient could be used to generate probes to screen 
cDNA expression arrays, or differentially expressed transcripts could be enriched by 
subtractive hybridisation. Finally, expression cloning could be tried. In this 
technique an appropriate cDNA library, cloned into an expression vector, would be 
used to transfect cells from the patient and these cells would then be screened for 
restoration of integrin function. After several rounds of cloning the cDNA from the 
positive cells is isolated and the gene identified. However, transfecting leukocytes is 
problematic. 
This patient also provides a unique opportunity to investigate physiological 
roles for affinity regulation of LFA-1. For example, it is reported that crosslinking 
CD31 increases the affinity of LFA-1 (Reedquist et al., 2000). It would be 
interesting to test whether this is possible with the patient's cells. 
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The differential effects of the (32 mAbs on PdBu- and Mg2+/EGTA-stimulated 
adhesion are worth further investigation. One likely possibility is that these mAbs 
block the clustering of LFA-1 that is required for PdBu-stimulated adhesion. 
Confocal microscopy could be used to determine whether this is the case. Peptides 
from the ß2-I-like domain could be tested in a similar manner to the I domain 
peptides in Chapter 4. 
203 
REFERENCES 
Abonour, R., D. A. Williams, L. Einhorn, K. M. Hall, J. Chen, J. Coffman, C. M. 
Traycoff, A. Bank, I. Kato, M. Ward, S. D. Williams, R. Hromas, M. J. Robertson, 
F. O. Smith, D. Woo, B. Mills, E. F. Srour, and K. Cornetta (2000) 
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into 
autologous human long-term repopulating hematopoietic stem cells 
Nat. Med. 6 652-658. 
Abraham, C., J. Grifith, and J. Miller (1999) 
The dependence for Leukocyte function-associated antigen- 1/ICAM-1 interactions in 
T cell activation cannot be overcome by expression of high density TCR ligand 
J. Immunol. 162 4399-4405. 
Adamson, P., S. Etienne, P. O. Couraud, V. Calder, and J. Greenwood (1999) 
Lymphocyte migration through brain endothelial cell monolayers involves signaling 
through endothelial ICAM-1 via a rho-dependent pathway 
J. Immunol. 162 2964-2973. 
Alonso-Lebrero, J. L., J. M. Serrador, C. Dominguez-Jimenez, 0. Barreiro, A. Luque, 
M. A. del Pozo, K. Snapp, G. Kansas, R. Schwartz-Albiez, H. Furthmayr, F. Lozano, 
and F. Sanchez-Madrid (2000) 
Polarization and interaction of adhesion molecules P-selectin glycoprotein ligand 1 
and intercellular adhesion molecule 3 with moesin and ezrin in myeloid cells 
Blood 95 2413-2419. 
Altieri, D. C., and T. S. Edgington (1988) 
The saturable high affinity association of factor X to ADP-stimulated monocytes 
defines a novel function of the Mac-1 receptor 
J. Biol. Chem. 263 7007-7015. 
Altieri, D. C., F. R. Agbanyo, J. Plescia, M. H. Ginsberg, T. S. Edgington, and E. F. 
Plow (1990) 
A unique recognition site mediates the interaction of fibrinogen with the leukocyte 
integrin Mac-1 (CDllb/CD18) 
J. Biol. Chem. 265 12119-12122. 
Altieri, D. C., A. Duperray, J. Plescia, G. B. Thornton, and L. R. Languino (1995) 
Structural recognition of a novel fibrinogen gamma chain sequence (117-133) by 
intercellular adhesion molecule-1 mediates leukocyte-endothelium interaction 
J. Biol. Chem. 270 696-699. 
Ambruso, D., C. Knall, A. N. Abell, J. Panepinto, A. Kurkchubasche, G. Thurman, C. 
Gonzalez-Aller, A. Hiester, M. deBoer, R. J. Harbeck, R. Oyer, G. L. Johnson, and D. 
Roos (2000) 
Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 
mutation. 
Proc. Natl. Acad. Sci. USA 27 4654-4659. 
204 
REFERENCES 
Anderson, D. C., T. K. Kishimoto, and C. W. Smith (1994) 
Leukocyte adhesion deficiency and other disorders of leukocyte adherence and 
motility 
In The metabolic and molecular bases of inherited disease Vol. III. 
C. R. Scriver, A. L. Beaudet, and D. Valle, editors. McGraw-Hill. pp3955-3993. 
Andrew, D., A. Shock, E. Ball, S. Ortlepp, J. Bell, and M. Robinson (1993) 
KIM185, a monoclonal antibody to CD18 which induces a change in the 
conformation of CD18 and promotes both LFA-1- and CR3-dependent adhesion 
Eur. J. Immunol. 23 2217-2222. 
Arnaout, M. A. (1990) 
Structure and function of the leukocyte adhesion molecules CD11/CD 18 
Blood 75 1037-1050. 
Arregui, C. O., J. Balsamo, and J. Lilien (1998) 
Impaired integrin-mediated adhesion and signalling in fibroblasts expressing a 
dominant-negative mutant PTP1B 
J. Cell Biol. 143 861-873. 
Arroyo, A. G., J. T. Yang, H. Rayburn, and R. O. Hynes (1996) 
Differential requirements for a4 integrins during fetal and adult hematopoiesis 
Cell 85.997-1008. 
Bachmann, M. F., K. McKall-Faienza, R. Schmits, D. Bouchard, J. Beach, D. E. 
Speiser, T. W. Mak, and P. S. Ohashi (1997) 
Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion 
versus costimulation 
Immunity 7 549-557. 
Bailly, P., P. Hermand, I. Callebaut, H. H. Sonneborn, S. Khamlichi, J. P. Mornon, 
and J. P. Cartron (1994) 
The LW blood group glycoprotein is homologous to intercellular adhesion molecules 
Proc. Nati. Acad. Sci. USA 2-15306-5310. 
Bailly, P., E. Tontti, P. Hermand, J. P. Cartron, and C. G. Gahmberg (1995) 
The red cell LW blood group protein is an intercellular adhesion molecule which 
binds to CD11/CD 18 leukocyte integrins 
Eur. J. Immunol. 25 3316-3320. 
Bajt, M. L., and J. C. Loftus (1994) 
Mutation of a ligand binding domain of 03 integrin. Integral role of oxygenated 
residues in aHbß3 (GPIIb-IIIa) receptor function 
J. Biol. Chem. 269 20913-20919. 
Bajt, M. L., T. Goodman, and S. L. McGuire (1995) 
02 (CD18) mutations abolish ligand recognition by I domain integrins LFA-1 ((xL02, 
CD11a/CD18) and Mac-1 ((XM02, CD1lb/CD18) 
J. Biol. Chem. 270 94-98. 
205 
REFERENCES 
Baldwin, E. T., R. W. Sarver, G. L. Bryant, K. A. Curry, M. B. Fairbanks, B. C. Finzel, 
R. L. Garlick, R. L. Heinrickson, N. C. Horton, L. -L. C. Kelley, A. M. Mildner, J. B. 
Moon, J. E. Mott, V. T. Mutchler, C. -S. C. Tomich, K. D. Watenpaugh, and V. H. Wiley 
(1998) 
Cation binding to the integrin CD! lb I domain and activation model assessment 
Structure 6 923-935. 
Baneres, J. -L., F. Roquet, M. Green, H. LeCalvez, and J. Parello (1998) 
The cation-binding domain from the a subunit of integrin a501 is a minimal domain 
for fibronectin recognition 
J. Biol. Chem. 273 24744-24753. 
Baneres, J. -L., F. Roquet, A. Martin, and J. Parello (2000) 
A minimised human integrin a5ß1 that retains ligand recognition 
J. Biol. Chem. 275 5888-5903. 
Baruch, D. I., J. A. Gormely, C. Ma, R. J. Howard, and B. L. Pasloske (1996) 
Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte 
receptor for adherence to CD36, thrombospondin, and intercellular adhesion 
molecule 1 
Proc. Natl. Acad. Sci. USA 93 3497-3502. 
Basani, R. B., G. Vilaire, S. J. Shattil, M. A. Kolodziej, J. S. Bennett, and M. Poncz 
(1996) 
Glanzmann Thrombasthenia due to a two amino acid deletion in the fourth calcium- 
binding domain of aIIb: demonstration of the importance of calcium-binding 
domains in the conformation of aIIb(33 
Blood 88 167-173. 
Bauer, T. R., B. R. Schwartz, W. Conrad Liles, H. D. Ochs, and D. D. Hickstein (1998) 
Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral 
blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1 
Blood 91 1520-1526. 
Bell, E. D., A. P. May, and D. L. Simmons (1998) 
The leukocyte function-associated antigen-1 (LFA-1)-binding site on ICAM-3 
comprises residues on both faces of the first immunoglobulin domain 
J. Immunol. 161 1363-1370. 
Bella, J., P. R. Kolatkar, C. W. Marlor, J. M. Greve, and M. G. Rossman (1998) 
The structure of the two amino-terminal domains of human ICAM-1 suggests how it 
functions as a rhinovirus receptor and as an LFA-1 integrin ligand 
Proc. Natl. Acad. Sci. USA 95.4140-4145. 
Bellamy, R., D. Kwiatkowski, and A. V. Hill (1998) 
Absence of an association between intercellular adhesion molecule 1, complement 
receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe 
malaria in a West African population 
Trans. R. Soc. Trop. Med. Hyg. 22 312-316. 
206 
REFERENCES 
Berendt, A. R., D. L. Simmons, J. Tansey, C. I. Newbold, and K. Marsh (1989) 
Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for 
Plasmodium falciparum 
Nature 34157-59. 
Berendt, A. R., A. McDowall, A. G. Craig, P. A. Bates, M. J. E. Sternberg, K. Marsh, 
N. I. Newbold, and N. Hogg (1992) 
The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes 
overlaps, but is distinct from, the LFA-1 binding site 
Cell 68 71-81. 
Berlin-Rufenach, C., F. Otto, M. Mathies, J. Westermann, M. J. Owen, A. Hamann, 
and N. Hogg (1999) 
Lymphocyte migration in Lymphocyte Function-associated Antigen (LFA)-1- 
deficient mice 
J. Exp. Med. 189 1467-1478. 
Bianchi, E., J. R. Bender, F. Blasi, and R. Pardi (1997) 
Through and beyond the wall: late steps in leukocyte transendothelial migration 
Immunol. Today 18 586-591. 
Bianchi, E., S. Denti, A. Granata, G. Bossi, J. Geginat, A. Villa, L. Rogge, and R. 
Pardi (2000) 
Integrin LFA-1 interacts with the transcriptional co-activator JAB 1 to modulate AP-1 
activity 
Nature 404 617-621. 
Bilsland, C. A. G., M. S. Diamond, and T. A. Springer (1994) 
The leukocyte integrin p150,95 (CD1lc/CD18) as as receptor for iC3b 
J. Immunol. 152 4582-4589. 
Bleul, C. C., R. C. Fuhlbrigge, J. M. Casasnovas, A. Aiuti, and T. A. Springer (1996) 
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 
(SDF-1) 
J. Exp. Med. 184 1101-1109. 
Bork, P., T. Doerks, T. A. Springer, and B. Snel (1999) 
Domains in plexins: links to integrins and transcription factors 
Trends Biochem. Sci. 24 261-263. 
Bossy, D., M. G. Mattei, and D. L. Simmons (1994) 
The human intercellular adhesion molecule 3 (ICAM3) gene is located in the 
19p13.2-pl3.3 region, close to the ICAM1 gene 
Genomics 23 712-713. 
Bubb, M. R., A. M. Senderowicz, E. A. Sausville, K. L. Duncan, and E. D. Korn (1994) 
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and 
competitively inhibits the binding of phalloidin to F-actin 
J. Biol. Chem. 269 14869-14871. 
207 
REFERENCES 
Calderwood, D. A., D. S. Tuckwell, J. Eble, K. Kühn, and M. J. Humphries (1997) 
The integrin al A-domain is a ligand binding site for collagens and laminin 
J. Biol. Chem. 272 12311-12317. 
Campanero, M. R., P. Sanchez-Mateos, M. A. del Pozo, and F. Sanchez-Madrid 
(1994) 
ICAM-3 regulates lymphocyte morphology and integrin-mediated T cell interaction 
with endothelial cell and extracellular matrix ligands 
J. Cell Biol. 127 867-878. 
Campbell, J. J., J. Hedrick, A. Zlotnik, M. A. Siani, D. A. Thompson, and E. C. Butcher 
(1998) 
Chemokines and the arrest of lymphocytes rolling under flow conditions 
Science 279 381-384. 
Cantrell, D. A., and K. A. Smith (1983) 
Transient expression of interleukin 2 receptors. Consequences for T cell growth 
J. Exp. Med. 18 1895-1911. 
Carlos, T. M., and J. M. Harlan (1994) 
Leukocyte-endothelial adhesion molecules 
Blood 84 2068-2101. 
Caron, E., A. J. Self, and A. Hall (2000) 
The GTPase Rapl controls functional activation of macrophage integrin ccM02 by 
LPS and other inflammatory mediators 
Curr. Biol. 10 974-978. 
Casasnovas, J. M., T. A. Springer, J. Liu, S. C. Harrison, and J. Wang (1997) 
Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface 
Nature 387 312-315. 
Casasnovas, J. M., J. K. Bickford, and T. A. Springer (1998a) 
The domain structure of ICAM-1 and the kinetics of binding to Rhinovirus 
J. Virol. 72 6244-6246. 
Casasnovas, J. M., T. Stehle, J. -H. Liu, J. -H. Wang, and T. A. Springer (1998b) 
A dimeric crystal structure for the N-terminal two domains of intercellular adhesion 
molecule-1 
Proc. Natl. Acad. Sci. USA 95 4134-4139. 
Casasnovas, J. M., C. Pieroni, and T. A. Springer (1999) 
Lymphocyte function-associated antigen-1 binding residues in intercellular adhesion 
molecule-2 (ICAM-2) and the integrin binding surface in the ICAM subfamily 
Proc. Natl. Acad. Sci. USA 96 3017-3022. 
208 
REFERENCES 
Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. 
Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. 
Fischer (2000) 
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. 
Science 288 669-672. 
Champe, M., B. W. McIntyre, and P. W. Berman (1995) 
Monoclonal antibodies that block the activity of leukocyte function-associated 
antigen 1 recognise three discrete epitopes in the inserted domain of CD11a 
J. Biol. Chem. 270 1388-1394. 
Chan, J. R., S. J. Hyduk, and M. I. Cybulsky (2000) 
a4(31 integrin/VCAM-1 interaction activates aL02 integrin-mediated adhesion to 
ICAM-1 in human T cells 
J. Immunol. 164 746-753. 
Chirathaworn, C., S. A. Tibbetts, M. A. Chan, and S. H. Benedict (1995) 
Cross-linking of ICAM-1 on T cells induces transient tyrosine phosphorylation and 
inactivation of cdc2 kinase 
J. Immunol. 155 5479-5482. 
Chung, S. C., T. V. McDonald, and P. Gardner (1994) 
Inhibition by SK&F 96365 of Ca" current, IL-2 production and activation in T 
lymphocytes 
Br. J. Pharmacol. 11 861-868. 
Cierniewski, C. S., T. Byzova, M. Papierak, T. A. Haas, J. Niewiarowska, L. Zhang, 
M. Cieslak, and E. F. Plow (1999) 
Peptide ligands can bind to distinct sites in integrin ctIIb(33 and ellicit different 
functional responses 
J. Biol. Chem. 274 16923-16932. 
Clapham, D. E. (1995) 
Calcium signaling 
Cell 80 259-268. 
Collier, N. C., and K. Wang (1982) 
Purification and properties of human platelet P235. A high molecular weight protein 
substrate of endogenous calcium-activated protease(s) 
J. Biol. Chem. 257 6937-6943. 
Cooray, P., Y. Yuan, S. M. Schoenwaelder, C. A. Mitchell, H. H. Salem, and S. P. 
Jackson (1996) 
Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain 
Biochem. J. 318 41-47. 
Corbi, A. L., R. S. Larson, T. K. Kishimoto, T. A. Springer, and C. C. Morton (1988) 
Chromosomal location of the genes encoding the leukocyte adhesion receptors LFA- 
1, Mac-1 and p150,95. Identification of a gene cluster involved in cell adhesion 
J. Exp. Med. 167 1597-1607. 
209 
REFERENCES 
Craig, A., D. Fernandez-Reyes, M. Mesri, A. McDowall, D. C. Altieri, N. Hogg, and 
C. Newbold (2000) 
A functional analysis of a natural variant of intercellular adhesion molecule-1 
(ICAM-1K`''fi) 
Hum. Molec. Gen. 9 525-530. 
Cramer, L. P. (1999) 
Role of actin-filament disassembly in lamellipodium protrusion in motile cells 
revealed using the drug jasplakinolide 
Curr. Biol. 9 1095-1105. 
Critchley, D. R. (2000) 
Focal adhesions - the cytoskeletal connection 
Curr. Opin. Cell Biol. 12133-139. 
D'Souza, S. E., M. H. Ginsberg, T. A. Burke, and E. F. Plow (1990) 
The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the 
second calcium binding domain of its a subunit 
J. Biol. Chem. 265 3440-3446. 
D'Souza, S. E., M. H. Ginsberg, G. R. Matsueda, and E. F. Plow (1991) 
A discrete sequence in a platelet integrin is involved in ligand recognition 
Nature 350 66-68. 
D'Souza, S. E., T. A. Haas, R. S. Piotrowicz, V. Byers-Ward, D. E. McGrath, H. R. 
Soule, C. Cierniewski, E. F. Plow, and J. W. Smith (1994) 
Ligand and cation binding are dual functions of a discrete segment of the integrin 03 
subunit: cation displacement is involved in ligand binding 
Cell 79 659-667. 
D'Souza, S. E., V. J. Byers-Ward, E. E. Gardiner, H. Wang, and S. -S. Sung (1996) 
Identification of an active sequence within the first immunoglobulin domain of 
intercellular cell adhesion molecule-1 (ICAM-1) that interacts with fibrinogen 
J. Biol. Chem. 27124270-24277. 
Davis, G. E. (1992) 
The Mac-1 and p150,95 02 integrins bind denatured proteins to mediate leukocyte 
cell-substrate adhesion 
Exp. Cell Res. 200 242-252. 
de Fougerolles, A. R., S. A. Stacker, R. Schwarting, and T. A. Springer (1991) 
Characterisation of ICAM-2 and evidence for a third counter-receptor for LFA-1 
J. Exp. Med. 174 253-267. 
de Fougerolles, A. R., L. B. Klickstein, and T. A. Springer (1993) 
Cloning and expression of intercellular adhesion molecule 3 reveals strong homology 
to other immunoglobulin family counter-receptors for lymphocyte function- 
associated antigen 1 
J. Exp. Med. 177 1187-1192. 
210 
REFERENCES 
de Fougerolles, A. R., M. S. Diamond, and T. A. Springer (1995) 
Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and 
p150,95 
Eur. J. Immunol. 25 1008-1012. 
del Pozo, M. A., R. Pulido, C. Munoz, V. Alvarez, A. Humbria, M. R. Campanero, 
and F. Sanchez-Madrid (1994) 
Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through 
a proteolytic shedding mechanism 
Eur. J. Immunol. 24 2586-2594. 
del Pozo, M. A., C. Cabanas, M. C. Montoya, A. Ager, P. Sanchez-Mateos, and F. 
Sanchez-Madrid (1997) 
ICAMs redistributed by chemokines to cellular uropods as a mechanism for 
recruitment of T lymphocytes 
J. Cell Biol. 137 493-508. 
Denizot, F., and R. Lang (1986) 
Rapid colorimetric assay for cell groth and survival. Modifications to the tetrazolium 
dye procedure giving improved sensitivity and reliability 
J. Immunol. Methods 22 271-277. 
Deshpande, R. V., J: M. Goust, A. K. Chakrabarti, E. Barbosa, E. L. Hogan, and N. L. 
Banik (1995) 
Calpain expression in lymphoid cells. Increased mRNA and protein levels after cell 
activation 
J. Biol. Chem. 270 2497-2505. 
Diacovo, T. G., A. R. de Fougerolles, D. F. Bainton, and T. A. Springer (1994) 
A functional integrin ligand on the surface of platelets: intercellular adhesion 
molecule-2 
J. Clin. Invest. 94 
_ 
1243-1251. 
Diamond, M. S., D. E. Staunton, A. R. de Fougerolles, S. A. Stacker, J. Garcia-Aguilar, 
M. L. Hibbs, and T. A. Springer (1990) 
ICAM-1 (CD54): a counter-receptor for Mac-1 (CD1 lb/CD18) 
J. Cell Biol. 1113129-3139. 
Diamond, M. S., D. E. Staunton, S. D. Marlin, and T. A. Springer (1991) 
Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like 
domain of ICAM-1 (CD54) and its regulation by glycosylation 
Cell 65 961-971. 
Diamond, M. S., J. Garcia-Aguilar, J. K. Bickford, A. L. Corbi, and T. A. Springer 
(1993) 
The I domain is a major recognition site on the leukocyte integrin (CD 1 lb/CD 18) for 
four distinct adhesion ligands 
J. Cell Biol. 120 1031-1043. 
211 
REFERENCES 
Dickeson, S. K., J. J. Walsh, and S. A. Santoro (1997) 
Contributions of the I and EF hand domains to the divalent cation-dependent 
collagen binding activity of the a2ß1 integrin 
J. Biol. Chem. 272 7661-7668. 
Ding, Z. M., J. E. Babensee, S. I. Simon, H. Lu, J. L. Perrard, D. C. Bullard, X. Y. Dai, 
S. K. Bromley, M. L. Dustin, M. L. Entman, C. W. Smith, and C. M. Ballantyne (1999) 
Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration 
J. Immunol. 163 5029-5038. 
Djinovic-Carugo, K., P. Young, M. Gautel, and M. Saraste (1999) 
Structure of the a-actinin rod: molecular basis for cross-linking of actin filaments 
Cell 98 537-546. 
Dooley, D. C., J. F. Simpson, and H. T. Meryman (1982) 
Isolation of large numbers of fully viable human neutrophils: a preparative technique 
using percoll density gradient centrifugation 
Exp. Hematol. 10 591-599. 
Douglass, W. A., R. H. Hyland, C. D. Buckley, A. Al-Shamkhani, J. M. Shaw, S. L. 
Scarth, D. L. Simmons, and S. K. A. Law (1998) 
The role of the cysteine-rich region of the ß2 integrin subunit in the leukocyte 
function-associated antigen-1 (LFA-1, aLß2, CD11a/CD18) heterodimer formation 
and ligand binding 
FEBS Letts. 440 414-418. 
Dransfield, I., and N. Hogg (1989) 
Regulated expression of Mg2+ binding epitope on leukocyte integrin a subunits 
EMBO J. 8_ 3759-3765. 
Dransfield, I., C. Cabanas, A. Craig, and N. Hogg (1992) 
Divalent cation regulation of the function of the leukocyte integrin LFA-1 
J. Cell Biol. 116 219-226. 
Du, X., M. Gu, J. W. Weisel, C. Nagaswami, J. S. Bennett, R. Bowditch, and M. H. 
Ginsberg (1993) 
Long range propagation of conformational changes in integrin aIIb(33 
J. Biol. Chem. 268 23087-23092. 
Du, X., T. C. Saido, S. Tsubuki, F. E. Indig, M. J. Williams, and M. H. Ginsberg (1995) 
Calpain cleavage of the cytoplasmic domain of the integrin ß3 subunit 
J. Biol Chem. 270 26146-26151. 
Duperray, A., L. R. Languino, J. Plescia, A. McDowall, N. Hogg, A. G. Craig, A. R. 
Berendt, and D. C. Altieri (1997) 
Molecular identification of a novel fibrinogen binding site on the first domain of 
ICAM-1 regulating leukocyte-endothelium bridging 
J. Biol. Chem. 272 435-441. 
212 
REFERENCES 
Dustin, M. L., and T. A. Springer (1989) 
T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1 
Nature 341619-624. 
Dustin, M. L., 0. Carpen, and T. A. Springer (1992) 
Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 
adhesion receptors 
J. Immunol. 148 2654-2663. 
Dustin, M. L., S. K. Bromley, Z. Kan, D. A. Peterson, and E. R. Unanue (1997) 
Antigen receptor engagement delivers a stop signal to migrating T lymphocytes 
Proc. Nati. Acad. Sci. USA 94 3909-3913. 
Edwards, C. P., M. Champe, T. Gonzalez, M. E. Wessinger, S. A. Spencer, L. G. 
Presta, P. W. Berman, and S. C. Bodary (1995) 
Identification of amino acids in the CD11a I-domain important for binding of the 
leukocyte function-associated antigen-1 (LFA-1) to intercellular adhesion molecule-1 
(ICAM-1) 
J. Biol. Chem. 27012635-12640. 
Edwards, C. P., K. L. Fisher, L. G. Presta, and S. C. Bodary (1998) 
Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted 
domain of leukocyte function-associated antigen-1 
J Biol. Chem. 273 28937-28944. 
Emsley, J., S. L. King, J. M. Bergelson, and R. C. Liddington (1997) 
Crystal structure of the I domain from integrin a2ß1 
J. Biol. Chem. 272 28512-28517. 
Emsley, J., C. G. Knight, R. W. Farndale, M. J. Barnes, and R. C. Liddington (2000) 
Structural basis of collagen recognition by integrin a2ß1 
Cell 10147-56. 
Etienne, S., P. Adamson, J. Greenwood, A. D. Strosberg, S. Cazaubon, and P. O. 
Couraud (1998) 
ICAM-1 signaling pathways associated with Rho activation in microvascular brain 
endothelial cells 
J. Immunol. 1615755-5761. 
Etienne-Manneville, S., J. B. Manneville, P. Adamson, B. Wilbourn, J. Greenwood, 
and P. O. Couraud (2000) 
ICAM-1-Coupled cytoskeletal rearrangements and transendothelial lymphocyte 
migration involve intracellular calcium signaling in brain endothelial cell lines 
J. Immunol. 165 3375-3383. 
Fassler, R., and M. Meyer (1995) 
Consequences of lack of 01 integrin gene expression in mice 
Genes Dev. 2 1896-1908. 
213 
REFERENCES 
Fawcett, J., C. L. Holness, L. A. Needham, H. Turley, K. C. Gatter, D. Y. Mason, and 
D. L. Simmons (1992) 
Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on 
resting leukocytes 
Nature 360 481-484. 
Fernandez-Reyes, D., A. G. Craig, S. A. Kyes, N. Peshu, R. W. Snow, A. R. Berendt, 
K. Marsh, and C. I. Newbold (1997) 
A high frequency African coding polymorphism in the N-terminal domain of ICAM- 
1 predisposing to cerebral malaria in Kenya 
Hum. Mol. Genet. 6 1357-1360. 
Fisher, K. L., J. Lu, L. Riddle, K. J. Kim, L. G. Presta, and S. C. Bodary (1997) 
Identification of the binding site in intercellular adhesion molecule 1 for its receptor, 
leukocyte function-associated antigen 1 
Mol. Biol. Cell 8 501-515. 
Fox, J. E. B., R. G. Taylor, M. Taffarel, J. K. Boyles, and D. E. Goll (1993) 
Evidence that activation of platelet calpain is induced as a consequence of binding of 
adhesive ligand to the integrin, glycoprotein IIb-IIIa 
J. Cell Biol. 1201501-1507. 
Gardiner, E. E., and S. E. D'Souza (1999) 
Sequences within fibrinogen and intercellular adhesion molecule-1 (ICAM-1) 
modulate signals required for mitogenesis 
J. Biol. Chem. 27411930-11936. 
Garnotel, R., L. Rittie, S. Poitevin, J. C. Monboisse, P. Nguyen, G. Potron, F. X. 
Maquart, A. Randoux, and P. Gillery (2000) 
Human blood monocytes interact with type I collagen through uXß2 integrin 
(CD 11 c-CD 18, gp 150-95) 
J. Immunol. 164 5928-5934. 
Gearing, A. J., and W. Newman (1993) 
Circulating adhesion molecules in disease 
Immunol. Today 14 506-512. 
Geginat, J., G. Bossi, J. R. Bender, and R. Pardi (1999) 
Anchorage dependence of mitogen-induced Gl to S transition in primary T 
lymphocytes 
J. Immunol. 162 5085-5093. 
Geiger, C., W. Nagel, T. Boehm, Y. van Kooyk, C. G. Figdor, E. Kremmer, N. Hogg, 
L. Zeitimann, H. Dierks, K. S. C. Weber, and W. Kolanus (2000) 
Cytohesin-1 regulates 0-2 integrin-mediated adhesion through both ARF-GEF 
function and interaction with LFA-1 
EMBO J. 19 2525-2536. 
214 
REFERENCES 
Geijtenbeek, T. B., R. Torensma, S. J. 
Y. van Kooyk, and C. G. Figdor (2000) 
Identification of DC-SIGN, a novel 
supports primary immune responses 
Cell 100 575-585. 
van Vliet, G. C. van Duijnhoven, G. J. Aderaa, 
dendritic cell-specific ICAM-3 receptor that 
George, J. N., J. P. Caen, and A. T. Nurden (1990) 
Glanzmann's Thrombasthenia: the spectrum of clinical disease 
Blood 75 1383-1395. 
Gerwin, N., J. A. Gonzalo, C. Lloyd, A. J. Coyle, Y. Reiss, N. Banu, B. Wang, H. Xu, 
H. Avraham, B. Engelhardt, T. A. Springer, and J. C. Gutierrez-Ramos (1999) 
Prolonged eosinophil accumulation in allergic lung interstitium of ICAM-2 deficient 
mice results in extended hyperresponsiveness 
Immunity 10 9-19. 
Gidwitz, S., S. Lyman, and G. C. White (2000) 
Expression and function of calcium binding domain chimeras of the integrins allb 
and a5 
J. Biol. Chem. 275 6680-6688. 
Glading, A., P. Chang, D. A. Lauffenburger, and A. Wells (2000) 
Epidermal growth factor receptor activation of calpain is required for fibroblast 
motility and occurs via an ERK/MAP kinase signalling pathway 
J. Biol. Chem. 275 2390-2398. 
Goodman, T. G., and M. L. Bajt (1996) 
Identifying the putative Metal Ion-dependent Adhesion Site in the 02 (CD18) subunit 
required for ccL02 and aM02 ligand interactions 
J. Biol. Chem. 27123729-23736. 
Goodman, T. G., M. E. DeGraaf, H. D. Fischer, and M. L. Bajt (1998) 
Expression of a structural domain of the 02 subunit essential for aM02 ligand 
recognition 
J. Leuk. Biol. 64 767-773. 
Gorlin, J. B., R. Yamin, S. Egan, M. Stewart, T. P. Stossel, D. J. Kwiatkowski, and 
J. H. Hartwig (1990) 
Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular 
leaf spring 
J. Cell Biol. 111 1089-1105. 
Grabovsky, V., S. Feigelson , C. Chen, D. A. Bleijs, A. Peled, 
G. Cinamon, F. 
Baleux, F. Arenzana-Seisdedos, T. Lapidot, Y. van Kooyk, R. R. Lobb, and R. Alon 
(2000) 
Subsecond induction of a4 integrin clustering by immobilised chemokines stimulates 
leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 
under flow conditions 
J. Exp. Med. 192 495-505. 
215 
REFERENCES 
Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and 
M. L. Dustin (1999) 
The immunological synapse: a molecular machine controlling T cell activation 
Science 285 221-227. 
Grayson, M. H., M. Van der Vieren, S. A. Sterbinsky, W. M. Gallatin, P. A. Hoffman, 
D. E. Staunton, and B. S. Bochner (1998) 
ccD02 integrin is expressed on human eosinophils and functions as an alternative 
ligand for vascular cell adhesion molecule 1 (VCAM-1) 
J. Exp. Med. 188 2187-2191. 
Greve, J. M., G. Davis, A. M. Meyer, C. P. Forte, S. C. Yost, C. W. Marlor, M. E. 
Kamarck, and A. McClelland (1989) 
The major human rhinovirus receptor is ICAM-1 
Cell 56 839-847. 
Grzesiak, J. J., and M. D. Pierschbacher (1995) 
Shifts in the concentrations of magnesium and calcium in early porcine and rat 
wound fluids activate the cell migratory response 
J. Clin. Invest. 95.227-233. 
Hall, H., E. J. Williams, S. E. Moore, F. S. Walsh, A. Prochiantz, and P. Doherty 
(1996) 
Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neunte outgrowth 
by a cell permeable phosphopeptide 
Curr. Biol. 6 580-587. 
Hantgan, R. R., C. Paumi, M. Rocco, and J. W. Weisel (1999) 
Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X= Phe, Trp, Ser) on ccIIbß3 
integrin conformation and oligomerisation 
Biochem. 38 14461-14474. 
Hayflick, J. S., J. Stine, R. Fox, D. Hoekstra, and W. M. Gallatin (1997) 
Functional mapping of the cytoplasmic region of intercellular adhesion molecule-3 
reveals important roles for serine residues 
J. Biol. Chem. 272 22207-22214. 
Helander, T. S., 0. Carpen, 0. Turunen, P. E. Kovanen, A. Vaheri, and T. Timonen 
(1996) 
ICAM-2 redistributed by ezrin as a target for killer cells 
Nature 382 265-268. 
Hemler, M. E. (1998) 
Integrin associated proteins 
Curr. Opin. Cell Biol. 10 578-585. 
216 
REFERENCES 
Hermand, P., M. Huet, I. Callebaut, P. Gane, E. Manus, C. G. Gahmberg, J. P. 
Cartron, and P. Bailly (2000) 
Binding Sites of Leukocyte 02 Integrins (LFA-1, Mac-1) on the Human ICAM- 
4/LW Blood Group Protein 
J. Biol. Chem. 275 26002-26010. 
Hibbs, M. L., H. Xu, S. A. Stacker, and T. A. Springer (1991) 
Regulation of adhesion to ICAM-1 by the cytoplasmic domain of LFA-1 integrin (3 
subunit 
Science 251 1611-1613. 
Hildreth, J. E. K., F. M. Gotch, P. D. K. Hildreth, and A. J. McMichael (1983) 
A human lymphocyte-associated antigen involved in cell-mediated lympholysis 
Eur. J. Immunol. 13 202-208. 
Hogg, N., M. P. Stewart, S. L. Scarth, R. Newton, J. M. Shaw, S. K. A. Law, and N. 
Klein (1999) 
A novel leukocyte adhesion deficiency caused by expressed but nonfunctional 02 
integrins Mac-1 and LFA-1 
J. Clin. Invest. 103 97-106. 
Hogg, N., and P. A. Bates (2000) 
Genetic analysis of integrin function in man: LAD-1 and other syndromes 
Matrix Biol. 19 211-222. 
Holland, J., and T. Owens (1997) 
Signaling through intercellular adhesion molecule 1 (ICAM-1) in aB cell lymphoma 
line 
J. Biol. Chem. 272 9108-9112. 
Holness, C. L., P. A. Bates, A. J. Little, C. D. Buckley, A. McDowall, D. Bossy, N. 
Hogg, and D. L. Simmons (1995) 
Analysis of the binding site on intercellular adhesion molecule 3 for the leukocyte 
integrin lymphocyte function-associated antigen 1 
J. Biol. Chem. 27 877-884. 
Hoover-Litty, H., and J. M. Greve (1993) 
Formation of rhinovirus-soluble ICAM-1 complexes and conformational changes in 
the virion 
J. Virol. 67 390-397. 
Horley, K. J., C. Carpenito, B. Baker, and F. Takei (1989) 
Molecular cloning of murine intercellular adhesion molecule (ICAM-1) 
EMBO J. 8 2889-2896. 
Huang, C., and T. A. Springer (1995) 
A binding interface on the I domain of lymphocyte function- associated antigen-1 
(LFA-1) required for specific interaction with intercellular adhesion molecule-1 
(ICAM-1) 
J. Biol. Chem. 270 19008-19016. 
217 
REFERENCES 
Huang, C., C. Lu, and T. A. Springer (1997) 
Folding of the conserved domain but not of flanking regions in the integrin 02 
subunit requires association with the a subunit 
Proc. Natl. Acad. Sci. USA 94 3156-3161. 
Huang, C., and T. A. Springer (1997) 
Folding of the ß-propeller domain of the integrin aL subunit is independent of the I 
domain and dependent on the 02 subunit 
Proc. Natl. Acad. Sci. USA 94 3162-3167. 
Huang, C., Q. Zang, J. Takagi, and T. A. Springer (2000) 
Structural and functional studies with antibodies to the integrin 02 subunit. A model 
for the I-like domain 
J. Biol. Chem. 275 21514-21524. 
Hughes, P. E., F. Diaz-Gonzalez, L. Leong, C. Wu, J. A. McDonald, S. J. Shattil, and 
M. H. Ginsberg (1996) 
Breaking the integrin hinge. A defined structural constraint regulates integrin 
signaling 
J. Biol. Chem. 2716571-6574. 
Huleatt, J. W., and L. Lefrancois (1996) 
02 integrins and ICAM-1 are invoved in establishment of the intestinal mucosal T 
cell compartment 
Immunity 5 263-273. 
Humphries, J. D., J. A. Askari, X. P. Zhang, Y. Takada, M. J. Humphries, and A. P. 
Mould (2000) 
Molecular basis of ligand recognition by integrin a5ß1. 
R. Specificity of Arg-Gly-Asp binding is determined by Trp157 of the a subunit 
J. Biol. Chem. 275 20337-20345. 
Huth, J. R., E. T. Olejniczak, R. Mendoza, H. Liang, E. A. Harris, M. L. Lupher, Jr., 
A. E. Wilson, S. W. Fesik, and D. E. Staunton (2000) 
NMR and mutagenesis evidence for an I domain allosteric site that regulates 
lymphocyte function-associated antigen 1 ligand binding 
Proc. Natl. Acad. Sci. USA 9-7 5231-5236. 
Huttenlocher, A., S. P. Palecek, Q. Lu, W. Zhang, R. L. Meligren, D. A. 
Lauffenburger, M. H. Ginsberg, and A. F. Horwitz (1997) 
Regulation of cell migration by the calcium-dependent protease calpain 
J. Biol. Chem. 272 32719-32722. 
Hynes, R. O. (1987) 
Integrins: a family of cell surface receptors 
Cell 48 549-554. 
218 
REFERENCES 
Hynes, R. O. (1992) 
Integrins: versatility, modulation and signalling in cell adhesion 
Cell 6911-25. 
Irie, A., T. Kamata, W. Puzon-McLaughlin, and Y. Takada (1995) 
Critical amino acid residues for ligand binding are clustered in a predicted ß-turn of 
the third N-terminal repeat in the integrin a4 and a5 subunits 
EMBO J. 14 5550-5556. 
Irie, A., T. Kamata, and Y. Takada (1997) 
Multiple loop structures critical for ligand binding of the integrin a4 subunit in the 
upper face of the ß-propeller model 
Proc. Natl. Acad. Sci. USA 94 7198-7203. 
Johnson, G. V. W., and R. P. Guttmann (1997) 
Calpains: intact and active? 
BioEssays 121011-1018. 
Johnson-Leger, C., M. Auffand-Lions, and B. A. Imhof (2000) 
The parting of the endothelium: miracle, or simply a junctional affair? 
J. Cell Sci. 11 921-933. 
Juan, M., O. Vinas, M. R. Pino-Otin, L. Places, E. Martinez-Caceres, J. J. Barcelo, A. 
Miralles, R. Vilella, M. A. de la Fuente, J. Vives, J. Yague and A. Gaya (1994) 
CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization 
and tyrosine phosphorylation through p59fyn and p561ck in Jurkat T cell line 
J. Exp. Med. 17 1747-1756. 
Kallen, J., K. Weizenbach, P. Ramage, D. Geyl, R. Kriwacki, G. Legge, S. Cottens, 
G. Weitz-Schmidt, and U. Hommel (1999) 
Structural basis for LFA-1 inhibition upon Lovastatin binding to CD1la I-domain 
J. Mol. Biol. 292 1-9. 
Kamata, T., and Y. Takada (1994) 
Direct binding of collagen to the I domain of integrin a2ß1 (VLA-2, CD49b/CD29) 
in a divalent cation-independent manner 
J. Biol. Chem. 269 26006-26010. 
Kamata, T., R. Wright, and Y. Takada (1995) 
Critical threonine and aspartic acid residues within the I domains of 02 integrins for 
interactions with intercellular adhesion molecule 1 (ICAM-1) and C3bi 
J. Biol. Chem. 270 12531-12535. 
Kamata, T., A. Irie, M. Tokuhira, and Y. Takada (1996) 
Critical residues of integrin allb subunit for binding of ccIIb(33 (glycoprotein IIb- 
h a) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and IJ-CP3) 
J. Biol. Chem. 271 18610-18615. 
219 
REFERENCES 
Kanner, S. B., L. S. Grosmaire, J. A. Ledbetter, and N. K. Damle (1993) 
02-integrin LFA-1 signalling through phospholipase C-yl activation 
Proc. Nati. Acad. Sci. USA 90 7099-7103. 
Käpylä, J., J. Ivaska, R. Riikonen, P. Nykvist, 0. Pentikäinen, M. Johnson, and J. 
Heino (2000) 
Integrin a2 I domain recognises type I and type IV collagens by different 
mechanisms 
J. Biol. Chem. 275 3348-3354. 
Kashiwagi, H., Y. Tomiyama, S. Tadokoro, S. Honda, M. Shiraga, H. Mizutani, M. 
Handa, Y. Kurata, Y. Matsuzawa, and S. J. Shattil (1999) 
A mutation in the extracellular cysteine-rich repeat region of the ß3 subunit activates 
integrins aMb03 and aV03 
Blood 93 2559-2568. 
Katagiri, K., M. Hattori, N. Minato, S. K. Irie, K. Takatsu, and T. Kinashi (2000) 
Rapl is a potent activation signal for leukocyte function-associated antigen 1 distinct 
from protein kinase C and phosphatidylinositol-3-OH kinase. 
Mol. Cell. Biol. 201956-1969. 
Kilgannon, P., T. Turner, J. Meyer, W. Wisdom, and W. M. Gallatin (1998) 
Mapping of the ICAM-5 (telencephalin) gene, a neuronal member of the ICAM 
family, to a location between ICAM-1 and ICAM-3 on human chromosome 19pl3.2 
Genomics 54 328-330. 
King, S. L., T. Kamata, J. A. Cunningham, J. Emsley, R. C. Liddington, Y. Takada, 
and J. M. Bergelson (1997) 
Echovirus 1 interaction with the human Very Late Antigen-2 (integrin (X201) I 
domain. Identification of two independent virus contact sites distinct from the metal 
ion-dependent adhesion site 
J. Biol. Chem. 272 28518-28522. 
Kirchhausen, T., D. E. Staunton, and T. A. Springer (1993) 
Location of the domains of ICAM-1 by immunolabeling and single-molecule 
electron microscopy 
J. Leukoc. Biol. 53 342-346. 
Kishimoto, T. K., K. O'Connor, A. Lee, T. M. Roberts, and T. A. Springer (1987) 
Cloning of the ß subunit of the leukocyte adhesion proteins: homology to an 
extracellular matrix receptor defines a novel supergene family 
Cell 48 681-690. 
Klickstein, L. B., M. R. York, A. R. de Fougerolles, and T. A. Springer (1996) 
Localisation of the binding site on intercellular adhesion molecule-3 (ICAM-3) for 
lymphocyte function-associated antigen 1 (LFA-1) 
J. Biol. Chem. 27123920-23927. 
220 
REFERENCES 
Knight, C. G., L. F. Morton, D. J. Onley, A. R. Peachey, A. J. Messent, P. A. Smethurst, 
D. S. Tuckwell, R. W. Farndale, and M. J. Barnes (1998) 
Identification in collagen type I of an integrin a2ß1-binding site containing an 
essential GER sequence 
J. Biol. Chem. 273 33286-33294. 
Knorr, R., and M. L. Dustin (1997) 
The lymphocyte function-associated antigen 1I domain is a transient binding module 
for intercellular adhesion molecule (ICAM)-1 and ICAM-3 in hydrodynamic flow 
J. Exp. Med. 18j 719-730. 
Kolanus, W., W. Nagel, B. Schiller, L. Zeitlmann, S. Godar, H. Stockinger, and B. 
Seed(1996) 
aL02 integrin/LFA-1 binding to ICAM-1 induced by Cytohesin-1, a cytoplasmic 
regulatory molecule 
Cell 86 233-242. 
Koyama, Y., Y. Tanaka, K. Saito, M. Abe, K. Nakatsuka, I. Morimoto, P. E. Auron, 
and S. Eto (1996) 
Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation 
and IL-10 transcri ption 
J. Immunol. 5577 5097-5103. 
Krauss, K., and P. Altevog (1999) 
Integrin Leukocyte Function-associated 
activated by clustering membrane rafts 
J. Biol. Chem. 274 36921-36927. 
Antigen- l-mediated cell binding can be 
Kucik, D. F., M. L. Dustin, J. M. Miller, and E. J. Brown (1996) 
Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 
in cultured lymphocytes 
J. Clin. Invest. 97 2139-2144. 
Kuijpers, T. W., R. A. W. van Lier, D. Hamann, M. de Boer, L. Y. Thung, R. S. 
Weening, A. J. Verhoeven, and D. Roos (1997) 
Leukocyte Adhesion Deficiency Type 1 (LAD-1)Nariant 
A novel immunodeficiency syndrome characterised by dysfunctional 02 integrins 
J. Clin. Invest. 100 1725-1733. 
Kulkarni, S., T. C. Saido, K. Suzuki, and J. E. B. Fox (1999) 
Calpain mediates integrin-induced signaling at a point upstream of Rho family 
members 
J. Biol. Chem. 274 21265-21275. 
Kupfer, A., and S. J. Singer (1989) 
The specific interaction of helper T cells and antigen-presenting cells 
IV. Membrane and cytoskeletal reorganisation in the bound T cell as a function of 
antigen dose 
J. Exp. Med. 170 1697-1713. 
221 
REFERENCES 
Kurzinger, K., T. Reynolds, R. N. Germain, D. Davignon, E. Martz, and T. A. 
Springer (1981) 
A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, 
quantitative expression, and structure 
J. Immunol. 127 596-602. 
Kyte, J., and R. F. Doolittle (1982) 
A simple method for displaying the hydropathic character of a protein 
J. Mol. Biol. 157 105-132. 
Laemmli, U. K. (1970) 
Cleavage of structural proteins during the assembly of the head of bacteriophage T4 
Nature 227 680-685. 
Lambright, D. G., J. Sondek, A. Bohm, N. P. Skiba, H. E. Hamm, and P. B. Sigler 
(1996) 
The 2.0 A crystal structure of a heterotrimeric G protein 
Nature 379 311-319. 
Landis, R. C., R. I. Bennett, and N. Hogg (1993) 
A novel LFA-1 activation epitope maps to the I domain 
J. Cell Biol. 1201519-1527. 
Landis, R. C., A. McDowall, C. L. L. Holness, A. J. Littler, D. L. Simmons, and N. 
Hogg (1994) 
Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and 
ICAM-3 
J. Cell Biol. 126 529-537. 
Languino, L. R., J. Plescia, A. Duperray, A. A. Brian, E. F. Plow, J. E. Geltosky, and 
D. C. Altieri (1993) 
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM- 
1-dependent pathway 
Cell 711423-1434. 
Languino, L. R., A. Duperray, K. J. Joganic, M. Fornaro, G. B. Thornton, and D. C. 
Altieri (1995) 
Regulation of leukocyte-endothelium interaction and leukocyte transendothelial 
migration by intercellular adhesion molecule 1-fibrinogen recognition 
Proc. Natl. Acad. Sci. USA 92 1505-1509. 
Larson, R. S., A. L. Corbi, L. Berman, and T. Springer (1989) 
Primary structure of the leukocyte function-associated molecule-1 a subunit: an 
integrin with an embedded domain defining a protein superfamily 
J. Cell Biol. 108 703-712. 
Law, S. K., J. Gagnon, J. E. Hildreth, C. E. Wells, A. C. Willis, and A. J. Wong (1987) 
The primary structure of the ß-subunit of the cell surface adhesion glycoproteins 
LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor 
EMBO J. 6 915-999. 
222 
REFERENCES 
Lawson, C., M. Ainsworth, M. Yacoub, and M. Rose (1999) 
Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a 
nuclear factor-kappaB-independent mechanism 
J. Immunol. 162 2990-2996. 
Lee, J. O., L. A. Bankston, M. A. Arnaout, and R. C. Liddington (1995a) 
Two conformations of the integrin A-domain (I-domain): a pathway for activation? 
Structure 3 1333-1340. 
Lee, J. O., P. Rieu, M. A. Arnaout, and R. Liddington (1995b) 
Crystal structure of the A-domain from the a-subunit of integrin CR3 
(CD l lb/CD 18) 
Cell 80 631-638. 
Leitinger, B., and N. Hogg (2000) 
Effects of I domain deletion on the function of the ß2 integrin Lymphocyte Function- 
associated Antigen-1 
biol. Biol. Cell 11677-690. 
Li, R., P. Rieu, D. L. Griffith, D. Scott, and M. A. Arnaout (1998) 
Two functional states of the CD! lb A-domain: correlations with key features of two 
Mn2+-complexed crystal structures 
J. Cell Biol. 1431523-1534. 
Liddington, R., and L. Bankston (1998) 
The integrin I domain: crystals, metals and related artefacts 
Structure 6 937-938. 
Liliental, J., and D. D. Chang (1998) 
Rackl, a receptor for activated protein kinase C, interacts with integrin ß subunit 
J. Biol. Chem. 27 2379-2383. 
Lin, E. C., B. I. Ratnikov, P. M. Tsai, C. P. Carron, D. M. Myers, C. F. Barbas, and J. W. 
Smith (1997a) 
Identificaton of a regon of the integrin 03 subunit that confers ligand binding 
specificity 
J. Biol. Chem. 272 23912-23920. 
Lin, E. C. K., B. I. Ratnikov, P. M. Tsai, E. R. Gonzalez, S. McDonald, A. J. Pelletier, 
and J. W. Smith (1997b) 
Evidence that the integrin 03 and 05 subunits contain a metal ion-dependent 
adhesion site-like motif but lack an I domain 
J. Biol. Chem. 272 14236-14243. 
Lipfert, L., B. Haimovich, M. D. Schaller, B. S. Cobb, J. T. Parsons, and J. S. Brugge 
(1992) 
Integrin-dependent phosphorylation and activation of the protein tyrosine kinase 
pp125FAK in platelets 
J. Cell Biol. 119 905-912. 
223 
REFERENCES 
Liu, Y. K., A. Nemoto, Y. Feng, and T. Uemura (1997) 
The binding ability to matrix proteins and the inhibitory effects on cell adhesion of 
synthetic peptides derived from a conserved sequence of integrins 
J. Biochem. 121961-968. 
Lloyd, A. R., J. J. Oppenheim, D. J. Kelvin, and D. D. Taub (1996) 
Chemokines regulate T cell adherence to recombinant adhesion molecules and 
extracellular matrix proteins 
J. Immunol. 156 932-938. 
Loike, J. D., B. Sodeik, L. Cao, S. Leucona, J. I. Weitz, P. A. Detmers, S. D. Wright, 
and S. C. Silverstein (1991) 
CD! lc/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha 
chain of fibrinogen 
Proc. Natl. Acad. Sci. USA 88 1044-1048. 
Lu, C., C. Oxvig, and T. A. Springer (1998) 
The structure of the (3-propeller domain and C-terminal region of the integrin aM 
subunit 
J. Biol. Chem. 273 15138-15147. 
Lu, H., C. W. Smith, J. Perrard, D. Bullard, L. Tang, S. B. Shappell, M. L. Entman, 
A. L. Beaudet, and C. M. Ballantyne (1997) 
LFA-1 is sufficient in mediating neutrophil emigration in Mac-l-deficient mice 
J. Clin. Invest. 99 1340-1350. 
Maki, M., H. Bagci, K. Hamaguchi, M. Ueda, T. Murachi, and M. Hatanaka (1989) 
Inhibition of calpain by a synthetic oligopetide corresponding to an exon of the 
human calpastatin gene 
J. Biol. Chem. 264 18866-18869. 
Marlin, S. D., C. C. Morton, D. C. Anderson, and T. A. Springer (1986) 
LFA-1 immunodeficiency disease. Definition of the genetic defect and chromosomal 
mapping of a and ß subunits of the lymphocyte function-associated antigen 1 (LFA- 
1) by complementation in hybrid cells 
J. Exp. Med. 164 855-867. 
Marlin, S. D., and T. A. Springer (1987) 
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte 
function-associated antigen 1 (LFA-1) 
Cell 5a 813-819. 
Martin, S., P. Rieckmann, I. Melchers, R. Wagner, J. Bertrams, A. E. Voskuyl, B. O. 
Roep, J. Zielasek, E. Heidenthal, I. Weichselbraun, W. M. Gallatin, and H. Kolb 
(1995) 
Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases 
and lack of association with cICAM-1 
J. Immunol. 154 1951-1955. 
224 
REFERENCES 
Masumoto, A., and M. E. Hemler (1993) 
Mutation of putative divalent cation sites in the a4 subunit of the integrin VLA-4: 
distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin 
J. Cell Biol. 123 245-253. 
McClelland, A., J. deBear, S. C. Yost, A. M. Meyer, C. W. Marlor, and J. M. Greve 
(1991) 
Identification of monoclonal antibody epitopes and critical residues for rhinovirus 
binding in domain 1 of intercellular adhesion molecule 1 
Proc. Natl. Acad. Sci. USA 88 7993-7997. 
McDowall, A., B. Leitinger, P. Stanley, P. A. Bates, A. M. Randi, and N. Hogg (1998) 
The I domain of integrin Leukocyte Function-associated Antigen-1 is involved in a 
conformational change leading to high affinity binding to ligand Intercellular 
Adhesion Molecule 1 (ICAM-1) 
J. Biol. Chem. 273 27396-27403. 
McGuire, S. L., and M. L. Bajt (1995) 
Distinct ligand binding sites in the I domain of integrin aMß2 that differentially 
affect a divalent cation-dependent conformation 
J. Biol. Chem. 270 25866-25871. 
McLaughlin, F., B. P. Hayes, C. M. Horgan, J. E. Beesley, C. J. Campbell, and A. M. 
Randi (1998) 
Tumor necrosis factor (TNF)-a and interleukin (IL)-10 down-regulate intercellular 
adhesion molecule (ICAM)-2 expression on the endothelium 
Cell Adhes. Commun. 6 381-400. 
Meacci, E., S. -C. Tsai, R. Adamik, J. Moss, and M. Vaughan (1997) 
Cytohesin-1, a cytosolic guanine nucleotide-exchange protein for ADP-ribosylation 
factor 
Proc. Natl. Acad. Sci. USA 94 1745-1748. 
Michishita, M., V. Videm, and M. A. Arnaout (1993) 
A novel divalent cation-binding site in the A domain of the 02 integrin CR3 
(CD! lb/CD18) is essential for ligand binding 
Cell 72 857-867. 
Miller, L., D. F. Bainton, N. Borregaard, and T. A. Springer (1987) 
Stimulated mobilisation of monocyte Mac-1 and p150,95 adhesion proteins from an 
intracellular vesicular compartment to the cell surface 
J. Clin. Invest. 80 535-544. 
Miller, J., R. Knorr, M. Ferrone, R. Houdei, C. P. Carron, and M. L. Dustin (1995) 
Intercellular adhesion molecule-1 dimerization and its consequences for adhesion 
mediated by lymphocyte function associated-1 
J. Exp. Med. 182 1231-1241. 
225 
REFERENCES 
Mizgerd, J. P., H. Kubo, G. J. Kutkoski, S. D. Bhagwan, K. Scharffetter-Kochanek, 
A. L. Beaudet, and C. M. Doerschuk (1997) 
Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for 
CD11/CD18 revealed by CD18-deficient mice 
J. Exp. Med. 186 1357-1364. 
Mizuno, T., Y. Yoshihara, J. Inazawa, H. Kagamiyama, and K. Mori (1997) 
cDNA cloning and chromsomal localization of the human telencephalin and its 
distictive interaction with lymphocyte function-associated antigen-1 
J. Biol. Chem. 272 1156-1163. 
Monks, C. R. F., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer (1998) 
Three-dimensional segregation of supramolecular activation clusters in T cells 
Nature 395 82-86. 
Mould, A. P., L. Burrows, and M. J. Humphries (1998) 
Identification of amino acid residues that form part of the ligand-binding pocket of 
integrin a5ß1 
J. Biol. Chem. 273 25664-25672. 
Moyle, M., D. L. Foster, D. E. McGrath, S. M. Brown, Y. Laroche, J. De Meutter, P. 
Stanssens, C. A. Bogowitz, V. A. Fried, J. A. Ely, H. R. Soule, and G. P. Vlasuk (1994) 
A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin 
CD11b/CD18 
J. Biol. Chem. 26910008-10015. 
Muchowski, P. J., L. Zhang, E. R. Chang, H. R. Soule, E. F. Plow, and M. Moyle 
(1994) 
Functional interaction between the integrin antagonist Neutrophil Inhibitory Factor 
and the I domain of CD11b/CD18 
J. Biol. Chem. 269 26419-26423. 
Nagel, W., L. Zeitlmann, P. Schilcher, C. Geiger, J. Kolanus, and W. Kolanus (1998) 
Phosphoinositide 3-OH kinase activates the 02 integrin adhesion pathway and 
induces membrane recruitment of cytohesin-1 
J. Biol. Chem. 273 14853-14861. 
Negulescu, P. A., T. B. Krasieva, A. Khan, H. H. Kerschbaum, and M. D. Cahalan 
(1996) 
Polarity of T cell shape, motility, and sensitivity to antigen 
Immunity 4 421-430. 
Newham, P., S. E. Craig, G. N. Seddon, N. R. Schofield, A. Rees, R. M. Edwards, E. Y. 
Jones, and M. J. Humphries (1997) 
a4 integrin binding interfaces on VCAM-1 and MAdCAM-1 
J. Biol. Chem. 272 19429-19440. 
226 
REFERENCES 
Nolte, M., R. B. Pepinsky, S. Y. Venyaminov, V. Koteliansky, P. J. Gotwals, and M. 
Karpusas (1999) 
Crystal structure of the a1ß1 integrin I-domain: insights into integrin I-domain 
function 
FEBS Letts. 452 379-385. 
Ockenhouse, C. F., R. Betageri, T. A. Springer, and D. E. Staunton (1992) 
Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from 
LFA-1, Mac-i, and human rhinovirus 
Cell 68 63-69. 
Olson, N. H., P. R. Kolatkar, M. A. Oliveira, R. H. Cheng, J. M. Greve, A. McClelland, 
T. S. Baker, and M. G. Rossmann (1993) 
Structure of a human rhinovirus complexed with its receptor molecule 
Proc. Natl. Acad. Sci. USA9 507-511. 
Oxvig, C., and T. A. Springer (1998) 
Experimental support for ß-propeller domain in integrin a-subunits and a calcium 
binding site on its lower surface 
Proc. Natl. Acad. Sci. USA 95 4870-4875. 
Oxvig, C., C. Lu, and T. A. Springer (1999) 
Conformational changes in tertiary structure near the ligand binding site of an 
integrin I domain 
Proc. Natl. Acad. Sci. USA 96 2215-2220. 
Papp, B., K. Paszty, T. Kovacs, B. Sarkadi, G. Gardos, J. Enouf, and A. Enyedi 
(1993) 
Characterization of the inositol trisphosphate-sensitive and insensitive calcium stores 
by selective inhibition of the endoplasmic reticulum-type calcium pump isoforms in 
isolated platelet membrane vesicles 
Cell Calcium 14 531-538. 
Patterson, R. L., D. B. van Rossum, and D. L. Gill (1999) 
Store-operated Ca2+ entry: evidence for a secretion-like coupling model 
Cell 98 487-499. 
Petruzzelli, L., L. Maduzia, and T. A. Springer (1995) 
Activation of lymphocyte function-associated molecule-1 (CD1la/CD18) and Mac- 
(CD 11 b/CD 18) mimicked by an antibody directed against CD 18 
J. Immunol. 5ý, 5 854-866. 
Pfaff, M., X. Du, and M. H. Ginsberg (1999) 
Calpain cleavage of integrin 0 cytoplasmic domains 
FEBS Letts. 46017-22. 
227 
REFERENCES 
Pierres, M., C. Goridis, and P. Golstein (1982) 
Inhibition of murine T cell-mediated cytolysis and T cell proliferation by a rat 
monoclonal antibody immunoprecipitating two lymphoid cell surface polypeptides of 
94 000 and 180 000 molecular weight 
Eur. J. Immunol. 12 60-69. 
Plow, E. F., and L. Zhang (1997) 
A Mac-1 attack: integrin functions directly challenged in knockout mice 
J. Clin. Invest. 9991145-1146. 
Pluskota, E., Y. Chen, and S. E. D'Souza (2000) 
Src Homology Domain 2-containing Tyrosine Phosphatase 2 Associates with 
Intercellular Adhesion Molecule 1 to Regulate Cell Survival 
J. Biol. Chem. 275 30029-30036. 
Pluskota, E., and S. E. D'Souza (2000) 
Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival 
Eur. J. Biochem. 267 4693-4704. 
Porter, J. C., and N. Hogg (1997) 
Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human 
T cells alters a4ß1- and a501-mediated function 
J. Cell Biol. 138 1437-1447. 
Potter, D. A., J. S. Tirnauer, R. Janssen, D. E. Croall, C. N. Hughes, K. A. Fiacco, J. W. 
Mier, M. Maki, and I. M. Herman (1998) 
Calpain regulates actin remodeling during cell spreading 
J. Cell Biol. 141647-662. 
Potts, A. J., D. E. Croall, and M. E. Hemler (1994) 
Proteolytic cleavage of the integrin 04 subunit 
Exp. Cell Res. 212 2-9. 
Pujades, C., R. Alon, R. L. Yauch, A. Masumoto, L. C. Burkly, C. Chen, T. A. 
Springer, R. R. Lobb, and M. E. Hemler (1997) 
Defining extracellular intgrin a-chain sites that affect cell adhesion and adhesion 
strengthening without altering soluble ligand binding 
Mol. Biol. Cell 8 2647-2657. 
Putney, J. W. (1999) 
"Kissin' cousins": intimate plasma membrane-ER interactions underlie capacitative 
calcium entry 
Cell 99 5-8. 
Puzon-McLaughlin, W., and Y. Takada (1996) 
Critical residues for ligand binding in an I domain-like structure of the integrin ß1 
subunit 
J. Biol. Chem. 27120438-20443. 
228 
REFERENCES 
Puzon-McLaughlin, W., T. Kamata, and Y. Takada (2000) 
Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding 
pocket in integrin alpha(IIb)beta(3) 
J. Biol. Chem. 275 7795-7802. 
Qu, A., and D. J. Leahy (1995) 
Crystal structure of the I-domain from the CD 11 a/CD 18 (LFA- 1, aLß2) integrin 
Proc. Natl. Acad. Sci. USA 92 10277-10281. 
Qu, A., and D. J. Leahy (1996) 
The role of the divalent cation in the structure of the I domain from the CD 11a/CD 18 
integrin 
Structure 4 931-942. 
Raja, S., S. Avraham, and H. Avraham (1997) 
Tyrosine phosphorylation of the novel protein-tyrosine kinase RAFTK during an 
early phase of platelet activation by an integrin glycoprotein IIb-IIla-independent 
mechanism 
J. Biol. Chem. 27210941-10947. 
Randi, A. M., and N. Hogg (1994) 
I domain of ß2 integrin lymphocyte function-associated antigen-1 contains a binding 
site for ligand intercellular adhesion molecule-1 
J. Biol. Chem. 269 12395-12398. 
Reedquist, K. A., E. Ross, E. A. Koop, R. M. Wolthuis, F. J. Zwartkruis, Y. van Kooyk, 
M. Salmon, C. D. Buckley, and J. L. Bos (2000) 
The small GTPase, Rapl, mediates CD31-induced integrin adhesion 
J. Cell Biol. 148 1151-1158. 
Rees, D. J., S. E. Ades, S. J. Singer, and R. O. Hynes (1990) 
Sequence and domain structure of talin 
Nature 3,, ý4 685-689. 
Register, R. B., C. R. Uncapher, A. M. Naylor, D. W. Lineberger, and R. J. Colonno 
(1991) 
Human-murine chimeras of ICAM-1 identify amino acid residues critical for 
rhinovirus and antibody binding 
J. Virol. 65 6589-6596. 
Reid, D. M., C. E. Jones, C. Y. Luo, and N. R. Shulman (1993) 
Immunoglobulins from normal sera bind platelet vinculin and talin and their 
proteolytic fragmants 
Blood 81745-751. 
Reilly, P. L., J. R. Woska, Jr., D. D. Jeanfavre, E. McNally, R. Rothlein, and B. J. 
Bormann (1995) 
The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. 
Correlation with binding to LFA-1. 
J. Immunol. 155 529-532. 
229 
REFERENCES 
Rey-Ladino, J. A., M. Huber, L. Liu, J. E. Damen, G. Krystal, and F. Takei (1999) 
The SH2-containing inositol-5'-phosphatase enhances LFA-1-mediated cell adhesion 
and defines two signaling pathways for LFA-1 activation 
J. Immunol. 162 5792-5799. 
Rieu, P., T. Ueda, I. Haruta, C. P. Sharma, and M. A. Arnaout (1994) 
The A-domain of 02 integrin CR3 (CD11b/CD 18) is a receptor for the hookworm- 
derived neutrophil adhesion inhibitor NIP 
J. Cell Biol. 127 2081-2091. 
Rieu, P., T. Sugimori, D. L. Griffith, and M. A. Arnaout (1996) 
Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin 
CR3 mediate its binding to the neutrophil inhibitory factor 
J. Biol. Chem. 271 15858-15861. 
Roberts, A. W., C. Kim, L. Zhen, J. B. Lowe, R. Kapur, B. Petryniak, A. Spaetti, J. D. 
Pollock, J. B. Borneo, G. B. Bradford, S. J. Atkinson, M. C. Dinauer, and D. A. 
Williams (1999) 
Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is 
characterized by abnormalities in neutrophil function and host defense. 
Immunity 10 183-196. 
Rock, M. T., W. H. Brooks, and T. L. Roszman (1997) 
Calcium-dependent signaling pathways in T cells. Potential roles of calpain, protein 
tyrosine phosphatase 1B, and pl30Cas in integrin-mediated signaling events 
J. Biol. Chem. 272 33377-33383. 
Rodriguez-Fernandez, J. L., M. Gomez, A. Luque, N. Hogg, F. Sanchez-Madrid, and 
C. Cabanas (1999) 
The interaction of activated integrin Lymphocyte Function-associated Antigen 1 with 
ligand Intercellular Adhesion Molecule 1 induces activation and redistribution of 
Focal Adhesion Kinase and Proline-rich Tyrosine Kinase 2 in T lymphocytes 
Mol. Biol. Cell 10 1891-1907. 
Roebuck, K. A., and A. Finnegan (1999) 
Regulation of intercellular adhesion molecule-1 (CD54) gene expression 
J. Leukoc. Biol. 66 876-888. 
Ross, G. D., and J. D. Lambris (1982) 
Identification of a C3bi-specific membrane complement receptor that is expressed on 
lymphocytes, monocytes, neutrophils, and erythrocytes 
J. Exp. Med. 15 5 96-110. 
Rothlein, R., M. L. Dustin, S. D. Marlin, and T. A. Springer (1986) 
A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1 
J. Immunol. 131270-1274. 
230 
REFERENCES 
Rothlein, R., E. A. Mainolfi, M. Czajkowski, and S. D. Marlin (1991) 
A form of circulating ICAM-1 in human serum 
J. Immunol. 147 3788-3793. 
Rothlein, R., T. K. Kishimoto, and E. Mainolfi (1994) 
Cross-linking of ICAM-1 induces co-signalling of an oxidative burst from 
mononuclear leukocytes 
J. Immunol. 152 2488-2495. 
Rudd, C. E. (1996) 
Upstream-downstream: CD28 cosignalling pathways and T cell function 
Immunity 4 527-534. 
Sadhu, C., B. Lipsky, H. P. Erickson, J. Hayflick, K. O. Dick, W. M. Gallatin, and 
D. E. Staunton (1994) 
LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous 
amino acids 
Cell Adhes. Commun. 2 429-440. 
Sanipath, R., P. J. Gallagher, and F. M. Pavalko (1998) 
Cytoskeletal interactions with the leukocyte integrin 02 cytoplasmic tail 
J. Biol. Chem. 273 33588-33594. 
Sansom, D., J. Borrow, E. Solomon, and J. Trowsdale (1991) 
The human ICAM2 gene maps to 17q23-25 
Genomics 11462464. 
Scharffetter-Kochanek, K., H. Lu, K. Norman, N. van Nood, F. Munoz, S. Grabbe, 
M. McArthur, I. Lorenzo, S. Kaplan, K. Ley, C. W. Smith, C. A. Montgomery, S. 
Rich, and A. L. Beaudet (1998) 
Spontaneous skin ulceration and defective T cell function in CD18 null mice 
J. Exp. Med. 188 119-131. 
Schmits, R., T. M. Kündig, D. M. Baker, G. Shumaker, J. J. L. Simard, G. Duncan, A. 
Wakeham, A. Shahinian, A. van der Heiden, M. F. Bachmann, P. S. Ohashi, T. W. 
Mak, and D. D. Hickstein (1996) 
LFA-1-deficient mice show normal CTL responses to virus but fail to reject 
immunogenic tumour 
J. Exp. Med. 183 1415-1426. 
Schoenwaelder, S. M., and K. Burridge (1999) 
Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small 
GTPase Rho 
J. Biol. Chem. 274 14359-14367. 
Sedwick, C. E., M. M. Morgan, L. Jusino, J. L. Cannon, J. Miller, and J. K. Burkhardt 
(1999) 
TCR, LFA-1, and CD28 play unique and complementary roles in signalling T cell 
cytoskeletal reorganisation 
J. Immunol. 162 1367-1375. 
231 
REFERENCES 
Selliah, N., W. H. Brooks, and T. L. Roszman (1996) 
Proteolytic cleavage of a-actinin by calpain in T cells stimulated with anti-CD3 
monoclonal antibody 
J. Immunol. 156 3215-3221. 
Sengelov, H., L. Kjeldsen, M. S. Diamond, T. A. Springer, and N. Borregaard (1993) 
Subcellular localisation and dynamics of Mac-1 (aM02) in human neutrophils 
J. Clin. Invest. 92.1467-1476. 
Serrador, J. M., J. L. Alonso-Lebrero, M. A. del Pozo, H. Furthmayr, R. Schwartz- 
Albiez, J. Calvo, F. Lozano, and F. Sanchez-Madrid (1997) 
Moesin interacts with the cytoplasmic region of Intercellular Adhesion Molecule-3 
and is redistributed to the uropod of T lymphocytes during cell polarization 
J. Cell Biol. 138 1409-1423. 
Seth, R., F. D. Raymond, and M. W. Makgoba (1991) 
Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune 
disorders 
Lancet 338 83-84. 
Sharma, C. P., R. M. Ezzell, and M. A. Arnaout (1995) 
Direct interaction of filamin (ABP-280) with the 02-integrin subunit CD18 
J. Immunol. 154 3461-3470. 
Shcherbina, A., A. Bretscher, D. M. Kenney, and E. Remold-O'Donnell (1999) 
Moesin, the major ERM protein of lymphocytes and platelets, differs from ezrin in 
its insensitivity to calpain 
FEBS Letts. 443 31-36. 
Shibagaki, N., K. Hanada, H. Yamashita, S. Shimada, and H. Hamada (1999) 
Overexpression of CD82 on human T cells enhances LFA-1/ICAM-1-mediated cell- 
cell adhesion: functional association between CD82 and LFA-1 in T cell activation 
Eur. J. Immunol. 29 4081-4091. 
Shibuya, K., L. L. Lanier, J. H. Phillips, H. D. Ochs, K. Shimizu, H. Nakayama, H. 
Nakauchi, and A. Shibuya (1999) 
Physical and functional association of LFA-1 with DNAM-1 adhesion molecule 
Immunity 11615-623. 
Shier, P., G. Otulakowski, K. Ngo, J. Panakos, E. Chourmouzis, L. Christjansen, 
C. Y. Lau, and W. -P. Fung-Leung (1996) 
Impaired immune responses towards alloantigens and tumor cells but normal thymic 
selection in mice deficient in the 02 integrin leukocyte function-associated antigen-1 
J. Immunol. 157 5375-5386. 
Shier, P., K. Ngo, and W. -P. Fung-Leung (1999) 
Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 
cannot be restored by increased TCR signalling 
J. Immunol. 163 4826-4832. 
232 
REFERENCES 
Shimaoka, M., J. M. Shifman, H. Jing, J. Takagi, S. L. Mayo, and T. A. Springer 
(2000) 
Computational design of an integrin I domain stabilized in the open high affinity 
conformation 
Nat. Struct. Biol. 7 674-678. 
Shimizu, Y., G. A. van Seventer, E. Ennis, W. Newman, K. J. Horgan, and S. Shaw 
(1992) 
Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T 
cell adhesion 
J. Exp, lied. 175 577-582. 
Shimizu, Y., D. M. Rose, and M. H. Ginsberg (1999) 
Integrins in the immune system 
Adv. Immunol. 72 325-380. 
Shiraha, H., A. Glading, K. Gupta, and A. Wells (1999) 
IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal 
growth factor receptor-mediated calpain activity 
J. Cell Biol. 146 243-253. 
Simmons, D., M. W. Makgoba, and B. Seed (1988) 
ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion 
molecule NCAM 
Nature 331624-627. 
Sims, PJ., M. H. Ginsberg, E. F. Plow, and S. J. Shattil (1991) 
Effect of platelet activation on the conformation of the plasma membrane 
glycoprotein Ilb-1111a complex 
J. Biol. Chem. 266 7345-7352. 
Skubitz, K. M., K. Ahmed, K. D. Campbell, and A. P. N. Skubitz (1995) 
CD50 (ICAM-3) is phosphorylated on tyrosine and is associated with tyrosine kinase 
activity in human neutrophils 
J. Immunol. 154 2888-2895. 
Sligh, J. E., Jr., C. M. Ballantyne, S. S. Rich, H. K. Hawkins, C. W. Smith, A. Bradley, 
and A. L. Beaudet (1993) 
Inflammatory and immune responses are impaired in mice deficient in intercellular 
adhesion molecule 1 
Proc. Nat!. Acad. Sci. USA 90 8529-8533. 
Smith, J. A., and M. J. Weidemann (1993) 
Further characterisation of the neutrophil oxidative burst by flow cytometry 
J. Immunol. Methods 162 261-268. 
233 
REFERENCES 
Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor, D. S. 
Peterson, R. Pinches, C. I. Newbold, and L. H. Miller (1995) 
Switches in expression of Plasmodium falciparum var genes correlate with changes 
in antigenic and cytoadherent phenotypes of infected erythrocytes 
Cell 82 101-110. 
Smith, C., D. Estavillo, J. Emsley, L. A. Bankston, R. C. Liddington, and M. A. Cruz 
(2000a) 
Mapping the collagen-binding site on the I domain of the glycoprotein Ia/IIa 
(integrin a2ß1) 
J. Biol. Chem. 27 4205-4209. 
Smith, J. D., A. G. Craig, N. Kriek, D. Hudson-Taylor, S. Kyes, T. Fagen, R. Pinches, 
D. I. Baruch, C. I. Newbold, and L. H. Miller (2000b) 
Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding 
domain: a parasite adhesion trait implicated in cerebral malaria 
Proc. Natl. Acad. Sci. USA 97 1766-1771. 
Soede, R. D. M., M. H. E. Driessens, L. Ruuls-Van Stalle, P. E. M. Van Hulten, A. 
Brink, and E. Roos (1999) 
LFA-1 to LFA-1 signals involve c-associated protein-70 (ZAP-70) tyrosine kinase: 
relevance for invasion and migration of aT cell hybridoma 
J. Immunol. 163 4253-4261. 
Sondek, J., A. Bohm, D. G. Lambright, H. E. Hamm, and P. B. Sigler (1996) 
Crystal structure of a G-protein beta gamma dimer at 2.1A resolution 
Nature 2 369-374. 
Sorimachi, H., S. Ishiura, and K. Suzuki (1997) 
Structure and physiological function of calpains 
Biochem. J. 328 721-732. 
Springer, T. A. (1994) 
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep 
paradigm 
Cell 76 301-314. 
Springer, T. A. (1997) 
Folding of the N-terminal, ligand binding region of integrin a-subunits into a f3- 
propeller domain 
Proc. Natl. Acad. Sci. USA 94 65-72. 
Springer, T. A., H. Jing, and J. Takagi (2000) 
A novel Cat' binding beta hairpin loop better resembles integrin sequence motifs 
than the EF hand 
Cell 102 275-277. 
Sriramarao, P., L. R. Languino, and D. C. Altieri (1996) 
Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces 
Blood 88 3416-3423. 
234 
REFERENCES 
Stanley, P., P. A. Bates, J. Harvey, R. I. Bennett, and N. Hogg (1994) 
Integrin LFA-1 a subunit contains an ICAM-1 binding site in domains V and VI 
E1'1BO J. 111790-1798. 
Stanley, P., and N. Hogg (1998) 
The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 
but not Gln-73 
J. Biol. Chem. 273 3358-3362. 
Stanley, P., A. McDowall, P. A. Bates, J. Brashaw, and N. Hogg (2000) 
The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the 
structural integrity of the leukocyte function associated antigen-1 (LFA-1) ligand- 
binding site in the first domain 
Biochem. J. 35179-86. 
Staunton, D. E., S. D. Marlin, C. Stratowa, M. L. Dustin, and T. A. Springer (1988) 
Primary structure of ICAM-1 demonstrates interaction between members of the 
immunoglobulin and integrin supergene families 
Cell 52 925-933. 
Staunton, D. E., M. L. Dustin, and T. A. Springer (1989a) 
Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to 
ICAM-1 
Nature %2 61-64. 
Staunton, D. E., V. J. Merluzzi, R. Rothlein, R. Barton, S. D. Marlin, and T. A. 
Springer (1989b) 
A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses 
Cell 56 849-853. 
Staunton, D. E., M. L. Dustin, H. P. Erikson, and T. A. Springer (1990) 
The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding 
sites for LFA-1 and rhinovirus 
Cell 61243-254. 
Stephens, P., J. T. Romer, M. Spitali, A. Shock, S. Ortlepp, C. G. Figdor, and M. K. 
Robinson (1995) 
KIM127, an antibody that promotes adhesion, maps to a region of CD18 that 
includes cysteine-rich repeats 
Cell Adhes. Commun. 3 375-384. 
Stewart, M. P., C. Cabanas, and N. Hogg (1996) 
T cell adhesion to Intercellular Adhesion Molecule-1 (ICAM-1) is controlled by cell 
spreading and the activation of integrin LFA-1 
J. Immunol. 156 1810-1817. 
Stewart, M. P., A. McDowall, and N. Hogg (1998) 
LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Cat+- 
dependent protease, calpain 
J. Cell Biol. 140 699-707. 
235 
REFERENCES 
Takagi, J., T. Kamata, J. Meredith, W. Puzon-McLaughlin, and Y. Takada (1997) 
Changing ligand specificities of aV ß1 and aV ß3 integrins by swapping a short 
diverse sequence in the ß subunit 
J. Biol. Chem. 272 19794-19800. 
Tamkun, J. W., D. W. DeSimone, D. Fonda, R. S. Patel, C. Buck, A. F. Horwitz, and 
R. O. Hynes (1986) 
Structure of integrin, a glycoprotein involved in the transmembrane linkage between 
fibronectin and actin 
Cell 46 271-282. 
Tan, S. M., R. H. Hyland, A. Al-Shamkhani, W. A. Douglass, J. M. Shaw, and S. K. 
Law (2000) 
Effect of integrin 02 subunit truncations on LFA-1 (CDlla/CD18) and Mac-1 
(CD! lb/CD 18) assembly, surface expression, and function 
J. Immunol. 165 2574-2581. 
Tanaka, Y., Y. Minami, S. Mine, H. Hirano, C. D. Hu, H. Fujimoto, K. Fujii, K. 
Saito, J. Tsukada, Y. van Kooyk, C. G. Figdor, T. Kataoka, and S. Eto (1999) 
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion 
of T cells 
J. Immunol. 163 6209-6216. 
Tian, L., Y. Yoshihara, T. Mizuno, K. Mori, and C. G. Gahmberg (1997) 
The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 
leukocyte integrin 
J. Immunol. 158 928-936. 
Tian, L., P. Kilgannon, Y. Yoshihara, K. Mori, W. M. Gallatin, 0. Carpen, and C. G. 
Gahmberg (2000a) 
Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) 
and characterization of its interaction with the leukocyte integrin CD 11 a/CD 18 
Eur. J. Immunol. 30 810-818. 
Tian, L., H. Nyman, P. Kilgannon, Y. Yoshihara, K. Mori, L. C. Andersson, S. 
Kaukinen, H. Rauvala, W. M. Gallatin, and C. G. Gahmberg (2000b) 
Intercellular adhesion molecule-5 induces dendritic outgrowth by homophilic 
adhesion 
J. Cell Biol. 150 243-252. 
Tidswell, M., R. Pachynski, S. W. Wu, S. -Q. Qiu, E. Dunham, N. Cochran, M. J. 
Briskin, P. J. Kilshaw, A. I. Lazarovtis, D. P. Andrew, E. C. Butcher, T. A. Yednock, 
and D. J. Erle (1997) 
Structure-function analysis of the integrin 07 subunit. Identification of domains 
involved in adhesion to MAdCAM-1. 
J. Immunol. 159 1497-1505. 
Tomoda, K., Y. Kubota, and J. Kato (1999) 
Degradation of the cyclin-dependent-kinase inhibitor p27Kipl is instigated by Jabl 
Nature 98160-165. 
236 
REFERENCES 
Tozer, E. C., R. C. Liddington, M. J. Sutcliffe, A. H. Smeeton, and J. C. Loftus (1996) 
Ligand binding to integrin alIbß3 is dependent on a MIDAS-like domain in the 03 
subunit 
J. Biol. Chem. 27121978-21984. 
Tozer, E. C., E. K. Baker, M. H. Ginsberg, and J. C. Loftus (1999) 
A mutation in the a subunit of the platelet integrin aIlbß3 identifies a novel region 
important for ligand binding 
Blood 2 918-924. 
Trask, B., A. Fertitta, M. Christensen, J. Youngblom, A. Bergmann, A. Copeland, P. 
de Jong, H. Mohrenweiser, A. Olsen, A. Carrano, and K. Tynan (1993) 
Fluorescence in situ hybridization mapping of human chromosome 19: cytogenetic 
band location of 540 cosmids and 70 genes or DNA markers 
Genomics 15 133-145. 
Tsuchida, J., S. Ueki, Y. Takada, Y. Saito, and J. Takagi (1998) 
The 'ligand-induced conformational change' of a5ß1 integrin. Relocation of a5 
subunit to uncover the 01 stalk region. 
J. Cell Sci. I 11 1759-1766. 
Tuckwell, D. S., M. J. Humphries, and A. Brass (1994) 
A secondary structure model of the integrin a subunit N-terminal domain based on 
analysis of multiple alignments 
Cell Adhes. Commun. 2 385-402. 
Tuckwell, D., D. A. Calderwood, L. J. Green, and M. J. Humphries (1995) 
Integrin a2 I-domain is a binding site for collagens 
J. Cell Sci. 108 1629-1637. 
Tuckwell, D. S., K. B. Reid, M. J. Barnes, and M. J. Humphries (1996) 
The A-domain of integrin a2 binds specifically to a range of collagens but is not a 
general receptor for the collagenous motif 
Eur. J. Biochem. 241732-739. 
Tuckwell, D. S., and M. J. Humphries (1997) 
A structure prediction for the ligand-binding of the integrin ß subunit: evidence for 
the presence of a von Willebrand factor A domain 
FEBS Letts. 400 297-303. 
Ueda, T., P. Rieu, J. Brayer, and M. A. Arnaout (1994) 
Identification of the complement iC3b binding site in the 02 integrin CR3 
(CDI lb/CD18) 
Proc. Natl. Acad. Sci. USA 91 10680-10684. 
237 
REFERENCES 
Van der Vieren, M., H. L. Trong, C. L. Wood, P. F. Moore, T. S. John, D. E. Staunton, 
and V. M. Gallatin (1995) 
A novel leukointegrin, aD032, binds preferentially to ICAM-3 
Immunity 3_ 683-690. 
Van der Vieren, M., D. T. Crowe, D. Hoekstra, R. Vazeux, P. A. Hoffman, M. H. 
Grayson, B. S. Bochner, W. M. Gallatin, and D. E. Staunton (1999) 
The leukocyte integrin aD02 binds VCAM-1: evidence for a binding interface 
between I domain and VCAM-1 
J. Immunol. 
, 
163 1984-1990. 
van Kooyk, Y., M. E. Binnerts, C. P. Edwards, M. Champe, P. W. Berman, C. G. 
Figdor, and S. C. Bodary (1996) 
Critical amino acids in the lymphocyte function-associated antigen-1 I domain 
mediate intercellular adhesion molecule 3 binding and immune function 
J. Exp. Med. 183 1247-1252. 
van Kooyk, Y., S. J. van Vliet, and C. G. Figdor (1999) 
The actin cytoskeleton regulates LFA-1 ligand binding through avidity rather than 
affinity changes 
J. Biol. Chem. 
, 
274 26869-26877. 
van Leeuwen, J. E., and L. E. Samelson (1999) 
T cell antigen-receptor signal transduction 
Curr. Opin. Immunol. 11242-248. 
Vazeux, R., P. A. Hoffman, J. K. Tomita, E. S. Dickinson, R. L. Jasman, T. St. John, 
and W. M. Gallatin (1992) 
Cloning and characterisation of a new intercellular adhesion molecule ICAM-R 
Nature 360 485-488. 
Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia (1999) 
T lymphocyte costimulation mediated by reorganisation of membrane microdomains 
Science 283 680-682. 
Volkov, Y., A. Long, and D. Kelleher (1998) 
Inside the crawling T cell: leukocyte function associated antigen-1 cross-linking is 
associated with microtubule-directed translocation of protein kinase C isoenzymes 
ß(I) and 81 
J. Immunol. 1616487-6495. 
Ward, S. G., K. Bacon, and J. Westwick (1998) 
Chemokines and T lymphocytes: more than an attraction 
Immunity 9 1-11. 
Wardlaw, A. J., M. L. Hibbs, S. A. Stacker, and T. A. Springer (1990) 
Distinct mutations in two patients with leukocyte adhesion deficiency and their 
functional correlates 
J. Exp. Med. 172 335-345. 
238 
REFERENCES 
Warnock, R. A., S. Askari, E. C. Butcher, and U. H. von Andrian (1998) 
Molecular mechanisms of lymphocyte homing to peripheral lymph nodes 
J. Exp. Med. 187 205-216. 
Weisel, J. W., C. Nagaswami, G. Vilaire, and J. S. Bennett (1992) 
Examination of the platelet membrane glycoprotein IIb-IIIa complex and its 
interaction with fibrinogen and other ligands by electron microscopy 
J. Blol. Chem. 267 16637-16643. 
Wilcox, D. A., J. C. Olsen, L. Ishizawa, P. F. Bray, D. L. French, D. A. Steeber, W. R. 
Bell, M. Griffith, and G. C. White (2000) 
Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the 
phenotypic correction of Glanzmann thrombasthenia. 
Blood 95 3645-3651. 
Williams, D. A., W. Tao, F. Yang, C. Kim, Y. Gu, P. Mansfield, J. E. Levine, B. 
Petryniak, C. W. Derrow, C. Harris, B. Jia, Y. Zheng, D. R. Ambruso, J. B. Lowe, S. J. 
Atkinson, M. C. Dinauer, and L. Boxer (2000) 
Dominant negative mutation of the hematopoietic-specific rho GTPase, rac2, is 
associated with a human phagocyte immunodeficiency 
Blood 96 1646-1654. 
Wong, D. A., E. M. Davis, M. LeBeau, and T. A. Springer (1996) 
Cloning and chromosomal localization of a novel gene-encoding a human beta 2- 
integrin alpha subunit 
Gene 171291-294. 
Xie, J., R. Li, P. Kotovuori, C. Vermot-Desroches, J. Wijdenes, M. A. Arnaout, P. 
Nortamo, and C. G. Gahmberg (1995) 
Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin 
CD11b/CD18 through the A domain 
J. Immunol. 1_555 3619-3628. 
Xiong, J. -P., R. Li, M. Essafi, T. Stehle, and M. A. Arnaout (2000) 
An isoleucine-based allosteric switch controls affinity and shape shifting in integrin 
CD 11 b A-domain 
J. Biol. Chem. in press. 
Xu, H., I. L. Tong, A. R. de Fougerolles, and T. A. Springer (1992) 
Isolation, characterization, and expression of mouse ICAM-2 complementary and 
genomic DNA 
J. Immunol. 149 2650-2655. 
Yalamanchili, P., C. Lu, C. Oxvig, and T. A. Springer (2000) 
Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated 
antigen-1 
J. Biol. Chem. 275 21877-21882. 
239 
REFERENCES 
Yang, J. T., H. Rayburn, and R. O. Hynes (1995) 
Cell adhesion events mediated by a4 integrins are essential in placental and cardiac 
development 
Development 121549-560. 
Yauch, R. L., D. P. Felsenfeld, S. -K. Kraeft, L. B. Chen, and M. E. Hemler (1997) 
Mutational evidence for control of cell adhesion through integrin 
diffusion/clustering, independent of ligand binding 
J. Exp. Med. 186 1347-1355. 
Yonemura, S., M. Hirao, Y. Doi, N. Takahashi, T. Kondo, and S. Tsukita (1998) 
Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster 
in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2 
J. Cell Biol. 144Q 885-895. 
Yoshihara, Y., S. Oka, Y. Nemoto, Y. Watanabe, S. Nagata, H. Kagamiyama, and K. 
Mori (1994) 
An ICAM-related neuronal glycoprotein, telencephalin, with brain segment-specific 
expression 
Neuron 12 541-553. 
Zang, Q., C. Lu, C. Huang, J. Takagi, and T. A. Springer (2000) 
The top of the inserted-like domain of the integrin lymphocyte function-associated 
antigen-10 subunit contacts the a subunit 0-propeller domain near ß-sheet 3 
J. Biol. Chem. 25 22202-22212. 
Zeller, Y., J. Lohr, M. Sammar, E. C. Butcher, and P. Altevog (1998) 
Asp-698 and Asp-811 of the integrin a4 are critical for the formation of a functional 
heterodimer 
J. Biol. Chem. 273 6786-6795. 
Zhang, L., and E. F. Plow (1996) 
A discrete site modulates activation of I domains. Application to integrin aM02 
J. Biol. Chem. 27129953-29957. 
Zhang, L., and E. F. Plow (1997) 
Identification and reconstruction of the binding site within aM02 for a specific and 
high affinity ligand, NIF 
J. Biol. Chem. 272 17558-17564. 
Zhang, X. -P., W. Puzon-McLaughlin, A. Irie, N. Kovach, N. L. Prokopishyn, S. 
Laferte, K. Takeuchi, T. Tsuji, and Y. Takada (1999) 
a3ß1 adhesion to laminin-5 and invasin: critical and differential role of integrin 
residues clustered at the boundary between a3 N-terminal repeats 2 and 3 
Biochem. 38 14424-14431. 
Zhou, L., D. H. S. Lee, J. Plescia, C. Y. Lau, and D. C. Altieri (1994) 
Differential ligand binding specificities of recombinant CD11b/CD18 integrin I- 
domain 
J. Biol. Chem. 2 69 17075-17079. 
240 
REFERENCES 
Zhou, X., and J. Li (2000) 
Macrophage-enriched myristoylated alanine-rich C kinase substrate and its 
phosphorylation is required for the phorbol ester-stimulated diffusion of 02 integrin 
molecules 
J. Biol. Chem. M 20217-20222. 
Zuckerman, LA., L. Pullen, and J. Miller (1998) 
Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T 
cell activation 
J. Immunol. 160 3259-3268. 
241 
APPENDIX I 
ONE AND THREE LETTER SYMBOLS FOR THE 
AMINO ACIDS 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lycine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Senne Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
The one letter symbol for an undetermined or non-standard amino acid is X 
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APPENDIX II 
GMEM-S MEDIUM 
Distilled water 400 ml 
Glasgow MEM 50 ml Gibco-BRL 
7.5% sodium bicarbonate 18.1 ml Gibco-BRL 
100 x MEM non-essential amino acids 5 ml Gibco-BRL 
100 x glutamine and asparagine 5 ml see below 
100 mM sodium pyruvate 5 ml Gibco-BRL 
50 x nucleosides 10 ml see below 
5000 units/ml penicillin-streptomycin 5 ml Gibco-BRL 
Dialysed FCS to desired % Gibco-BRL 
100 x glutamine and asparagine 
600 mg L-glutamic acid (Sigma) and 600 mg L-asparagine (Sigma) in 100 ml 
distilled water. Filter sterilised and stored at 4°C. 
50 x nucleosides 
35 mg each of adenosine, guanosine, cytidine and uridine and 12 mg of thymidine 
(all from Sigma) in 100 ml distilled water. Filter sterilised and stored at 4°C. 
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APPENDIX III 
COMPANIES AND ADDRESSES 
American Type Culture Collection 
10801 University Boulevard, Manassas, VA, USA 
Amersham Pharmacia Biotech. UK Ltd. 
Amersham Place, Little Chalfont, Buckinghamshire, UK 
Anachem Ltd. 
Anachem House, Charles Street, Luton, Bedfordshire, UK 
Becton Dickinson UK Ltd. 
Between Towns Road, Oxford, UK 
Bio-Rad Laboratories Ltd. 
Bio-Rad House, Marylands Avenue, Hemel Hempstead, Hertfordshire, UK 
Calbiochem 
CN Biosciences UK, Boulevard Industrial Estate, Nottingham, UK 
Cambridge Bioscience 
24-25 Signet Court, Cambridge, UK 
Chemicon International Ltd. 
2 Admiral Way, Harrow, UK 
Chiron UK Ltd. 
Salamander Quay West, Harefield, Middlesex, UK 
Corning Costar UK 
1 The Valley Centre, Gordon Road, High Wycombe, Buckinghamshire, UK 
Dako Ltd. 
Denmark House, Angel Drove, Ely, Cambridge, UK 
Dynex Technologies 
Action Court, Ashford, Middlesex, UK 
Eurogenetics UK Ltd. 
Kingsway Business Park, Oldfield Road, Hampton, UK 
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Genetic Research Instrumentation Ltd. 
Gene House, Queensborough Lane, Rayne, Essex, UK 
Gibco-BRL 
Life Technologies Ltd., Inchinnan Business Park, Paisley, UK 
Jackson Immunoresearch Laboratories 
UK distributor. Stratech Scientific Ltd., Dudley Street, Luton, Bedfordshire, UK 
Millipore (UK) Ltd. 
The Boulevard, Blackmoor Lane, Watford, Hertfordshire, UK 
Molecular Probes 
UK distributor. Cambridge Bioscience 
Murex Biotech Ltd. 
Central Road, Temple Hill, Dartford, UK 
National Blood Service - South Thames 
75 Cranmer Terrace, Tooting, London, UK 
Nycomed 
Oslo, Norway 
PeproTech EC Ltd. 
23 St. James' Square, London, UK 
PerSeptive Biosystems 
Birchwood Science Park North, Warrington, Cheshire, UK 
Photon Technologies International 
Suite 3, The Sanctuary, Oakhill Grove, Surbiton, Surrey, UK 
Pierce 
Pierce and Warriner (UK) Ltd., 44 Upper Northgate Street, Chester, Cheshire, UK 
Santa Cruz Biotechnology Inc. 
UK distributor: Autogen Bioclear UK Ltd., Holly Ditch Farm, Mile Elm, Calne, 
Wiltshire, UK 
Serotec Ltd. 
22 Bankside, Kidlington, Oxford, UK 
Sigma 
Sigma-Aldrich Company Ltd., Fancy Road, Poole, Dorset, UK 
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Scanalytics. 
8550 Lee Highway, Fairfax, VA, USA 
Southern Biotechnology Associates Inc. 
UK distributor. Cambridge Bioscience 
Titertek 
UK distributor. Biological Instrumentation Services Ltd., Kirkham Trading Park, 
Kirkham, Lancashire, UK 
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